VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 13 (1-16 julio / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

Neumonía: Uno de los retos de vacunación a vencer en la post pandemia

1 jul. De acuerdo con datos de la Secretaría de Salud de México, durante los años 2015 y 2016 se alcanzaron coberturas adecuadas de vacunación. Sin embargo, los actuales datos recopilados por el Observatorio Mexicano de Vacunación (OMEVAC) en noviembre de 2021, revelan un panorama preocupante para los menores de edad. Sólo 20.7% de los niños de dos años, 31.7% de los de tres años y 44.5% de los infantes de cuatro años han completado el esquema básico de vacunación, evidenciando así el riesgo que enfrentan.

Específicamente hablando de la vacuna antineumocócica, se estima que la cobertura global de la tercera dosis es de 49%. Esta cifra sugiere que un gran número de niños están expuestos a un riesgo latente de contraer enfermedades neumocócicas. Estos padecimientos incluyen afecciones graves como neumonía, meningitis y bacteriemia febril, así como otras condiciones como otitis media, sinusitis y bronquitis.

En los últimos años los índices de vacunación han disminuido por diferentes factores, por ejemplo, la pandemia de COVID-19 alteró el sistema de salud provocando que alrededor de 23 millones de niños no recibieran vacunas en 2020. De manera alarmante, el número de niños que no recibieron ninguna vacuna aumentó en 3.4 millones durante ese mismo año.

“Ante este panorama, es importante resaltar que la vacunación contra el neumococo es la mejor forma de reducir el riesgo de contraer neumonía, por ello es importante inmunizar a los niños y adultos mayores, ya que, si no se detecta a tiempo, esta enfermedad puede ser fatal. La introducción de las vacunas antineumocócicas conjugadas ha representado un gran avance en la prevención de este grupo de enfermedades, estas vacunas han evolucionado a través de los años para ajustarse a los serotipos predominantes y hacer frente a la problemática de resistencia antimicrobiana, puntualiza el doctor Marcelo Díaz Conde, Líder Médico de Vacuna Antineumocócica en Pfizer México.

Reducir la incidencia de la neumonía

“En la actualidad, sabemos que aproximadamente 70% por ciento de las infecciones en niños por *S. pneumoniae* que ocurren en el mundo son causadas por entre 6 y 11 de sus serotipos más comunes. Por fortuna, hay dos vacunas conjugadas disponibles contra el neumococo que han demostrado un sustancial impacto contra las neumonías”, añade el especialista.

Neumonía en México y el mundo

En México, la neumonía, por su alta incidencia, se coloca como la séptima causa de mortalidad, de acuerdo con datos del INEGI 2023. Por su parte, la Organización Mundial de la Salud (OMS) registra anualmente alrededor de 450 millones de casos a nivel global que derivan en unos 4 millones de muertes, con mayor impacto en menores de cinco años y mayores de 75.

Especialistas de la Organización Panamericana de la Salud (OPS) han identificado al neumococo *S. pneumoniae* como el segundo agente causante de neumonía adquirida en la comunidad (NAC) que requiere hospitalización. Los menores de cinco años, principalmente en países de ingresos medios o bajos, son los más afectados por este tipo de infecciones, pues se calcula que más del 95% de todos los episodios de neumonía clínica y más de 99% de muertes por neumonía recaen en este sector de la población.

Los adultos de 65 años y más tienen 3.8 veces más posibilidades de enfermar de neumonía por neumococo en comparación con los adultos sanos. Este peligro aumenta si además padecen alguna enfermedad crónica como diabetes mellitus (2.8 veces más), algún trastorno cardiovascular (3.8 veces más), asma (5.9 veces más) y el EPOC (7.7 veces más). Además, tienen 10 veces más probabilidad de ser hospitalizados por esta causa.

"Las primeras manifestaciones clínicas tras la infección por *S. pneumoniae* demoran entre 1 y 3 días en aparecer. Cabe destacar que los síntomas que experimente el paciente dependerán de la parte del cuerpo afectada. En el caso de la neumonía neumocócica, derivada de la infección pulmonar, incluye dolor torácico, tos, fiebre con escalofríos, respiración rápida o dificultad para respirar", detalla el doctor Marcelo Díaz Conde.

Fuente: Vértigo Político. Disponible en https://acortar.link/xR5zAw

La FDA aprueba la vacuna V116 de MSD para la prevención de la enfermedad neumocócica invasiva

2 jul. La compañía Merck Sharp and Dohme (MSD) ha anunciado que la Administración de Alimentos y Medicamentos de EE.UU. (FDA) ha aprobado V116 en Estados Unidos y que se encuentra en proceso de revisión por la Agencia Europea de Medicamentos (EMA). La aprobación se produce tras la 'revisión prioritaria' de la FDA solicitada por MSD.

"La aprobación de hoy es un testimonio de nuestra estrategia específica para la población detrás de V116, que mostró una inmunogenicidad sólida en una variedad de poblaciones adultas y está impulsada por una comprensión profunda de la enfermedad neumocócica", ha dicho el Dr. Dean Y. Li, presidente de MSD Research Laboratories.

"Estamos orgullosos de ofrecer V116 como una nueva opción específicamente diseñada para ayudar a proteger frente a la mayoría de los serotipos invasivos causantes de la enfermedad neumocócica en adultos."

V116 es la vacuna antineumocócica conjugada 21-valente indicada para la inmunización activa para la prevención de la enfermedad invasiva y la neumonía en adultos de 18 años o más. Esta terapia está específicamente diseñada para ayudar a hacer frente a los serotipos de *Streptococcus pneumoniae* predominantemente responsables de la enfermedad neumocócica invasiva (ENI) en adultos.

La enfermedad neumocócica es una infección causada por una bacteria llamada *Streptococcus pneumoniae*. Existen unos 100 tipos diferentes, denominados serotipos, de bacterias neumocócicas, que pueden afectar de forma diferente a los adultos que a los niños. La enfermedad neumocócica puede ser invasiva o no invasiva. La neumonía neumocócica es un tipo de neumonía bacteriana, que constituye la presentación clínica más frecuente de esta patología en adultos.

"Las complicaciones de la enfermedad neumocócica invasiva pueden provocar hospitalización, daños orgánicos e incluso la muerte. Muchos casos de enfermedad en adultos están causados por serotipos no incluidos en otras vacunas antineumocócicas conjugadas aprobadas", indica el Dr. Walter Orenstein, profesor

emérito de medicina, epidemiología, salud global y pediatría de la Universidad de Emory y miembro del Comité Científico Asesor de MSD.

"V116 está diseñada para incluir los serotipos que causan la mayoría de los casos de enfermedad neumocócica invasiva en adultos, ayudando a proteger a los adultos contra la ENI y la neumonía neumocócica", añade Orenstein.

Esta indicación para la prevención de la neumonía causada por los serotipos indicados con anterioridad, está aprobada en EE.UU. por la FDA bajo aprobación acelerada basada en las respuestas inmunitarias medidas por la actividad opsonofagocítica (OPA). La continuación de la aprobación para esta indicación puede depender de la verificación y descripción del beneficio clínico en un ensayo confirmatorio.

"V116 está diseñada para incluir los serotipos que causan la mayoría de los casos de enfermedad neumocócica invasiva en adultos"

Se espera que el Comité Asesor sobre Prácticas de Inmunización de los Centros para el Control y la Prevención de Enfermedades de Estados Unidos (CDC por sus siglas en inglés) se reúna este mes para discutir y hacer recomendaciones sobre el uso de V116 en adultos.

Según los datos del CDC de 2018-2021, los serotipos cubiertos por V116 son responsables de más casos de enfermedad neumocócica invasiva en adultos en comparación con PCV20 (vacuna neumocócica conjugada 20-valente). Por un lado, en adultos de 50 años o más, V116 cubre los serotipos responsables de aproximadamente el 84% de los casos de ENI, frente al 52% que cubre PCV20. Y en segundo lugar, en adultos de 65 años o más, V116 cubre los serotipos responsables de aproximadamente el 85% de los casos de ENI, en comparación con aproximadamente el 51% cubierto por PCV20.

Estos valores se basan en datos epidemiológicos del CDC y no reflejan la eficacia de las respectivas vacunas. Actualmente no hay estudios que comparen la eficacia de CAPVAXIVE y PCV20.

V116 incluye ocho serotipos únicos no cubiertos por otras vacunas antineumocócicas actualmente aprobadas; esos serotipos fueron responsables de aproximadamente el 27% de los casos de ENI en adultos de 50 años o más y de aproximadamente el 30% en adultos de 65 años o más, según los mismos datos del CDC.

Entre los datos clínicos que respaldan la aprobación se encuentran los resultados del estudio pivotal de Fase 3 STRIDE-3 (NCT05425732), que evaluó V116 en comparación con PCV20 en adultos de 18 años o más que no habían recibido previamente una vacuna neumocócica. La aprobación también se basa en los resultados de los estudios de Fase 3 STRIDE-5 (NCT05526716) y STRIDE-6 (NCT05420961), que evaluaron V116 en adultos con y sin experiencia previa en vacunación.

Fuente: ConSalud.es. Disponible en https://acortar.link/lfpOzc

First qualitative research study conducted in Turkmenistan focuses on HPV vaccination

Jul 4. Within the framework of a WHO–European Union joint project on immunization in central Asia, the WHO Country Office in Turkmenistan and the Ministry of Health and Medical Industry of Turkmenistan jointly conducted the country's first qualitative research study.

The project aimed at identifying factors influencing parents' decisions related to human papillomavirus (HPV) vaccination for their children. Consisting of focus-group discussions and in-depth interviews, the research provided an understanding of parents' attitudes and beliefs about HPV as well as barriers to HPV vaccination.

The results of the research conducted over 3 weeks in late 2023 will serve as the basis for activities to increase public awareness about HPV and sustain confidence in HPV vaccination in the future.

HPV vaccination in Turkmenistan

Turkmenistan included the HPV vaccine in its routine immunization schedule starting in 2016, for boys and girls at 9 years of age. Although national vaccination coverage remains high, a slight downward trend has been observed in both urban and rural areas: from 99.2% in 2021 to 98.5% in 2023.

With a relatively young population increasingly turning to the internet for information, it is important that evidence-based answers to potential questions about vaccination are readily available. However, official online information about vaccines remains limited, creating an opportunity for misinformation to spread with the potential to decrease vaccination uptake in the coming years.

The Ministry asked WHO to conduct a qualitative research study to identify what parents know about HPV, the diseases it can cause, the effectiveness of vaccination in preventing these diseases, and especially what questions or concerns they have on HPV vaccination that need to be addressed in a transparent and accessible manner.

The study, conducted jointly by experts from the Ministry and WHO, aimed to develop targeted interventions to better inform the public and health-care workers about HPV vaccines. Focus groups and in-depth interviews with health-care providers, parents and staff of public organizations were conducted to identify participants' knowledge, attitudes and behavioural determinants for uptake of HPV vaccine and childhood

vaccines in general.

The study was conducted in cities, including the capital, as well as in rural sites in 2 regions. Data collection and analysis were conducted using the COM-B framework, which looks at 3 key components: capability, opportunity and motivation for behaviour change.

Study outcomes

Study findings revealed that attitudes toward HPV were generally positive, partially due to positive attitudes toward vaccination in general but also due to preparatory steps taken by health authorities prior to introducing the HPV vaccine in 2016.

These steps included informing and training health workers to administer and answer questions about the vaccine and to inform parents and children about the benefits of HPV vaccination in preventing HPV infection, emphasizing its role in preventing the spread of the virus rather than only in preventing cervical cancer.

Despite high levels of knowledge and trust in vaccination, study participants did reveal certain gaps in knowledge and potential vulnerability to misinformation. Based on the findings, researchers proposed several measures, including:

making up-to-date information on childhood vaccination available through a single online portal to ensure accessibility and availability for the public;

training health workers to increase their capacity to effectively communicate with parents on HPV and other vaccines in the routine immunization schedule; and

using existing facility-level data and ongoing activities to conduct local, community-based interventions to effectively engage the minority of parents delaying or rejecting vaccination.

Based on these recommendations, the Ministry is developing an action plan that will include regular training for health workers and provision of information to parents via online resources and individual consultations.

With an eye to sustaining high demand for vaccination in the future, the Ministry is also planning to pilot an education module for 10–12-year-olds called Immune Patrol in several schools. WHO developed Immune Patrol to increase health literacy, resistance to misinformation, and knowledge about the immune system and immunization. WHO will provide technical support to the Ministry to implement the action plan and to pilot the Immune Patrol package in 2024 and beyond.

Fuente: World Health Organization. Disponible en https://acortar.link/j7sghl

Vacuna contra COVID-19 que provoca una respuesta inmunitaria superior a las demás

5 jul. Nuevos avances para tratar el coronavirus. La farmacéutica Moderna ha anunciado que su vacuna combinada contra la influenza (gripe) y la COVID-19 provoca una respuesta inmunitaria superior a las demás. El nuevo fármaco ha conseguido pasar la fase 3 del ensayo y ha cumplido con sus criterios de valoración primarios, provocando una respuesta inmunitaria más alta que las vacunas de comparación autorizadas utilizadas en el estudio.

"Las vacunas combinadas tienen el potencial de reducir la carga de los virus respiratorios en los sistemas de salud y las farmacias, así como de ofrecer a las personas opciones de vacunación más convenientes que

podrían mejorar el cumplimiento y brindar una mayor protección contra las enfermedades estacionales", dijo Stéphane Bancel, director ejecutivo de Moderna.

Al igual que las vacunas pioneras contra el coronavirus, esta se basa en el ARNm, que son aquellas en las que se emplea ácido ribonucleico para lograr el desarrollo de una respuesta inmune. El rápido éxito de Moderna demuestra que el ARN puede ayudar a superar algunas de estas dificultades, afirma James Thaventhiran, inmunólogo clínico de la Universidad de Cambridge (Reino Unido), "es un gran ejemplo de por qué la tecnología es apasionante", afirma, y añade que las vacunas combinadas que utilizan ARNm son "sólo el principio" de la tecnología del ARN.

La vacuna combinada contra la influenza y la COVID-19 de Moderna / Juan Manuel Serrano Arce - Europa Press - Archivo.

¿Cómo funcionan?

Las vacunas basadas en ARNm inyectan ARNm en las células para que hagan copias de los antígenos que el sistema inmunitario debe reconocer. Así, en lugar de tener que fabricar un montón de componentes diferentes, este tipo de vacunas simplemente envuelven un conjunto de instrucciones en una capa de lípidos y luego las envían al cuerpo para que las células produzcan sus propios antígenos. "Una sola inyección bastará para protegerse tanto de la gripe como de COVID", agrega Thaventhiran . En general, el desarrollo de vacunas combinadas de ARNm demuestra "que el ARN tiene un futuro positivo. No es solo una casualidad".

Fuente: El Periódico de España. Disponible en https://acortar.link/sjFZZP

Presidente de Cuba felicita a creadores de nueva vacuna infantil

6 jul. El presidente de Cuba, Miguel Díaz-Canel, felicitó al equipo científico del Instituto Finlay de Vacunas (IFV) que desarrolló el inyectable Quimi-Vio contra enfermedades respiratorias. En su perfil en la red social X el mandatario escribió: La ciencia cubana lo volvió a hacer: ¡tenemos nueva vacuna para nuestros niños! Se trata de Quimi-Vio, que protege contra neumonías, meningitis, otitis y otras enfermedades causadas por neumococo. Resultado de quince años de estudio. Gracias al equipo que hizo realidad el sueño, apuntó.

La vacuna antineumocócica cubana Quimi-Vio recibió la víspera el registro sanitario por parte el Centro para el control Medicamentos, Equipos y Dispositivos Médicos de la República de Cuba, luego de concluir todos los ensayos clínicos requeridos, que demostraron su calidad, seguridad y eficacia.

De acuerdo con la directora de Investigaciones del IFV, Dagmar García, se trata de una vacuna muy compleja, que permitirá mejorar significativamente los indicadores de salud de la infancia, en términos de morbilidad de las enfermedades respiratorias, y de mortalidad infantil por infecciones.

La científica detalló recientemente que el primer estudio con Quimi-Vio se llevó a cabo en la central provincia de Cienfuegos en 2023, donde se vacunó a más del 90 por ciento de los niños entre uno y cinco años (aproximadamente, 11 mil 600 pequeños).

También allí realizaron un ensayo clínico comunitario, en el que se inyectó al 93 por ciento de todos los niños entre uno y cinco años de edad.

Al año de haberlos inmunizado se observó un 63 por ciento de reducción de las tasas de hospitalizaciones por enfermedad respiratoria; y un 73 por ciento de reducción de la enfermedad neumocócica invasiva, por los serotipos que están contenidos en la vacuna, señaló.

En junio de este año, se anunció que un estudio de intervención contra la enfermedad neumococócica en lactantes menores de un año (que tengan dos, cuatro y 11 meses) tendrá lugar con Quimi-Vio también en territorio cienfueguero.

Según la investigadora principal del IPK, María Eugenia Toledo, Quimi-Vio protegerá a los infantes menores de un año de 11 serotipos que producen la enfermedad neumococócica.

Fuente: Prensa Latina. Disponible en https://acortar.link/WH8T9N

Africa surpasses global averages in vaccination

Jul 7. The breadth of vaccine protection in Gavi-supported countries, many of which are in Africa, has surpassed global averages, achieving 56 percent coverage compared to the worldwide average of 53 percent, says a recent report by Gavi, the Vaccine Alliance.

PHOTO | SHUTTERSTOCK

In a remarkable milestone for global health, at least 54 vaccine programmes originally introduced with Gavi funding are now self-financed by countries as of 2022, up from 40 in 2018.

Countries contributed a record $162 million towards the co-financing of Gavi-supported vaccines in 2022, demonstrating strong ownership and financial sustainability.

Despite facing fiscal challenges, climate change, conflict and instability, Gavi-supported countries maintained or increased domestic resources for vaccine co-financing in 2022.

This commitment brought their total contribution to $1.5 billion since the introduction of the co-financing policy in 2008. Notably, 2.6 million more children received basic routine immunisations in 2022 compared to 2021.

The Vaccine Alliance has successfully vaccinated over 1 billion children through routine immunisation programmes from 2000 to 2022.

In 2022, Gavi supported 40 vaccine introductions and preventive campaigns, in addition to 40 outbreak response vaccination campaigns.

This achievement highlights the substantial impact of efforts in combating some of the world's deadliest diseases. In 2022 alone, more than 68 million children were vaccinated.

Gavi plays a crucial role in immunising more than half of the world's children.

From 2000 to 2022, the Alliance facilitated over 1.8 billion vaccinations through preventive campaigns and averted more than 17.3 million future deaths.

The COVID-19 Vaccine Global Access (Covax) initiative further prevented over 2.7 million deaths across participating low- and middle-income countries.

Fuente: The East African. Disponible en https://acortar.link/hdmS0k

Un estudio alerta de que aumentan los casos de enfermedad neumocócica en España


'Streptococcus pneumoniae' o neumococo.

9 jul. Un equipo del Laboratorio de Referencia de Neumococos del Centro Nacional de Microbiología (CNM) del Instituto de Salud Carlos III (ISCIII) en colaboración con el Centro de Investigación Biomédica en Red (CIBER) ha publicado una investigación que analiza la situación de la enfermedad neumocócica invasiva en España entre los años 2019 y 2023 en población pediátrica y adulta, caracterizando el impacto que ha tenido la pandemia por COVID-19. El estudio también ha analizado el impacto que podrían tener las nuevas vacunas conjugadas recientemente aprobadas, así como las que están en fase de desarrollo clínico para la prevención de los nuevos serotipos emergentes aparecidos tras la pandemia.

El trabajo, que se ha publicado en la revista *Journal of Infection*, demuestra que el uso de medidas no farmacológicas como el uso de mascarillas, lavado de manos, el confinamiento, así como el distanciamiento social provocaron una disminución importante de casos de enfermedad neumocócica en los dos primeros años de pandemia. Sin embargo, tras el levantamiento y flexibilización de estas medidas, la enfermedad neumocócica repuntó y actualmente existen niveles incluso superiores a los que había antes de la pandemia por la COVID-19.

El equipo responsable del trabajo está liderado por el investigador del CNM-ISCIII José Yuste. También participan en la investigación Julio Sempere, Covadonga Pérez-García, Samantha Hita, Aída Úbeda, Erick Joan Vidal, Joaquín Llorente y Mirian Domenech, del Laboratorio de Referencia de Neumococos del Instituto. Además, colaboran investigadores e investigadoras de las Áreas de Enfermedades Respiratorias (CIBERES) y de Epidemiología y Salud Pública (CIBERESP) del CIBER-ISCIII, de la Dirección General de Salud Pública del Ministerio de Sanidad, y de diversas universidades y hospitales españoles.

Entre los serotipos que más han aumentado, según el trabajo, se encuentra el serotipo 3, que es uno de los relacionados con una mayor mortalidad, y que afecta principalmente a población menor de 5 años y a

personas adultas por encima de 65 años. También destaca la presencia del serotipo 4, ligado a infecciones en adultos jóvenes. Por otro lado, el serotipo 24F en población pediátrica, y el serotipo 8 en población adulta, siguen teniendo también importancia en la incidencia de la enfermedad.

Streptococcus pneumoniae o neumococo es la principal causa de las neumonías comunitarias de etiología bacteriana, así como de sepsis y meningitis. Este estudio liderado desde el ISCIII confirma el aumento de casos por cepas invasivas, algunas de ellas asociadas altos niveles de resistencia a los antibióticos, lo que supone una importante preocupación para la salud pública. En este sentido, este mismo equipo investigador ya señaló en 2022, en un estudio publicado en *Lancet Microbe*, del posible aumento de casos por cepas resistentes al principio de la pandemia. Además, otro estudio previo, publicado en *Clinical Infectious Diseases* con datos de los años 2009-2019, había permitido generar un 'mapa' de la enfermedad neumocócica invasiva en España en la última década, señalando un aumento de casos.

El equipo liderado por el doctor Yuste concluye que el uso de las nuevas vacunas conjugadas, con más espectro de protección y/o inmunogenicidad que las que había anteriormente y que se han autorizado recientemente en España, podrían ayudar a prevenir muchos de estos casos, incluyendo nuevos serotipos emergentes. Según apunta, es importante recordar que, en población adulta, la vacunación frente a neumococo no es estacional y que, por tanto, se puede administrar en cualquier momento del año; a diferencia de las vacunas contra la gripe, que al modificarse todos los años hay que administrarse cada año, la vacuna frente al neumococo se administra generalmente una sola vez en la vida.

Fuente: Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología.
Disponible en https://acortar.link/QUyAmi

Pfizer recibe el visto bueno de la Comisión Europea para una nueva vacuna contra la COVID-19

10 jul. La farmacéutica estadounidense y la biotecnológica BioNTech han desarrollado una vacuna actualizada contra el coronavirus adaptada al linaje Ómicron JN.1. El compuesto se aprueba para personas a partir de seis meses de edad.

Pfizer y BioNTech persisten en el mercado de las vacunas contra la COVID-19. Ambas compañías han anunciado que la Comisión Europea (CE) ha concedido la aprobación de la vacuna monovalente adaptada a ómicron JN.1 para la inmunización activa frente al coronavirus en personas a partir de los seis meses de edad.



Esta nueva adaptación se basa en las recomendaciones del Grupo Consultivo Técnico sobre la Composición de las Vacunas frente a la COVID-19 de la Organización Mundial de la Salud (OMS) y del Grupo de Trabajo de Emergencia (ETF) de la Agencia Europea del Medicamento (EMA, por sus siglas en inglés) para actualizar las vacunas frente a la variante JN.1 en la campaña 2024 y 2025.

Esta autorización sigue a la reciente opinión positiva por parte del Comité de Medicamentos de Uso Humano (Chmp, por sus siglas en inglés) de la EMA. La autorización es válida en los 27 Estados miembros de la Unión Europea (UE), además de Islandia, Liechtenstein y Noruega.

Pfizer y BioNTech también han presentado una solicitud ante la Administración de Alimentos y Medicamentos de Estados Unidos

Tras la decisión de la CE, la vacuna actualizada ya está disponible para su envío inmediato a los estados miembros de la UE para su uso conforme a las recomendaciones oficiales de cada uno de ellos. Pfizer y BioNTech han desarrollado la vacuna monovalente frente a la COVID-19 adaptada a Ómicron JN.1 para garantizar la disponibilidad del suministro de cara a la próxima temporada de otoño e invierno, momento del año en el que se espera que aumente la demanda de vacunación frente al virus.

La aprobación de la CE se basa en todo el conjunto de resultados clínicos, preclínicos y en vida real anteriores que respaldan la seguridad y la eficacia de las vacunas frente a la COVID-19 de Pfizer y BioNTech.

Pfizer y BioNTech también han presentado una solicitud ante la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) solicitando la aprobación de la vacuna monovalente frente a la COVID-19 adaptada a ómicron KP.2 para personas a partir de seis meses de edad.

Fuente: Planta Doce. Disponible en https://acortar.link/V54klb

OMS alerta sobre menor vacunación contra COVID-19; aún registran 1,500 muertes semanales

11 jul. El director general de la OMS aseguró que se registra un grave descenso en la vacunación de grupos vulnerables contra la COVID-19.

Datos de la Organización Mundial de la Salud (OMS) indican un descenso en la vacunación contra COVID-19 incluso en grupos de riesgo, pese a que esta enfermedad sigue causando unas 1,500 muertes semanales, advirtió este jueves el director general de la agencia, Tedros Adhanom Ghebreyesus.

"Nuestros datos muestran que la cobertura de vacunación ha descendido entre trabajadores sanitarios y personas mayores de 60, que son dos de los principales grupos de riesgo", alertó el experto etíope en su rueda de prensa semanal para repasar los principales temas sanitarios a nivel global.

"Recomendamos que las personas de estos grupos de riesgo sigan recibiendo vacunas contra la covid-19 doce meses después de su última dosis", agregó Tedros.

Fuente: Forbes México. Disponible en https://acortar.link/pGzYMN

WHO publishes guidance for HPV vaccine developers to help tackle cervical cancer

Jul 11. In more than nine out of ten cases, the HPV virus leads to cervical cancer, the fourth most common cancer in women globally.

The World Health Organization (WHO) has published a new report to guide vaccine developers when creating innovative vaccines to treat human papillomavirus (HPV) infections in adults.

Currently the main cause of cervical cancer – the fourth most common cancer in women globally – HPV is a very common group of viruses that leads to cervical cancer in more than nine out of every ten cases.

Despite already-existing WHO-prequalified vaccines, including Merck & Co's – known as MSD outside the US and Canada – Gardasil 9 (HPV 9-valent, recombinant) and GSK's Cervarix (HPV bivalent (types 16, 18) vaccine, recombinant), to prevent HPV infections, there are currently no vaccines that can treat them.

However, new therapeutic vaccines are being developed using the latest immunotherapy advances to clear HPV or treat precancerous cells in people already exposed to the virus.

The WHO Preferred Product Characteristics for Therapeutic HPV Vaccines report calls on developers and outlines how they can ensure that their products meet global public health needs and how to quickly roll out vaccines if approved, while considering medical indications for potential use of such a vaccine, target populations, safety and efficacy criteria, as well as practical considerations such as delivery strategy, storage and dosage schedules, and affordability.

Currently, there are more than 20 therapeutic HPV vaccine candidates that are at different stages of development, with several in clinical trials, that are likely to be most beneficial for adult women who did not receive the HPV vaccination prior to contracting the virus.

In addition, these new potential therapeutic vaccines align with WHO's Cervical Cancer Elimination Initiative, which aims to vaccinate 90% of girls with preventive HPV vaccines, screen 70% of women with a high-performance test and treat 90% of women who have precancerous cells in the cervix or cervical cancer by 2030.

Dr Sami Gottlieb, medical doctor and epidemiologist, department of sexual and reproductive health and research, WHO, commented: "Therapeutic HPV vaccines could be a catalytic innovation to complement these efforts, increasing options for the millions of women who have already acquired HPV and reducing their risks of developing life-threatening cancer in the future."

Fuente: PM Live. Disponible en https://acortar.link/ImweYC

Belarusian Ministry of Health grants registration to Cuban vaccine Cimavax

Jul 12. The Ministry of Health of the Republic of Belarus reports that the Center for Expertise and Testing in Health Care has granted registration to the Cuban vaccine Cimavax, it was learned here today.

Developed by the Cuban Center for Molecular Immunology, it is the world's first officially patented and registered therapeutic vaccine against lung cancer.

The Cuban Ambassador to the Slavic nation, Santiago Pérez, commented that the decision of the regulatory agency of this European country to grant registration to Cimavax is an undeniable achievement of Cuban biotechnology in a country with such high standards and requirements as Belarus.

Pérez recalled that Belarus was the first country on the continent to register the Cuban vaccine Soberana, developed against COVID-19.

The Cuban diplomat said the registration is a sign of progress in bilateral relations, especially in the economic commercial field, which would allow an increase in Cuba's exports.

Likewise, it shows the progress made in cooperation between the scientific communities of the two countries, and perhaps it is the beginning of a more dynamic process of mutual registration of medicines both in Belarus and Cuba, said Perez. (Source: PL)

Fuente: RADIO HABANA CUBA. Disponible en https://acortar.link/zrTt2o

China Proceeds with mRNA RSV Vaccine Candidate

Jul 13. The board of directors of CSPC Pharmaceutical Group Limited announced on July 11, 2024, that the mRNA Respiratory Syncytial Virus (RSV) vaccine candidate (SYS6016) has obtained approval from the National Medical Products Administration of the People's Republic of China to conduct human clinical trials in China.

Currently, there is no vaccine available in China that protects people from RSV infection.

In preclinical studies, SYS6016 translated into the prefusion conformation F-protein in vivo and induced high titers of long-lasting neutralizing antibodies.

CSPC wrote that this vaccine candidate exhibits good protection against RSV-A and RSV-B subtype viral strains and has a good safety profile.

CSPC confirmed it would endeavor to advance the clinical research and market SYS6016 as soon as possible to create value for society and shareholders.

As of July 13, 2024, three RSV vaccines and one monoclonal antibody for infants (Beyfortus) were approved for use in the United States.

Fuente: Precision Vaccinations. Disponible en https://acortar.link/Wi5O3V

Oxford scientists testing two new respiratory vaccines

Jul 14. Scientists at the University of Oxford have launched a new study to test a two-in-one respiratory vaccine.

The phase one study will test a vaccine targeting both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and another for RSV alone in five to eight-month-old infants.

RSV is a common virus affecting children across the globe. Within their first two years, up to 90 per cent of children contract the virus and it frequently reinfects older children and adults.

Although RSV usually causes mild respiratory illness, some infants experience severe bronchiolitis, which leads to the inflammation of the small airways, sometimes causing extreme breathing difficulties.

In the UK, about one in 50 children under the age of one are admitted to hospital as a result of RSV infections.

Closely related to RSV, hMPV is a respiratory pathogen, associated with a range of illnesses from mild infection to severe bronchiolitis and pneumonia.

These potential jabs are being developed by pharmaceutical company Moderna.

Dr Simon Drysdale, consultant in paediatric infectious diseases and immunology at the Oxford Vaccine Group, and principal investigator on the study, said: "RSV and hMPV are two of the leading causes of respiratory infections in children, the elderly and immunocompromised patients worldwide.

"This trial is an important early step in the development of a paediatric vaccine against RSV and hMPV."

The jabs are messenger RNA vaccines. They work by instructing cells in the body to produce a specific protein, triggering an immune response.

This prompts the immune system to remember the protein, enabling a rapid and effective reaction if the individual contracts the actual virus in the future.

The Rhyme study is the first attempt to create a vaccine that could simultaneously protect against RSV and hMPV.

It aims to enrol approximately 60 paediatric participants between five and eight months old across seven UK sites.

Over the course of around 24 months, each participant will receive three injections at 56-day intervals.

The sites participating in the trial are Norfolk and Norwich University Hospitals NHS Foundation Trust, Alder Hey Children's NHS Foundation Trust, Imperial College Healthcare NHS Trust and St George's University Hospitals NHS Foundation Trust.

Also taking part are Oxford University Hospitals NHS Foundation Trust, University Hospital Southampton NHS

Foundation Trust and University Hospitals Bristol and Weston NHS Foundation Trust, with the research being sponsored by Moderna.

The study is supported by the National Institute for Health and Care Research Clinical Research Network Thames Valley and South Midlands.

It has been reviewed and approved by the Health and Social Care Research Ethics Committee.

Fuente: Oxford Mail. Disponible en https://acortar.link/Dlvef6

La vacunación infantil en el mundo se estanca, alerta la ONU

15 jul. Las tasas de vacunación infantil en el mundo se están estancando y aún no han recuperado los niveles previos a la pandemia de COVID-19, alertó la ONU el lunes.

Comparado con el nivel de 2019, 2,7 millones de niños más no fueron vacunados o lo fueron de manera incompleta en 2023, según un comunicado conjunto de UNICEF y la OMS.

"Las últimas tendencias demuestran que muchos países continúan desatendiendo demasiados niños", lamentó la directora ejecutiva de UNICEF, Catherine Russell.

En 2023 solo 84 % de los niños, es decir 108 millones, recibieron tres dosis de la vacuna contra la difteria, el tétanos y la tos ferina (DTAP), siendo la tercera dosis un indicador clave de la cobertura global de vacunación, según datos publicados por las agencias de salud y de infancia de la ONU.

Este porcentaje no cambió desde el año pasado, lo que significa que los modestos avances observados en 2022, después de la fuerte caída debido a la COVID-19, se detuvieron, señalan las organizaciones.

Esta tasa era del 86 % en 2019, antes de la pandemia.

"Estamos retrasados", admitió ante la prensa Kate O'Brien, responsable de vacunación en la OMS.

En 2023, 14,5 millones de niños en el mundo eran considerados "cero dosis", es decir, no habían recibido ninguna dosis de vacuna, una cifra en aumento desde los 13,9 millones en 2022 y los 12,8 millones en 2019, según los datos publicados el lunes.

La mitad de los niños no vacunados en el mundo viven en 31 países afectados por conflictos.

6,5 millones de niños en el mundo no recibieron su tercera dosis de la vacuna DTAP, necesaria para asegurar la protección contra enfermedades en lactantes y niños pequeños.

Estas disparidades en la cobertura de vacunación favorecen el desarrollo de ciertas enfermedades como el sarampión.

"Los brotes de sarampión son una señal de advertencia, que revelan lagunas existentes en la vacunación y golpean a los más vulnerables", declaró el director general de la OMS, Tedros Adhanom Ghebreyesus, en el comunicado.

En 2023, 83 % de los niños en el mundo recibieron su primera dosis de la vacuna contra el sarampión a

través de los servicios de salud básicos, el mismo nivel que en 2022, pero aún por debajo del 86 % antes de la pandemia.

Más de 300.000 casos de sarampión fueron registrados en 2023, casi tres veces más que el año anterior, destacó Ephrem Lemango, responsable de vacunación en UNICEF.

Al menos 103 países experimentaron brotes en los últimos cinco años.

En cambio, 91 países con una sólida cobertura de vacunación contra el sarampión no registraron brote alguno.

Fuente: FRANCE 24. Disponible en https://acortar.link/7wmibN

Ministry of Health and Wellness receives 50,000 doses of Pediatric Pneumococcal Vaccine (PCV) Vaccine from Brazil

Jul 16. On July 15, 2024, the Belizean Ministry of Health & Wellness received 50,000 doses of the Pediatric Pneumococcal Vaccine (PCV) donated by the Government of Brazil. The PCV vaccine will prevent pneumonia, meningitis and other complications caused by pneumococcal disease in children under five years of age.

The Ministry noted that Vaccinated children will benefit from less hospital visits and less hospital stay (Hospitalization); their growth and development will not be compromised due to pneumococcal infection.

The Ministry of Health & Wellness extended gratitude and appreciation to the Government and Ambassador of Brazil for the donation of the Pneumococcal Pediatric Vaccine, and encourages parents to get their children five years and under vaccinated. The vaccine is available at all public health facilities and mobile clinics.

Fuente: Breaking Belize News BBN. Disponible en https://acortar.link/K0ey9L

VACCIMONITOR

VacciMonitor es una revista dedicada a la vacunología y temas afines como Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Validación, Aspectos regulatorios, entre otros. Arbitrada, de acceso abierto y bajo la Licencia *Creative Commons* está indexada en:

EBSCO Information Services · Scopus · DOAJ Directory of Open Access Journals · SciELO · redalyc.org · FreeMedical Journals · HINARI Research in Health · latindex Sistema Regional de Información en Línea para Revistas Científicas de América Latina, el Caribe, España y Portugal · SeCiMed

Síganos en redes sociales

@vaccimonitor

@finlayediciones

@finlayediciones

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2024/07/01"[Date - Publication] : "2024/07/16"[Date - Publication])) 781 records.

Opioid vaccine clinical testing: lessons learned.
Luba R, Comer SD.Curr Opin Psychiatry. 2024 Jul 1;37(4):264-269. doi: 10.1097/YCO.0000000000000945. Epub 2024 May 1.PMID: 38726813

Inborn Errors of Immunity.
Baloh CH, Chong H.Med Clin North Am. 2024 Jul;108(4):703-718. doi: 10.1016/j.mcna.2023.08.006.PMID: 38816112

cGAS-STING pathway agonists are promising vaccine adjuvants.
Tian X, Ai J, Tian X, Wei X.Med Res Rev. 2024 Jul;44(4):1768-1799. doi: 10.1002/med.22016. Epub 2024 Feb 7.PMID: 38323921

Breaking Down Barriers in Vaccine Coverage.
Maves RC, Gaglani B.Chest. 2024 Jul;166(1):5-6. doi: 10.1016/j.chest.2024.03.020.PMID: 38986642

Exploring future perspectives and pipeline progression in vaccine research and development.
Vecchio R, Gentile L, Tafuri S, Costantino C, Odone A.Ann Ig. 2024 Jul-Aug;36(4):446-461. doi: 10.7416/ai.2024.2614. Epub 2024 Mar 1.PMID: 38436081

Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis.
Wang B, Mohammed H, Andraweera P, McMillan M, Marshall H.J Infect. 2024 Jul 8;89(3):106225. doi: 10.1016/j.jinf.2024.106225. Online ahead of print.PMID: 38986746

A comprehensive comparison of DNA and RNA vaccines.
Wang C, Yuan F.Adv Drug Deliv Rev. 2024 Jul;210:115340. doi: 10.1016/j.addr.2024.115340. Epub 2024 May 27.PMID: 38810703

Nanosafety: a Perspective on Nano-Bio Interactions.
Fadeel B, Keller AA.Small. 2024 Jul;20(28):e2310540. doi: 10.1002/smll.202310540. Epub 2024 Apr 10.PMID: 38597766

The biology and pathogenesis of vivax malaria.
Anstey NM, Tham WH, Shanks GD, Poespoprodjo JR, Russell BM, Kho S.Trends Parasitol. 2024 Jul;40(7):573-590. doi: 10.1016/j.pt.2024.04.015. Epub 2024 May 15.PMID: 38749866

Alopecia areata following COVID-19 vaccine: a systematic review.
Zhu Y, Ouyang X, Zhang D, Wang X, Wu L, Yu S, Tan Y, Li W, Li C.Eur J Med Res. 2024 Jul 5;29(1):356. doi: 10.1186/s40001-024-01956-8.PMID: 38970130

Faith and vaccination: a scoping review of the relationships between religious beliefs and vaccine hesitancy.
Tiwana MH, Smith J.BMC Public Health. 2024 Jul 6;24(1):1806. doi: 10.1186/s12889-024-18873-4.PMID: 38971784

Rationing, Responsibility, and Vaccination during COVID-19: A Conceptual Map.
Park JK, Davies B.Am J Bioeth. 2024 Jul;24(7):66-79. doi: 10.1080/15265161.2023.2201188. Epub 2023 Apr 27.PMID: 37104661

Funding Postauthorization Vaccine-Safety Science.
Salmon DA, Orenstein WA, Plotkin SA, Chen RT.N Engl J Med. 2024 Jul 11;391(2):102-105. doi: 10.1056/NEJMp2402379. Epub 2024 Jul 6.PMID: 38973739

Implications of subclinical tuberculosis for vaccine trial design and global effect.
Churchyard GJ, Houben RMGJ, Fielding K, Fiore-Gartland AL, Esmail H, Grant AD, Rangaka MX, Behr M, Garcia-Basteiro AL, Wong EB, Hatherill M, Mave V, Dagnew AF, Schmidt AC, Hanekom WA, Cobelens F, White RG.Lancet Microbe. 2024 Jul 1:S2666-5247(24)00127-7. doi: 10.1016/S2666-5247(24)00127-7. Online ahead of print.PMID: 38964359

A systematic review of interventions to promote human papillomavirus (HPV) vaccination in Africa.
Olaoye O, Macdonald S.Public Health. 2024 Jul 1;234:47-57. doi: 10.1016/j.puhe.2024.05.015. Online ahead of print.PMID: 38954882

Establishment of human post-vaccination SARS-CoV-2 standard reference sera.
Xiang J, Katz L, Winokur PL, Chaudhary A, Digmann B, Bradford R, Rashid S, Ghosh S, Robertson A, Menetski J, Xu M, Gao P, Chen CZ, Lee T, Poelaert B, Eastman RT, Hall MD, Stapleton JT.J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.PMID: 38823574

Cardiovascular Safety of the COVID-19 Vaccine in Team USA Athletes.
Shah AB, Rizzo SM, Finnoff JT, Baggish AL, Adams WM.Sports Health. 2024 Jul-Aug;16(4):504-506. doi: 10.1177/19417381231208677. Epub 2023 Nov 9.PMID: 37946492

Association between COVID-19 vaccination and menstruation: a state of the science review.
Payne LA, Wise LA, Wesselink AK, Wang S, Missmer SA, Edelman A.BMJ Sex Reprod Health. 2024 Jul 12;50(3):212-225. doi: 10.1136/bmjsrh-2024-202274.PMID: 38857991

Priming antibody responses to the fusion peptide in rhesus macaques.
Cottrell CA, Pratap PP, Cirelli KM, Carnathan DG, Enemuo CA, Antanasijevic A, Ozorowski G, Sewall LM, Gao H, Allen JD, Nogal B, Silva M, Bhiman J, Pauthner M, Irvine DJ, Montefiori D, Crispin M, Burton DR, Silvestri G, Crotty S, Ward AB.NPJ Vaccines. 2024 Jul 12;9(1):126. doi: 10.1038/s41541-024-00918-9.PMID: 38997302

Preventing herpes zoster in immunocompromised patients: Current concepts.
Calabrese C, Kirchner E, Fernandez J, Calabrese LH.Cleve Clin J Med. 2024 Jul 1;91(7):437-445. doi: 10.3949/ccjm.91a.24019.PMID: 38950984

Genetic diversity and natural selection analysis of VAR2CSA and vir genes: implication for vaccine development.
Hawadak J, Arya A, Chaudhry S, Singh V.Genomics Inform. 2024 Jul 15;22(1):11. doi: 10.1186/s44342-024-00009-0.PMID: 39010183

Psychosocial dimensions of vaccine hesitancy: A systematic review.
Rizzo M, Gattino S, Trombetta T, Calandri E, De Piccoli N.J Community Psychol. 2024 Jul 10. doi: 10.1002/jcop.23133. Online ahead of print.PMID: 38988066

The changing landscape of infections in the lung transplant recipient.
Lum J, Koval C.Curr Opin Pulm Med. 2024 Jul 1;30(4):382-390. doi: 10.1097/MCP.0000000000001060. Epub 2024 Feb 26.PMID: 38411211

Prevention and treatment of HPV-related cancer through a mRNA vaccine expressing APC-targeting antigen.
Li X, Wang H, Lai W, Liao J, Mo W, Huang K, He L, Liang X, Yu Z, Xu J, Hua X, Hou F, Ding J, Jia WW, Zhang K, Wang Y.Immunology. 2024 Jul;172(3):375-391. doi: 10.1111/imm.13777. Epub 2024 Mar 12.PMID: 38471664

Is HIV epidemic control by 2030 realistic?
Beyrer C, Tomaras GD, Gelderblom HC, Gray GE, Janes HE, Bekker LG, Millett G, Pantaleo G, Buchbinder S, Corey L.Lancet HIV. 2024 Jul;11(7):e489-e494. doi: 10.1016/S2352-3018(24)00098-5.PMID: 38925732

Reflections on The Advisory Committee on Immunization Practices during the COVID-19 Pandemic.
Poehling KA, Lee GM.Acad Pediatr. 2024 Jul 5:S1876-2859(24)00239-0. doi: 10.1016/j.acap.2024.06.019. Online ahead of print.PMID: 38972350

Enteroviruses: epidemic potential, challenges and opportunities with vaccines.
Jartti M, Flodström-Tullberg M, Hankaniemi MM.J Biomed Sci. 2024 Jul 15;31(1):73. doi: 10.1186/s12929-024-01058-x.PMID: 39010093

Fruit and Vegetable Consumption, Food Acquisition Behavior, and Food Insecurity Before and After the COVID-19 Vaccine Rollout.
Hosler AS, Chen J, Arroyo MT, Neff RA, Bozlak CT, Romeiko XX, Feingold BJ.J Public Health Manag Pract. 2024 Jul-Aug 01;30(4):550-557. doi: 10.1097/PHH.0000000000001946. Epub 2024 Jun 12.PMID: 38870372

Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and Beagle dogs.
Park SJ, Park H, Back SM, Lee YJ, Seo JW, Kim D, Lee JH, Kwak C, Han KH, Son HY, Kim YB.Arch Toxicol. 2024 Jul;98(7):2185-2197. doi: 10.1007/s00204-024-03746-x. Epub 2024 Apr 12.PMID: 38607375

Dynamics of measles immunity from birth and following vaccination.
Wang W, O'Driscoll M, Wang Q, Zhao S, Salje H, Yu H.Nat Microbiol. 2024 Jul;9(7):1676-1685. doi: 10.1038/s41564-024-01694-x. Epub 2024 May 13.PMID: 38740931

Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
Kafadar AH, Sabatini S, Jones KA, Dening T.Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.06.059. Online ahead of print.PMID: 38960789

Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine.
Klein NP, Wiesner A, Bautista O, Group T, Kanu K, Li ZL, McCauley J, Saxena K, Tota J, Luxembourg A, Bonawitz R.Pediatrics. 2024 Jul 9:e2023064693. doi: 10.1542/peds.2023-064693. Online ahead of print.PMID: 38978512

Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.
Limaye RJ, Fesshaye B, Singh P, Jalang'o R, Njogu RN, Miller E, Schue J, Sauer M, Lee C, Karron RA.Health Policy Plan. 2024 Jul 2:czae059. doi: 10.1093/heapol/czae059. Online ahead of print.PMID: 38955674

Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1.
Xu J, Zhou T, McKee K, Zhang B, Liu C, Nazzari AF, Pegu A, Shen CH, Becker JE, Bender MF, Chan P, Changela A, Chaudhary R, Chen X, Einav T, Kwon YD, Lin BC, Louder MK, Merriam JS, Morano NC, O'Dell S, Olia AS, Rawi R, Roark RS, Stephens T, Teng IT, Tourtellott-Fogt E, Wang S, Yang ES, Shapiro L, Tsybovsky Y, Doria-Rose NA, Casellas R, Kwong PD.Adv Sci (Weinh). 2024 Jul;11(26):e2309268. doi: 10.1002/advs.202309268. Epub 2024 May 5.PMID: 38704686

Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs.
Song H, Waheed Abdullah S, Yin S, Dong H, Zhang Y, Tan S, Bai M, Ding Y, Teng Z, Sun S, Guo H.Vaccine. 2024 Jul 11;42(18):3789-3801. doi: 10.1016/j.vaccine.2024.04.092. Epub 2024 May 6.PMID: 38714448

4CMenB journey to the 10-year anniversary and beyond.
Abitbol V, Martinón-Torres F, Taha MK, Nolan T, Muzzi A, Bambini S, Borrow R, Toneatto D, Serino L, Rappuoli R, Pizza M.Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8.PMID: 38976659

FDA approves mRNA-based RSV vaccine.
Mullard A.Nat Rev Drug Discov. 2024 Jul;23(7):487. doi: 10.1038/d41573-024-00095-3.PMID: 38849520

Human papillomavirus (HPV) vaccination in Japan.
Miyagi E.J Obstet Gynaecol Res. 2024 Jul 9. doi: 10.1111/jog.16020. Online ahead of print.PMID: 38979785

Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.
Chen L, Ren W, Lei H, Wang J, Que H, Wan D, Alu A, Peng D, Fu M, Hong W, Huang Y, Song X, Lu G, Wei X.Genes Dis. 2023 Aug 3;11(4):101066. doi: 10.1016/j.gendis.2023.06.035. eCollection 2024 Jul.PMID: 38550714

A prognostic insight of the mRNA vaccine against antibiotic-resistant bacteria.
Abusalah MAH, Choudhary P, Bargui H, Ahmed N, Abusalah MAH, Choudhary OP.Ann Med Surg (Lond). 2024 Apr 10;86(7):3801-3805. doi: 10.1097/MS9.0000000000001970. eCollection 2024 Jul.PMID: 38989193

Advances in understanding immune homeostasis in latent tuberculosis infection.
Niu L, Wang H, Luo G, Zhou J, Hu Z, Yan B.WIREs Mech Dis. 2024 Jul-Aug;16(4):e1643. doi: 10.1002/wsbm.1643. Epub 2024 Feb 13.PMID: 38351551

Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review.
Suares JE, Khan S, Aadrika A, Poojari PG, Rashid M, Thunga G.Expert Opin Drug Saf. 2024 Jul;23(7):855-867. doi: 10.1080/14740338.2024.2359616. Epub 2024 May 30.PMID: 38813942

The impact of regional disparities on the availability of meningococcal vaccines in the US.
Schley K, Jodar E, Presa JV, Willis SJ, Prener CG.BMC Public Health. 2024 Jul 3;24(1):1771. doi: 10.1186/s12889-024-19081-w.PMID: 38961431

Momentum of hope: The journey toward a universal TB vaccine.
Gulumbe BH, Shehu A.Trop Doct. 2024 Jul;54(3):233-234. doi: 10.1177/00494755241244833. Epub 2024 Apr 2.PMID: 38562088

Policies and cultural beliefs: Community perceptions about COVID-19 vaccine hesitancy in Indonesia.
Efendi F, Dewi YS, Arifin H, Hargono A, Apriyanto Y, Adnani QES, Gouda ADK, Susanti IA.Public Health Nurs. 2024 Jul-Aug;41(4):736-744. doi: 10.1111/phn.13318. Epub 2024 Apr 13.PMID: 38613243

Nonclinical safety and immunogenicity assessment of a combined DTacP vaccine in animal models.
Li S, Fu H, Yu S, Zhao Y, Liu T, Wang L, Zhang N, Wang W, Yang B, He P, Guo Y, Qiu S, Zhang Y.J Appl Toxicol. 2024 Jul 8. doi: 10.1002/jat.4668. Online ahead of print.PMID: 38977376

Top 100 cited research on COVID-19 vaccines: A bibliometric analysis and evidence mapping.
Yu L, Xu C, Zhang M, Zhou Y, Hu Z, Li L, Li Y, Tian J, Xu M.Hum Vaccin Immunother. 2024 Dec 31;20(1):2370605. doi: 10.1080/21645515.2024.2370605. Epub 2024 Jul 8.PMID: 38977415

Vaccine Politics.
Hughes R 4th.Health Aff (Millwood). 2024 Jul;43(7):1047-1051. doi: 10.1377/hlthaff.2024.00636.PMID: 38950295

How to and should we target EBV in MS?
Eckert S, Jakimovski D, Zivadinov R, Hicar M, Weinstock-Guttman B.Expert Rev Clin Immunol. 2024 Jul;20(7):703-714. doi: 10.1080/1744666X.2024.2328739. Epub 2024 Mar 15.PMID: 38477887

Next-Generation Vaccine Development with Nanomaterials: Recent Advances, Possibilities, and Challenges.
Shetty S, Alvarado PC, Pettie D, Collier JH.Annu Rev Biomed Eng. 2024 Jul;26(1):273-306. doi: 10.1146/annurev-bioeng-110122-124359.PMID: 38959389

Influenza Vaccine - Low-Hanging Fruit for Prevention of Myocardial Infarction.
MacIntyre CR, Akhtar Z, Moa A.NEJM Evid. 2024 Jul;3(7):EVIDe2400178. doi: 10.1056/EVIDe2400178. Epub 2024 Jun 25.PMID: 38916419

CD38 and extracellular NAD(+) regulate the development and maintenance of Hp vaccine-induced CD4(+) T(RM) in the gastric epithelium.
Tong J, Chen S, Gu X, Zhang X, Wei F, Xing Y.Mucosal Immunol. 2024 Jul 1:S1933-0219(24)00065-5. doi: 10.1016/j.mucimm.2024.06.011. Online ahead of print.PMID: 38960319

Nigeria leads pentavalent meningitis vaccine rollout.
Boisson-Walsh A.Lancet Infect Dis. 2024 Jul;24(7):e421. doi: 10.1016/S1473-3099(24)00366-9.PMID: 38908384

Chronic urticaria following COVID-19 mRNA vaccines.
Özdemir Ö.JAAD Case Rep. 2024 May 7;49:77-78. doi: 10.1016/j.jdcr.2024.04.041. eCollection 2024 Jul.PMID: 38883179

Immunoinformatics and structural aided approach to develop multi-epitope based subunit vaccine against Mycobacterium tuberculosis.
Sethi G, Varghese RP, Lakra AK, Nayak SS, Krishna R, Hwang JH.Sci Rep. 2024 Jul 10;14(1):15923. doi: 10.1038/s41598-024-66858-5.PMID: 38987613

Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination.
Gravenstein S, DeVone F, Oyebanji OA, Abul Y, Cao Y, Chan PA, Halladay CW, Rudolph JL, Nugent C, Bosch J, King CL, Wilson BM, Balazs AB, White EM, Canaday DH, McConeghy KW.EBioMedicine. 2024 Jul;105:105180. doi: 10.1016/j.ebiom.2024.105180. Epub 2024 Jun 10.PMID: 38861869

COVID-19 Vaccine Side Effects and Long-Term Neutralizing Antibody Response : A Prospective Cohort Study.
Dutcher EG, Epel ES, Mason AE, Hecht FM, Robinson JE, Drury SS, Prather AA.Ann Intern Med. 2024 Jul;177(7):892-900. doi: 10.7326/M23-2956. Epub 2024 Jun 11.PMID: 38857503

Vaccine Therapy for Heart Failure Targeting the Inflammatory Cytokine Igfbp7.
Katoh M, Nomura S, Yamada S, Ito M, Hayashi H, Katagiri M, Heryed T, Fujiwara T, Takeda N, Nishida M, Sugaya M, Kato M, Osawa T, Abe H, Sakurai Y, Ko T, Fujita K, Zhang B, Hatsuse S, Yamada T, Inoue S, Dai Z, Kubota M, Sawami K, Ono M, Morita H, Kubota Y, Mizuno S, Takahashi S, Nakanishi M, Ushiku T, Nakagami H, Aburatani H, Komuro I.Circulation. 2024 Jul 11. doi: 10.1161/CIRCULATIONAHA.123.064719. Online ahead of print.PMID: 38991046

Biomarkers associated with vaccine-associated enhanced respiratory disease following influenza A virus infection in swine.
Wymore Brand M, Souza CK, Gauger P, Arruda B, Vincent Baker AL.Vet Immunol Immunopathol. 2024 Jul;273:110787. doi: 10.1016/j.vetimm.2024.110787. Epub 2024 May 23.PMID: 38815504

COVID-19 Vaccine Hesitancy Among People Living with HIV: A Systematic Review and Meta-Analysis.
Liu X, Wu Y, Huo Z, Zhang L, Jing S, Dai Z, Huang Y, Si M, Xin Y, Qu Y, Tang S, Su X.AIDS Behav. 2024 Jul;28(7):2183-2192. doi: 10.1007/s10461-024-04344-9. Epub 2024 Apr 16.PMID: 38625625

A Historical Perspective on Respiratory Syncytial Virus Prevention: A Journey Spanning Over Half a Century From the Setback of an Inactive Vaccine Candidate to the Success of Passive Immunization Strategy.
Noor A, Krilov LR.J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S103-S109. doi: 10.1093/jpids/piae027.PMID: 38577737

Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
Källmark H, Bergström T, Nagel J, Gullstrand B, Einarsson JT, Bengtsson AA, Kapetanovic MC.Rheumatology (Oxford). 2024 Jul 1;63(7):2024-2033. doi: 10.1093/rheumatology/kead552.PMID: 37851412

Proteomic analysis of Neobenedenia sp. and Rhabdosynochus viridisi (Monogenea, Monopisthocotylea): Insights into potential vaccine targets and diagnostic markers for finfish aquaculture.
Caña-Bozada VH, Huerta-Ocampo JÁ, Bojórquez-Velázquez E, Elizalde-Contreras JM, May ER, Morales-Serna FN.Vet Parasitol. 2024 Jul;329:110196. doi: 10.1016/j.vetpar.2024.110196. Epub 2024 May 10.PMID: 38763120

Mucoadhesive film for oral delivery of vaccines for protection of the respiratory tract.
Esih H, Mezgec K, Billmeier M, Malenšek Š, Benčina M, Grilc B, Vidmar S, Gašperlin M, Bele M, Zidarn M, Zupanc TL, Morgan T, Jordan I, Sandig V, Schrödel S, Thirion C, Protzer U, Wagner R, Lainšček D, Jerala R.J Control Release. 2024 Jul;371:179-192. doi: 10.1016/j.jconrel.2024.05.041. Epub 2024 May 29.PMID: 38795814

Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
Chime N, Anspach B, Jain V, Laajalahti O, Ollinger T, Yaplee D, Kim JH.J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093/infdis/jiae342. Online ahead of print.PMID: 38970327

Nonadjuvanted Bivalent Respiratory Syncytial Virus Vaccination and Perinatal Outcomes.
Son M, Riley LE, Staniczenko AP, Cron J, Yen S, Thomas C, Sholle E, Osborne LM, Lipkind HS.JAMA Netw Open. 2024 Jul 1;7(7):e2419268. doi: 10.1001/jamanetworkopen.2024.19268.PMID: 38976271

Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
Toreli ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, Miranda E, Fechio L, Silva Santos Duarte A, Basso A, Duarte G, Souza Medina S, Pericole F, Benites B, Jones K, Singh H, Farmaha J, Vashisht A, Kolhe R, Mondal AK, Saad STO, de Souza CA, Cortes JE, Pagnano K.Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057. Online ahead of print.PMID: 38967518

Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies.
Wang J, Wang Q, Ma L, Lv K, Han L, Chen Y, Zhou R, Zhou H, Chen H, Wang Y, Zhang T, Yi D, Liu Q, Zhang Y, Li X, Cheng T, Zhang J, Huang C, Dong Y, Zhang W, Cen S.Mol Ther. 2024 Jul 3;32(7):2340-2356. doi: 10.1016/j.ymthe.2024.04.036. Epub 2024 May 6.PMID: 38715363

Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults.
Boyce TG, Levine MZ, McClure DL, King JP, Flannery B, Nguyen HQ, Belongia EA.Hum Vaccin Immunother. 2024 Dec 31;20(1):2370087. doi: 10.1080/21645515.2024.2370087. Epub 2024 Jul 9.PMID: 38982712

Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers.
Demidova A, Douguet L, Fert I, Wei Y, Charneau P, Majlessi L.Expert Rev Vaccines. 2024 Jul 8. doi: 10.1080/14760584.2024.2374287. Online ahead of print.PMID: 38978164

Predicting Efficacies of Fractional Doses of Vaccines by Using Neutralizing Antibody Levels: Systematic Review and Meta-Analysis.
Du Z, Liu C, Bai Y, Wang L, Lim WW, Lau EHY, Cowling BJ.JMIR Public Health Surveill. 2024 Jul 12;10:e49812. doi: 10.2196/49812.PMID: 39012087

Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
Agarwal S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, Kumar Panda A, Meena J.Vaccine. 2024 Jul 11;42(18):3899-3915. doi: 10.1016/j.vaccine.2024.04.082. Epub 2024 May 7.PMID: 38719691

Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.
Litt J, Cunningham AL, Arnalich-Montiel F, Parikh R.Infect Dis Ther. 2024 Jul;13(7):1439-1459. doi: 10.1007/s40121-024-00990-7. Epub 2024 Jun 4.PMID: 38834857

Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
Kim DH, Lee SH, Kim J, Lee J, Jeong JH, Kim JY, Song SU, Lee H, Cho AY, Hyeon JY, Youk S, Song CS.Vaccine. 2024 Jul 11;42(18):3756-3767. doi: 10.1016/j.vaccine.2024.04.088. Epub 2024 May 9.PMID: 38724417

Safety and immunogenicity of an adjuvanted recombinant spike protein-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, SpikeVet, in selected Carnivora, Primates and Artiodactyla in Australian zoos.
McLelland DJ, Lynch M, Vogelnest L, Eden P, Wallace A, Weller J, Young S, Vaughan-Higgins R, Antipov A, Honda-Okubo Y, Petrovsky N.J Vet Pharmacol Ther. 2024 Jul;47(4):308-321. doi: 10.1111/jvp.13429. Epub 2024 Feb 12.PMID: 38345094

Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
Slamanig S, González-Domínguez I, Chang LA, Lemus N, Lai TY, Martínez JL, Singh G, Dolange V, Abdeljawad A, Kowdle S, Noureddine M, Warang P, Singh G, Lee B, García-Sastre A, Krammer F, Schotsaert M, Palese P, Sun W.EBioMedicine. 2024 Jul;105:105185. doi: 10.1016/j.ebiom.2024.105185. Epub 2024 Jun 7.PMID: 38848648

Vaccination homophily in ego contact networks during the COVID-19 pandemic.
Stefkovics Á, Albert F, Ligeti AS, Dávid B, Rudas S, Koltai J.Sci Rep. 2024 Jul 5;14(1):15515. doi: 10.1038/s41598-024-65986-2.PMID: 38969667

Immunogenicity and vaccine potential of clinical isolate Mycobacterium kansasii strain against Mycobacterium tuberculosis infection.
Kim H, Shin SJ.Microbiol Spectr. 2024 Jul 9:e0081924. doi: 10.1128/spectrum.00819-24. Online ahead of print.PMID: 38980025

Integrating pan-genome and reverse vaccinology to design multi-epitope vaccine against Herpes simplex virus type-1.
Roy A, Swetha RG, Basu S, Biswas R, Ramaiah S, Anbarasu A.3 Biotech. 2024 Jul;14(7):176. doi: 10.1007/s13205-024-04022-6. Epub 2024 Jun 5.PMID: 38855144

Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies.
Al-Zayadi FQJ, Shakir AS, Kareem AS, Ghasemian A, Behmard E.BMC Biotechnol. 2024 Jul 5;24(1):45. doi: 10.1186/s12896-024-00873-2.PMID: 38970027

Complex vaccination strategies prevent the emergence of vaccine resistance.
Rella SA, Kulikova YA, Minnegalieva AR, Kondrashov FA.Evolution. 2024 Jul 11:qpae106. doi: 10.1093/evolut/qpae106. Online ahead of print.PMID: 38990788

Mortality risk information and health-seeking behavior during an epidemic.
Purcell H, Kohler IV, Ciancio A, Mwera J, Delavande A, Mwapasa V, Kohler HP.Proc Natl Acad Sci U S A. 2024 Jul 9;121(28):e2315677121. doi: 10.1073/pnas.2315677121. Epub 2024 Jul 3.PMID: 38959039

Impact of COVID-19 Vaccine Persuasion Strategies on Social Endorsement and Public Response on Chinese Social Media.
Ji J, Hu T, Chen M.Health Commun. 2024 Jul 7:1-12. doi: 10.1080/10410236.2024.2375478. Online ahead of print.PMID: 38973185

The COVID-19 Vaccine Gamble-By luck they worked in the oldest, frailest people.
Soiza RL, Niven M.Rev Esp Geriatr Gerontol. 2024 Jul-Aug;59(4):101427. doi: 10.1016/j.regg.2023.101427. Epub 2024 Feb 24.PMID: 38402747

Preparation and immunological activity evaluation of an intranasal protein subunit vaccine against ancestral and mutant SARS-CoV-2 with curdlan sulfate/O-linked quaternized chitosan nanoparticles as carrier and adjuvant.
Chen Y, Wang Y, Li Z, Jiang H, Pan W, Liu M, Jiang W, Zhang X, Wang F.Int J Biol Macromol. 2024 Jul 11:133733. doi: 10.1016/j.ijbiomac.2024.133733. Online ahead of print.PMID: 39002905

Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice.
Wang Y, Li Q, Peng P, Zhang Q, Huang Y, Hu J, Hu Z, Liu X.Vet Microbiol. 2024 Jul;294:110108. doi: 10.1016/j.vetmic.2024.110108. Epub 2024 May 9.PMID: 38729093

Epidemiological and bacterial profile of childhood meningitis in Tunisia.

Dhraief S, Meftah K, Mhimdi S, Khiari H, Aloui F, Borgi A, Haddad-Boubaker S, Brik A, Menif K, Kechrid A, Bouafsoun A, Smaoui H.Acta Microbiol Immunol Hung. 2024 May 21;71(2):148-154. doi: 10.1556/030.2024.02208. Print 2024 Jul 2.PMID: 38771654

TRP-2 / gp100 DNA vaccine and PD-1 checkpoint blockade combination for the treatment of intracranial tumors.
Pearson JRD, Puig-Saenz C, Thomas JE, Hardowar LD, Ahmad M, Wainwright LC, McVicar AM, Brentville VA, Tinsley CJ, Pockley AG, Durrant LG, McArdle SEB.Cancer Immunol Immunother. 2024 Jul 2;73(9):178. doi: 10.1007/s00262-024-03770-x.PMID: 38954031

A new era in meningitis prevention: implications of Nigeria's 5-in-1 vaccine rollout.
Anand A, Verma A, Woldehana NA, Satapathy P, Sharma RK, Sharma D, Arora M, Khatib MN, Gaidhane S, Zahiruddin QS, Rustagi S.Ann Med Surg (Lond). 2024 May 20;86(7):3820-3821. doi: 10.1097/MS9.0000000000002199. eCollection 2024 Jul.PMID: 38989189

Oral health care practitioners as vaccine administrators: The scenario in the United States.
Villa A, Saremi M, Klausner JD, Murphy ME.J Am Dent Assoc. 2024 Jul;155(7):556-558.e1. doi: 10.1016/j.adaj.2023.08.006. Epub 2023 Sep 15.PMID: 37715780

Oral health care practitioners as vaccine administrators: The scenario in the United States.
Villa A, Saremi M, Klausner JD, Murphy ME.J Am Dent Assoc. 2024 Jul;155(7):556-558.e1. doi: 10.1016/j.adaj.2023.08.006. Epub 2023 Sep 15.PMID: 37715780

Structural proteomics guided annotation of vaccine targets and designing of multi-epitopes vaccine to instigate adaptive immune response against Francisella tularensis.
Khan A, Ali SS, Khan A, Zahid MA, Alshabrmi FM, Waheed Y, Agouni A.Microb Pathog. 2024 Jul 11:106777. doi: 10.1016/j.micpath.2024.106777. Online ahead of print.PMID: 39002657

Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.
Eiden J, Fierro C, White A, Davis M, Rhee M, Turner M, Murray B, Herber R, Aitchison R, Marshall D, Moser MJ, Belshe R, Greenberg H, Coelingh K, Kawaoka Y, Neumann G, Bilsel P.Lancet Infect Dis. 2024 Jul 11:S1473-3099(24)00351-7. doi: 10.1016/S1473-3099(24)00351-7. Online ahead of print.PMID: 39004096

The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus.
Tregoning JS.Mol Ther. 2024 Jul 3:S1525-0016(24)00414-3. doi: 10.1016/j.ymthe.2024.06.031. Online ahead of print.PMID: 38964331

The whole genome sequence of Polish vaccine strain Mycobacterium bovis BCG Moreau.
Krysztopa-Grzybowska K, Lach J, Polak M, Strapagiel D, Dziadek J, Olszewski M, Zasada AA, Darlińska A, Lutyńska A, Augustynowicz-Kopeć E.Microbiol Spectr. 2024 Jul 2;12(7):e0425923. doi: 10.1128/spectrum.04259-23. Epub 2024 May 17.PMID: 38757975

Immunogenic Material Vaccine for Cancer Immunotherapy by Structure-Dependent Immune Cell Trafficking and Modulation.

Yang W, Cao J, Di S, Chen W, Cheng H, Ren H, Xie Y, Chen L, Yu M, Chen Y, Cui X.Adv Mater. 2024 Jul;36(27):e2402580. doi: 10.1002/adma.202402580. Epub 2024 Apr 24.PMID: 38630978

An mRNA vaccine for pancreatic cancer designed by applying in silico immunoinformatics and reverse vaccinology approaches.
Masum MHU, Wajed S, Hossain MI, Moumi NR, Talukder A, Rahman MM.PLoS One. 2024 Jul 8;19(7):e0305413. doi: 10.1371/journal.pone.0305413. eCollection 2024.PMID: 38976715

Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.
Muñoz-Gómez MJ, Ryan P, Quero-Delgado M, Martin-Vicente M, Cuevas G, Valencia J, Jiménez E, Blanca-López N, Lara-Álvarez MÁ, Hernández-Rivas JÁ, Redondo G, Mas V, Sepúlveda-Crespo D, Vázquez M, Torres-Macho J, Martínez I, Resino S.J Infect Public Health. 2024 Jul;17(7):102473. doi: 10.1016/j.jiph.2024.102473. Epub 2024 Jun 7.PMID: 38865774

A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in mice.
Li H, Li Q, Hao Z, Zhang L, Zheng X, Zhu L, Huo Y, Tian H, He L, Hao Z.Vaccine. 2024 Jul 11;42(18):3774-3788. doi: 10.1016/j.vaccine.2024.04.091. Epub 2024 May 6.PMID: 38714443

Human Papillomavirus Vaccination by Birth Fiscal Year in Japan.
Yagi A, Ueda Y, Oka E, Nakagawa S, Kimura T.JAMA Netw Open. 2024 Jul 1;7(7):e2422513. doi: 10.1001/jamanetworkopen.2024.22513.PMID: 39012629

Demographic changes in COVID-19 mortality during the pandemic: analysis of trends in disparities among workers using California's mortality surveillance system.
Gebreegziabher E, Bui D, Cummings KJ, Frederick M, Nguyen A, Collins C, Melton D, Yang A, Jain S, Vergara X.BMC Public Health. 2024 Jul 9;24(1):1822. doi: 10.1186/s12889-024-19257-4.PMID: 38977988

The mRNA vaccine platform for veterinary species.
Fazel F, Doost JS, Raj S, Boodhoo N, Karimi K, Sharif S.Vet Immunol Immunopathol. 2024 Jul 4;274:110803. doi: 10.1016/j.vetimm.2024.110803. Online ahead of print.PMID: 39003921

Exploring meningococcal serogroup B vaccination conversations under shared clinical decision-making in the US.
Herrera-Restrepo O, Clements DE, Hebert ZN, McCracken C.Curr Med Res Opin. 2024 Jul;40(7):1253-1263. doi: 10.1080/03007995.2024.2362924. Epub 2024 Jun 14.PMID: 38860982

Design and Implementation of a Federal Program to Engage Community Partners to Reduce Disparities in Adult COVID-19 Immunization Uptake, United States, 2021-2022.
Ashenafi SG, Martinez GM, Jatlaoui TC, Koppaka R, Byrne-Zaaloff M, Falcón AP, Frank A, Keitt SH, Matus K, Moss S, Ruddock C, Sun T, Waterman MB, Wu TY.Public Health Rep. 2024 Jul-Aug;139(1_suppl):23S-29S. doi: 10.1177/00333549231208642. Epub 2023 Dec 18.PMID: 38111108

Healthcare Providers' and Frontline Workers' Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo.

Zola Matuvanga T, Bolombo FB, Paviotti A, Larivière Y, Lemey G, Salloum M, Osang'ir BI, Matangila J, Maketa V, Esanga E, Milolo S, Mitashi P, Van Damme P, Muhindo-Mavoko H, Van Geertruyden JP.Am J Trop Med Hyg. 2024 Jul 2:tpmd230581. doi: 10.4269/ajtmh.23-0581. Online ahead of print.PMID: 38955200

The efficacy and safety of a quadrivalent live attenuated influenza nasal vaccine in Japanese children: A phase 3, randomized, placebo-controlled study.
Nakayama T, Hayashi T, Makino K, Oe K.J Infect Chemother. 2024 Jul 2:S1341-321X(24)00178-8. doi: 10.1016/j.jiac.2024.06.023. Online ahead of print.PMID: 38959995

Influenza vaccine uptake in juvenile idiopathic arthritis: a multi-centre cross-sectional study.
Maritsi D, Dasoula F, Ziv A, Bizjak M, Balažiová B, Matošević M, Yildiz M, Alpert N, Lamot L, Kasapcopur O, Dallos T, Uziel Y, Toplak N, Heshin-Bekenstein M.Eur J Pediatr. 2024 Jul;183(7):2937-2944. doi: 10.1007/s00431-024-05552-0. Epub 2024 Apr 15.PMID: 38619568

Comparative analysis of two novel complete genomes of myxoma virus vaccine strains.
Volodina S, Titov I, Zhivoderov S, Yurkov S, Malogolovkin A.Virus Genes. 2024 Jul 11. doi: 10.1007/s11262-024-02090-7. Online ahead of print.PMID: 38990486

A Rapid Review of the Effects of the COVID-19 Vaccine Among Individuals Taking Clozapine.
Das A, Sawyer AT, Bagla P.J Clin Psychopharmacol. 2024 Jul-Aug 01;44(4):397-401. doi: 10.1097/JCP.0000000000001854. Epub 2024 Apr 19.PMID: 38639430

Hepatitis-B immune status and vaccination in Family Medicine Practice: A retrospective study.
Goktas O.Pak J Med Sci. 2024 Jul;40(6):1163-1167. doi: 10.12669/pjms.40.6.8371.PMID: 38952534

Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.
Zeng S, Xing S, Zhang Y, Wang H, Liu Q.J Zhejiang Univ Sci B. 2024 Jul 11;25(7):557-567. doi: 10.1631/jzus.B2300392.PMID: 39011676

Exploring Hesitancy, Motivations, and Practical Issues for COVID-19 Vaccination Among Vaccine-Hesitant Adopter Parents Using the Increasing Vaccination Model.
Purvis RS, Moore R, Willis DE, Li J, Selig JP, Kraleti S, Imran T, McElfish PA.J Pediatr Health Care. 2024 Jul-Aug;38(4):456-467. doi: 10.1016/j.pedhc.2024.01.009. Epub 2024 Mar 2.PMID: 38430095

mRNA vaccine development and applications: A special focus on tumors (Review).
Chen B, Yang Y, Wang X, Yang W, Lu Y, Wang D, Zhuo E, Tang Y, Su J, Tang G, Shao S, Gu K.Int J Oncol. 2024 Aug;65(2):81. doi: 10.3892/ijo.2024.5669. Epub 2024 Jul 12.PMID: 38994758

Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.
Edosa M, Jeon Y, Gedefaw A, Hailu D, Mesfin Getachew E, Mogeni OD, Jang GH, Mukasa D, Yeshitela B, Getahun T, Lynch J, Bouhenia M, Worku Demlie Y, Hussen M, Wossen M, Teferi M, Park SE.Clin Infect Dis. 2024 Jul 12;79(Supplement_1):S20-S32. doi: 10.1093/cid/ciae194.PMID: 38996040

Socioeconomic determinants and reasons for non-acceptance to vaccination recommendations during the 3rd - 5th waves of the COVID-19 pandemic in Hungary.

Ligeti AS, Oroszi B, Luca C, Bilics E, Ágoston J, Röst G, Koltai J.BMC Public Health. 2024 Jul 5;24(1):1796. doi: 10.1186/s12889-024-19267-2.PMID: 38969991

Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
Naskar S, Harsukhbhai Chandpa H, Agarwal S, Meena J.Vaccine. 2024 Jul 11;42(18):3857-3873. doi: 10.1016/j.vaccine.2024.04.009. Epub 2024 Apr 16.PMID: 38616437

Induction of protective immune responses at respiratory mucosal sites.
Park SC, Wiest MJ, Yan V, Wong PT, Schotsaert M.Hum Vaccin Immunother. 2024 Dec 31;20(1):2368288. doi: 10.1080/21645515.2024.2368288. Epub 2024 Jul 2.PMID: 38953250

Parental willingness to pay and preference for human papillomavirus vaccine for girls aged 9-14 in subsidy scenarios in Shanghai, China.
Zhou W, Lu X, Lu J, Zhang Q, Fu X, Sun X, Guo X, Lu Y.Hum Vaccin Immunother. 2024 Dec 31;20(1):2372883. doi: 10.1080/21645515.2024.2372883. Epub 2024 Jul 8.PMID: 38977424

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP).
Aga A, Bekteshi E, Ajasllari G, Kosta A, Vajushi E, Kortoci R, Filauro M, Muka T, Peretti G.Eur Arch Otorhinolaryngol. 2024 Jul;281(7):3693-3700. doi: 10.1007/s00405-024-08653-6. Epub 2024 Apr 18.PMID: 38637412

COVID-19 Vaccine Intention Among Iranian Health Workers: Application of the HBM Model.
Maleki A, Zahraei SM, Mahmoudi S, Gouya MM, Kamali K, Hoseinzade Z, Farsadeghi M, Hajimiri K, Heidari Z, Mohamadi S, Bigdeli Z, Shoghli A.Soc Work Public Health. 2024 Jul 3;39(5):434-443. doi: 10.1080/19371918.2024.2325553. Epub 2024 Apr 23.PMID: 38651536

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination.
Yan Y, Huang X, Yuan L, Ngai T, Ma G, Xia Y.Biomaterials. 2024 Jul 2;311:122697. doi: 10.1016/j.biomaterials.2024.122697. Online ahead of print.PMID: 38968687

Sixth monovalent XBB.1.5 vaccine elicits robust immune response against emerging SARS-CoV-2 variants in heart transplant recipients.
Peled Y, Afek A, Patel JK, Raanani E, Segev A, Ram E, Fardman A, Beigel R, Jurkowicz M, Atari N, Kliker L, Nemet I, Mandelboim M.J Heart Lung Transplant. 2024 Jul;43(7):1188-1192. doi: 10.1016/j.healun.2024.03.014. Epub 2024 Mar 24.PMID: 38522765

Review of the Knowledge, Barriers, and Facilitators of HPV Vaccination among Latino Migrant and Seasonal Farmworkers in the United States.
Hornberger S, Messmore N, Munguia-Vazquez R.J Community Health. 2024 Jul 4. doi: 10.1007/s10900-024-01367-0. Online ahead of print.PMID: 38965135

Dendritic Cell-Hitchhiking In Vivo for Vaccine Delivery to Lymph Nodes.
Zhou L, Zhao L, Wang M, Qi X, Zhang X, Song Q, Xue D, Mao M, Zhang Z, Shi J, Si P, Liu J.Adv Sci (Weinh). 2024 Jul 4:e2402199. doi: 10.1002/advs.202402199. Online ahead of print.PMID: 38962939

Development of Promising Interventions to Improve Human Papillomavirus Vaccination in a School-Based Program in Quebec, Canada: Results From a Formative Evaluation Using a Mixed Methods Design.
Dionne M, Sauvageau C, Etienne D, Kiely M, Witteman H, Dubé E.JMIR Form Res. 2024 Jul 8;8:e57118. doi: 10.2196/57118.PMID: 38976317

Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
Sartori AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leão O, Ramos Flores T, Dâmaso Bertoldi A, Curi Hallal P, Freitas da Silveira M.Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.07.006. Online ahead of print.PMID: 38991916

Application prospects of the 2BS cell-adapted China fixed rabies virus vaccine strain 2aG4-B40.
Xu Y, Weng L, Wang X, Li M, Guo W, Liu Y, Li X, Wang Z, Liu X, Xu S, He F, Hou Q, Li T, Du W, Zhang Y, Chang S, Zhang L, Zhang Y.Virol J. 2024 Jul 8;21(1):154. doi: 10.1186/s12985-024-02416-9.PMID: 38978059

Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy.
Gianella S, Anderson C, Chaillon A, Wells A, Porrachia M, Caballero G, Meneses M, Lonergan J, Woodworth B, Gaitan NC, Rawlings SA, Muttera L, Harkness L, Little SJ, May S, Smith D.AIDS. 2024 Jul 1;38(8):1131-1140. doi: 10.1097/QAD.0000000000003882. Epub 2024 Mar 22.PMID: 38526550

COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group.JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258.PMID: 38949812

Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
Xu Z, Zhou H, Li T, Yi Q, Thakur A, Zhang K, Ma X, Qin JJ, Yan Y.Drug Resist Updat. 2024 Jul;75:101098. doi: 10.1016/j.drup.2024.101098. Epub 2024 Jun 1.PMID: 38833804

Childhood PFAS exposure and immunotoxicity: a systematic review and meta-analysis of human studies.
Antoniou EE, Dekant W.Syst Rev. 2024 Jul 9;13(1):176. doi: 10.1186/s13643-024-02596-z.PMID: 38982538

Inactivated Aeromonas salmonicida impairs adaptive immunity in lumpfish (Cyclopterus lumpus).
Chakraborty S, Gnanagobal H, Hossain A, Cao T, Vasquez I, Boyce D, Santander J.J Fish Dis. 2024 Jul;47(7):e13944. doi: 10.1111/jfd.13944. Epub 2024 Mar 24.PMID: 38523320

CodonBert large language model for mRNA vaccines.
Li S, Moayedpour S, Li R, Bailey M, Riahi S, Kogler-Anele L, Miladi M, Miner J, Pertuy F, Zheng D, Wang J, Balsubramani A, Tran K, Zacharia M, Wu M, Gu X, Clinton R, Asquith C, Skaleski J, Boeglin L, Chivukula S, Dias A, Strugnell T, Montoya FU, Agarwal V, Bar-Joseph Z, Jager S.Genome Res. 2024 Jul 1:gr.278870.123. doi: 10.1101/gr.278870.123. Online ahead of print.PMID: 38951026

Construction of recombinant Omp25 or EipB protein loaded PLGA nanovaccines for Brucellosis protection.
Akmayan I, Oztav S, Coksu I, Abamor ES, Acar S, Ozbek T.Nanotechnology. 2024 Jul 12;35(39). doi: 10.1088/1361-6528/ad5b66.PMID: 38917779

Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.
Kundu J, Le HT, Logan M, Hockman D, Landi A, Crawford K, Wininger M, Johnson J, Kundu JK, Tiffney EA, Urbanowicz RA, Ball JK, Bailey JR, Bukh J, Law M, Foung S, Tyrrell DL, Houghton M, Law JL.J Hepatol. 2024 Jul 8:S0168-8278(24)02335-3. doi: 10.1016/j.jhep.2024.06.029. Online ahead of print.PMID: 38986744

Political determinants of COVID-19 restrictions and vaccine rollouts: The case of regional elections in Italy and Spain.
Arija Prieto P, Antonini M, Ammi M, Genie M, Paolucci F.Health Policy. 2024 Jul;145:105082. doi: 10.1016/j.healthpol.2024.105082. Epub 2024 May 16.PMID: 38781708

Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review.
Griskaitis M, Thielemann I, Schönfeld V, Falman A, Scholz S, Reinacher U, Haas L, Wichmann O, Harder T.J Infect. 2024 Jul 10:106228. doi: 10.1016/j.jinf.2024.106228. Online ahead of print.PMID: 38996818

COVID-19 Vaccination in the First Trimester and Major Structural Birth Defects Among Live Births.
Kharbanda EO, DeSilva MB, Lipkind HS, Romitti PA, Zhu J, Vesco KK, Boyce TG, Daley MF, Fuller CC, Getahun D, Jackson LA, Williams JTB, Zerbo O, Weintraub ES, Vazquez-Benitez G.JAMA Pediatr. 2024 Jul 1:e241917. doi: 10.1001/jamapediatrics.2024.1917. Online ahead of print.PMID: 38949821

When Should I Get My Next COVID-19 Vaccine? Data From the Surveillance of Responses to COVID-19 Vaccines in Systemic Immune-Mediated Inflammatory Diseases (SUCCEED) Study.
Bowdish DME, Chandran V, Hitchon CA, Kaplan GG, Avina-Zubieta JA, Fortin PR, Larché MJ, Boire G, Gingras AC, Dayam RM, Colmegna I, Lukusa L, Lee JLF, Richards DP, Pereira D, Watts TH, Silverberg MS, Bernstein CN, Lacaille D, Benoit J, Kim J, Lalonde N, Gunderson J, Allard-Chamard H, Roux S, Quan J, Hracs L, Turnbull E, Valerio V, Bernatsky S; SUCCEED Investigative Team.J Rheumatol. 2024 Jul 1;51(7):721-727. doi: 10.3899/jrheum.2023-1214.PMID: 38621797

Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
Park SE, Gedefaw A, Hailu D, Jeon Y, Mogeni OD, Jang GH, Mukasa D, Mraidi R, Kim DR, Getahun T, Mesfin Getachew E, Yeshitela B, Ayele Abebe S, Hussen M, Worku Demlie Y, Teferi M.Clin Infect Dis. 2024 Jul 12;79(Supplement_1):S33-S42. doi: 10.1093/cid/ciae233.PMID: 38996035

Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country.
Moradi N, Zarei L, Hajimoladarvish N, Meshkani Z, Zanganeh M, Babapour J, Lankarani KB.Pharmacoecon Open. 2024 Jul;8(4):559-568. doi: 10.1007/s41669-024-00494-7. Epub 2024 May 18.PMID: 38761343

Immunogenicity and protective capacity of a CpG ODN adjuvanted alum adsorbed bivalent meningococcal outer membrane vesicle vaccine.

Canavar Yildirim T, Ozsurekci Y, Yildirim M, Evcili I, Yazar V, Aykac K, Guler U, Salih B, Gursel M, Gursel I.Int Immunol. 2024 Jul 13;36(8):393-404. doi: 10.1093/intimm/dxae016.PMID: 38536954

Assessing the impact of COVID-19 on routine immunization in Sierra Leone.
Sesay U, Serna-Chavez HM, Gebru GN, Kangbai JB, Ogbonna U, Squire JS, Bakker MI.BMC Public Health. 2024 Jul 5;24(1):1795. doi: 10.1186/s12889-024-19221-2.PMID: 38970039

Effect of doubled dose administration of foot-and-mouth disease vaccine against heterologous virus infection in cattle.
Kawaguchi R, Nishi T, Fukai K, Ikezawa M, Kokuho T, Morioka K.J Vet Med Sci. 2024 Jul 2;86(7):777-786. doi: 10.1292/jvms.24-0115. Epub 2024 May 9.PMID: 38719616

Incorporating social determinants of health into transmission modeling of COVID-19 vaccine in the US: a scoping review.
Duong KNC, Nguyen DT, Kategeaw W, Liang X, Khaing W, Visnovsky LD, Veettil SK, McFarland MM, Nelson RE, Jones BE, Pavia AT, Coates E, Khader K, Love J, Vega Yon GG, Zhang Y, Willson T, Dorsan E, Toth DJA, Jones MM, Samore MH, Chaiyakunapruk N.Lancet Reg Health Am. 2024 Jun 7;35:100806. doi: 10.1016/j.lana.2024.100806. eCollection 2024 Jul.PMID: 38948323

The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment.
McElwee F, Newall A.Pharmacoeconomics. 2024 Jul;42(Suppl 2):187-197. doi: 10.1007/s40273-024-01396-6. Epub 2024 May 31.PMID: 38819720

The dimensionality of vaccination intentions: One strain or multiple strains?
Matthijssen MAM, van Leeuwen F, Cloin M, van de Goor I, Achterberg P.Health Psychol. 2024 Jul;43(7):539-549. doi: 10.1037/hea0001367. Epub 2024 Apr 4.PMID: 38573690

Enhanced effectiveness in preventing Nocardia seriolae infection utilizing heterologous prime-boost approach in orange-spotted grouper Epinephelus coioides.
Nguyen PTD, Giovanni A, Maekawa S, Wang PC, Chen SC.Fish Shellfish Immunol. 2024 Jul;150:109663. doi: 10.1016/j.fsi.2024.109663. Epub 2024 May 29.PMID: 38821228

Synthesis of BLF1-containing trimethyl chitosan nanoparticles and evaluation of its immunogenicity and protection in syrian mice by oral and subcutaneous injections.
Fazeli A, Honari H, Sadeghi D, Bakhtiari H.Protein Expr Purif. 2024 Jul;219:106462. doi: 10.1016/j.pep.2024.106462. Epub 2024 Mar 30.PMID: 38556142

Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine.
Cen L, Zhang Z, Sun Y, Wu N, Shao J, Qian Z, Tian M, Ke Y, Liu B.Cancer Cell Int. 2024 Jul 3;24(1):232. doi: 10.1186/s12935-024-03421-2.PMID: 38961429

An integrated comparative genomics, subtractive proteomics and immunoinformatics framework for the rational design of a Pan-Salmonella multi-epitope vaccine.

Bhattacharjee A, Hosen MR, Lamisa AB, Ahammad I, Chowdhury ZM, Jamal TB, Sohag MMH, Hossain MU, Das KC, Keya CA, Salimullah M.PLoS One. 2024 Jul 3;19(7):e0292413. doi: 10.1371/journal.pone.0292413. eCollection 2024.PMID: 38959229

Atypical hemolytic-uremic syndrome after COVID-19 vaccine: A case report.
Campos MAG, Ataídes RJC, Ferreira MC, Alves AS, Silva GEB.Immun Inflamm Dis. 2024 Jul;12(7):e1270. doi: 10.1002/iid3.1270.PMID: 38967360

Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
Huang J, Wang W, Li H, Bai Y, Song Y, Jiao C, Jin H, Huang P, Zhang H, Xia X, Yan F, Li Y, Wang H.Antiviral Res. 2024 Jul;227:105905. doi: 10.1016/j.antiviral.2024.105905. Epub 2024 May 11.PMID: 38740191

A Causality Assessment Framework for COVID-19 Vaccines and Adverse Events at the COVID-19 Vaccine Safety Research Center.
Kim S, Kim JA, Park H, Park S, Oh S, Jung SE, Shin HS, Lee JK, Han HC, Woo JH, Park BJ, Choi NK, Kim DH.J Korean Med Sci. 2024 Jul 8;39(26):e220. doi: 10.3346/jkms.2024.39.e220.PMID: 38978490

In Silico Design of CT26 Polytope and its Surface Display by ClearColi-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma.
Sharif E, Nezafat N, Ahmadi FM, Mohit E.Appl Biochem Biotechnol. 2024 Jul 3. doi: 10.1007/s12010-024-04971-x. Online ahead of print.PMID: 38958886

A Pediatric Level III Trauma Center Experience With Dog Bite Injuries.
Mattice T, Schnaith A, Ortega HW, Segura B, Kaila R, Amoni I, Shanley R, Louie JP.Clin Pediatr (Phila). 2024 Jul;63(7):914-920. doi: 10.1177/00099228231200097. Epub 2023 Sep 13.PMID: 37705176

Coverage of Two-Dose Preemptive Cholera Mass Vaccination Campaign in High-Priority Hotspots in Shashemene, Oromia Region, Ethiopia.
Park SE, Gedefaw A, Hailu D, Jeon Y, Mogeni OD, Jang GH, Mukasa D, Mraidi R, Kim DR, Getahun T, Mesfin Getachew E, Yeshitela B, Ayele Abebe S, Hussen M, Worku Demlie Y, Teferi M.Clin Infect Dis. 2024 Jul 12;79(Supplement_1):S33-S42. doi: 10.1093/cid/ciae233.PMID: 38996035

COVID-19 vaccine mistrust, health literacy, conspiracy theories, and racial discrimination among a representative ethnically diverse sample in Canada: The vulnerability of Arab, Asian, Black, and Indigenous peoples.
Cénat JM, Moshirian Farahi SMM, Dalexis RD, Caulley L, Xu Y, Beogo I, Pongou R.J Med Virol. 2024 Jul;96(7):e29795. doi: 10.1002/jmv.29795.PMID: 39007429

A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice.
Wang Z, Sun W, Li D, Sun Y, Zhu M, Wang W, Zhang Y, Li E, Yan F, Wang T, Feng N, Yang S, Xia X, Gao Y.Virus Res. 2024 Jul;345:199378. doi: 10.1016/j.virusres.2024.199378. Epub 2024 Apr 23.PMID: 38643857

Preferences regarding COVID-19 vaccination among 12,000 adults in China: A cross-sectional discrete choice experiment.
Yu F, Jiao L, Chen Q, Wang Q, De Allegri M, Cao Z, Chen W, Ma X, Wang C, Wachinger J, Jin Z, Bunker A, Geldsetzer P, Yang J, Xue L, Bärnighausen T, Chen S.PLOS Glob Public Health. 2024 Jul 11;4(7):e0003387. doi: 10.1371/journal.pgph.0003387. eCollection 2024.PMID: 38990924

Administration sequence- and formation-dependent vaccination using acid-degradable polymeric nanoparticles with high antigen encapsulation capability.
Choi YS, Felgner J, Jan S, Hernandez-Davies JE, Davies DH, Kwon YJ.J Mater Chem B. 2024 Jul 10;12(27):6577-6586. doi: 10.1039/d3tb02834h.PMID: 38872501

A randomised trial of malaria vaccine R21/Matrix-M with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B, Mukaka M, Jittamala P, Poovorawan K, Pongsuwan P, Stockdale L, Provstgaard-Morys S, Chotivanich K, Tarning J, Hoglund RM, Chimjinda N, Ewer K, Ramos-Lopez F, Day NPJ, Dondorp AM, Hill AV, White NJ, von Seidlein L, Pukrittayakamee S.NPJ Vaccines. 2024 Jul 6;9(1):124. doi: 10.1038/s41541-024-00920-1.PMID: 38971837

Influence of bovine pestivirus heterogeneity on serological responses to 10 different commercial vaccine formulation.
Camargo L, Resende da Silva GF, Baccili CC, Flores EF, Gomes V.Vet Microbiol. 2024 Jul 3;296:110155. doi: 10.1016/j.vetmic.2024.110155. Online ahead of print.PMID: 38996750

Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE.Clin Microbiol Infect. 2024 Jul;30(7):930-936. doi: 10.1016/j.cmi.2024.03.028. Epub 2024 Mar 28.PMID: 38552793

Neutralizing antibody responses assessment after vaccination in people living with HIV using a surrogate neutralization assay.
Batchi-Bouyou AL, Djontu JC, Ingoba LL, Mougany JS, Mouzinga FH, Dollon Mbama Ntabi J, Kouikani FY, Christ Massamba Ndala A, Diafouka-Kietela S, Ampa R, Ntoumi F.BMC Immunol. 2024 Jul 10;25(1):43. doi: 10.1186/s12865-024-00625-z.PMID: 38987686

Evaluation of vaccine candidates against Rhodococcus equi in BALB/c mice infection model: cellular and humoral immune responses.
Liu L, Cai P, Gu W, Duan X, Gao S, Ma X, Ma Y, Ma S, Li G, Wang X, Cai K, Wang Y, Cai T, Zhao H.BMC Microbiol. 2024 Jul 8;24(1):249. doi: 10.1186/s12866-024-03408-z.PMID: 38977999

Designing multi-epitope vaccine against human cytomegalovirus integrating pan-genome and reverse vaccinology pipelines.
Biswas R, Swetha RG, Basu S, Roy A, Ramaiah S, Anbarasu A.Biologicals. 2024 Jul 13;87:101782. doi: 10.1016/j.biologicals.2024.101782. Online ahead of print.PMID: 39003966

Enhancing cross-protection against influenza by heterologous sequential immunization with mRNA LNP and protein nanoparticle vaccines.
Dong C, Zhu W, Wei L, Kim JK, Ma Y, Kang SM, Wang BZ.Nat Commun. 2024 Jul 10;15(1):5800. doi: 10.1038/s41467-024-50087-5.PMID: 38987276

Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
Jitender, Vikram Kumar B, Singh S, Verma G, Kumar R, Mishra PM, Kumar S, Nagaraj SK, Nag J, Joy CM, Nikam B, Singh D, Pooja, Kalidas N, Singh S, Mumtaz, Bhardwaj AK, Mankotia DS, Ringe RP, Gupta N, Tripathi S, Mishra RPN.Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.06.066. Online ahead of print.PMID: 38981743

Oral HPV infection clearance and acquisition after nonavalent vaccination in men who have sex with men and transgender women: a prospective analysis.
Rossotti R, Nava A, Baiguera C, Baldassari L, Moioli MC, Fanti D, D'Amico F, Calzavara D, Bossolasco S, Tamburini AM, Canetti D, Bana NB, Cernuschi M, Vismara C, Puoti M.Eur J Clin Microbiol Infect Dis. 2024 Jul 2. doi: 10.1007/s10096-024-04887-8. Online ahead of print.PMID: 38954164

Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.
Zinnecker T, Reichl U, Genzel Y.Hum Vaccin Immunother. 2024 Dec 31;20(1):2373521. doi: 10.1080/21645515.2024.2373521. Epub 2024 Jul 15.PMID: 39007904

An inactivated PDCoV vaccine induces robust neutralizing antibodies and immune protection in pigs lasting for three months.
Fan L, Wang W, Yi X, Yuan X, Chen Z, Xiao L, Lu C, Guo R, Fan B, Ma J, Zha Y, Shu J, Li J, Li B.Microb Pathog. 2024 Jul;192:106714. doi: 10.1016/j.micpath.2024.106714. Epub 2024 May 25.PMID: 38801864

Immunogenicity study of a Novel DNA-Based HCV vaccine candidate.
Salem EA, Tabll A, Salem TZ, El-Abd YS, El-Shenawy R, Shawky H, Shoman S.Egypt J Immunol. 2024 Jul;31(3):95-112.PMID: 38995715

Primary prevention of HPV-related diseases from the patients' perspective in Poland.
Trojnarska D, Jach R.Eur J Cancer Prev. 2024 Jul 1;33(4):299-308. doi: 10.1097/CEJ.0000000000000866. Epub 2023 Nov 30.PMID: 38113130

Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
Zinsou JF, Diemert DJ, Dejon-Agobé JC, Adégbité BR, Honkpehedji YJ, Vodonou KG, Bikangui R, Edoa JR, Massinga Loembe M, Li G, Yazdanbakhsh M, Bottazzi ME, van Leeuwen R, Kremsner PG, Hotez PJ, Bethony JM, Grobusch MP, Adegnika AA.Lancet Infect Dis. 2024 Jul;24(7):760-774. doi: 10.1016/S1473-3099(24)00104-X. Epub 2024 Mar 18.PMID: 38513684

Improving HPV-Related Oropharyngeal Cancer Knowledge and HPV Vaccination Rates via Virtual Workshops.

Evans LK, Azar SS, Chen H, Saad M, Subhash S, Su-Velez BM, St John MA.Laryngoscope. 2024 Jul;134(7):3096-3101. doi: 10.1002/lary.31351. Epub 2024 Feb 24.PMID: 38400791

The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
Shani M, Hermesh I, Feldhamer I, Reges O, Lavie G, Arbel R, Sagy YW.Vaccine. 2024 Jul 11;42(18):3830-3837. doi: 10.1016/j.vaccine.2024.04.097. Epub 2024 May 10.PMID: 38729910

Coronavirus disease 2019 vaccination acceptance and associated factors among residents of Dire Dawa Administration, Eastern Ethiopia: a community-based cross-sectional study.
Jidha TD, Deginet E, Tefera B, Amenu D, Beressa G, Hailu M.BMC Infect Dis. 2024 Jul 11;24(1):689. doi: 10.1186/s12879-024-09556-x.PMID: 38992646

Polymeric nanocarrier-based adjuvants to enhance a locally produced mucosal coryza vaccine in chicken.
Ibrahim HM, Mohammed GM, Sayed RH, Elshoky HA, Ahmed MM, El Sayed MF, Elsaady SA.Sci Rep. 2024 Jul 3;14(1):15262. doi: 10.1038/s41598-024-65267-y.PMID: 38961116

Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
Li Y, Li J, Dang Y, Chen Y, Tao C.JMIR Public Health Surveill. 2024 Jul 15;10:e51007. doi: 10.2196/51007.PMID: 39008362

Reverse vaccinology-based multi-epitope vaccine design against Indian group A rotavirus targeting VP7, VP4, and VP6 proteins.
Kuri PR, Goswami P.Microb Pathog. 2024 Jul 1;193:106775. doi: 10.1016/j.micpath.2024.106775. Online ahead of print.PMID: 38960216

Comparison of homologous and heterologous inactivated and mRNA vaccination programme against SARS-CoV-2 in dialysis patients.
Yasar E, Yildiz Y, Ozturk E, Gok Oguz E, Coskun Yenigun E, Ozturk R, Helvaci O, Ozger HS, Keles M, Karacin C, Ugras Dikmen A, Caglar K, Duranay M, Ayli MD, Dizbay M, Erten Y, Guz G, Derici U.Nephrology (Carlton). 2024 Jul;29(7):405-414. doi: 10.1111/nep.14292. Epub 2024 Mar 14.PMID: 38485143

EGR3 Inhibits Tumor Progression by Inducing Schwann Cell-Like Differentiation.
Chen CH, Chen Y, Li YN, Zhang H, Huang X, Li YY, Li ZY, Han JX, Wu XY, Liu HJ, Sun T.Adv Sci (Weinh). 2024 Jul 7:e2400066. doi: 10.1002/advs.202400066. Online ahead of print.PMID: 38973154

Assessing farmers' willingness to pay for FMD vaccines and factors influencing payment: a contingent valuation study in central Oromia, Ethiopia.
Layessa ML, Gebremedhin EZ, Sarba EJ, Bune WM.BMC Vet Res. 2024 Jul 15;20(1):313. doi: 10.1186/s12917-024-04169-7.PMID: 39010130

Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis.
Chang E, Li H, Zheng W, Zhou L, Jia Y, Gu W, Cao Y, Zhu X, Xu J, Liu B, You M, Liu K, Wang M, Huang W.Appl Health Econ Health Policy. 2024 Jul;22(4):457-470. doi: 10.1007/s40258-024-00880-6. Epub 2024 Apr 10.PMID: 38598091

Vaccine hesitancy throughout the COVID-19 vaccination trajectory among immigrant and non-immigrant older adults: a cohort study.
Zlotnick C, Cohen Castel O.Public Health. 2024 Jul 6;234:105-111. doi: 10.1016/j.puhe.2024.06.007. Online ahead of print.PMID: 38972228

Strategies to Enhance COVID-19 Vaccine Uptake among Prioritized Groups, Uganda-Lessons Learned and Recommendations for Future Pandemics.
Kiiza D, Semanda JN, Kawere BB, Ajore C, Wasswa CK, Kwiringira A, Tumukugize E, Sserubidde J, Namyalo N, Wadria RB, Mukiibi P, Kasule J, Chemos I, Ruth AW, Atugonza R, Banage F, Wibabara Y, Ampaire I, Driwale A, Vosburgh W, Nelson L, Lamorde M, Boore A.Emerg Infect Dis. 2024 Jul;30(7):1326-1334. doi: 10.3201/eid3007.231001.PMID: 38916545

Corrigendum to "BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats" [Reprod. Toxicol. 126 (2024) 108587].
Lee JY, Lee JA, Lee HK, Kim YB, Lee SM, Nam CJ.Reprod Toxicol. 2024 Jul 4:108652. doi: 10.1016/j.reprotox.2024.108652. Online ahead of print.PMID: 38969529

Chimeric antigen carried by extracellular vesicles induces stronger protective immunity against Mycobacterium tuberculosis infection.
Ji L, Fu Y, Xiong S.Immunobiology. 2024 Jul 2;229(5):152834. doi: 10.1016/j.imbio.2024.152834. Online ahead of print.PMID: 38968836

Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma.
Johanns TM, Garfinkle EAR, Miller KE, Livingstone AJ, Roberts KF, Rao Venkata LP, Dowling JL, Chicoine MR, Dacey RG, Zipfel GJ, Kim AH, Mardis ER, Dunn GP.Clin Cancer Res. 2024 Jul 1;30(13):2729-2742. doi: 10.1158/1078-0432.CCR-23-3077.PMID: 38639919

African mpox surges show lack of vaccine access.
Adepoju P.Lancet. 2024 Jul 6;404(10447):18. doi: 10.1016/S0140-6736(24)01393-X.PMID: 38972316

Vaccine-Sensitive Allocation - Another Divide to Divide Us?
Robertson-Preidler J, Schuman O.Am J Bioeth. 2024 Jul;24(7):97-99. doi: 10.1080/15265161.2024.2353802. Epub 2024 Jun 24.PMID: 38913483

Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
McGovern I, Chastek B, Bancroft T, Webb N, Imran M, Pelton SI, Haag MDM.Int J Infect Dis. 2024 Jul 3:107160. doi: 10.1016/j.ijid.2024.107160. Online ahead of print.PMID: 38969330

Photodynamic Therapy Derived Personalized Whole Cell Tumor Vaccine Prevents Postsurgery Tumor Recurrence and Metastasis.
Yang C, Jiang Y, Zhang K, Zhu X, Li J, Yu H, Chen J, Gu X, Gan Z, Yu Q.Small. 2024 Jul;20(28):e2308456. doi: 10.1002/smll.202308456. Epub 2024 Feb 11.PMID: 38342675

A Cross-Sectional Study of Vaccination-Related Education in Pharmacy Programs in the Middle East.
El Hajj MS, Saleh M, Ibrahim N, El-Awaisi A, Baraka M, Stewart D, Nasr ZG.Am J Pharm Educ. 2024 Jul;88(7):100715. doi: 10.1016/j.ajpe.2024.100715. Epub 2024 May 29.PMID: 38750820

Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines.
Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, Levitz SM.PLoS Pathog. 2024 Jul 8;20(7):e1012220. doi: 10.1371/journal.ppat.1012220. Online ahead of print.PMID: 38976694

Impact of COVID-19 pandemic on influenza vaccine uptake.
Nair VB, Abraham SV, Padmanabhan A.Lung India. 2024 Jul 1;41(4):327-328. doi: 10.4103/lungindia.lungindia_510_23. Epub 2024 Jun 28.PMID: 38953201

Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence.
Chaithongwongwatthana S, Wijagkanalan W, Wanlapakorn N, Fortuna L, Yuwaree V, Kerdsomboon C, Poredi IK, Mansouri S, Pham HT, Poovorawan Y.Int J Infect Dis. 2024 Jul;144:107047. doi: 10.1016/j.ijid.2024.107047. Epub 2024 Apr 11.PMID: 38609035

Poly(allylamine)-tripolyphosphate polymeric nanoparticle as an NLRP3-dependent systemic adjuvant for the vaccine development.
Rizzo GP, Sanches RC, Chavero C, Bianchi DS, Apuzzo E, Herrera SE, Agazzi ML, Keitelman IA, Trevani AS, Oliveira SC, Azzaroni O, Smaldini PL, Docena GH.bioRxiv [Preprint]. 2024 Jul 4:2024.07.01.601578. doi: 10.1101/2024.07.01.601578.PMID: 39005275

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study.
Díez-Domingo J, Simkó R, Icardi G, Chong CP, Zocchetti C, Syrkina O, Bchir S, Bertrand-Gerentes I.Infect Dis Ther. 2024 Jul 2. doi: 10.1007/s40121-024-01009-x. Online ahead of print.PMID: 38955966

Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.
Li Y, Li J, Dang Y, Chen Y, Tao C.JMIR Public Health Surveill. 2024 Jul 15;10:e51007. doi: 10.2196/51007.PMID: 39008362

Effect of parenteral micronutrient supplementation at birth on immunity, growth, and health in preweaning dairy heifers.
Carlson H, Cullens-Nobis FM, Owczarzak EJ, Abuelo A.J Dairy Sci. 2024 Jul;107(7):4926-4941. doi: 10.3168/jds.2023-24292. Epub 2024 Feb 7.PMID: 38331183

Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice.
Mancebo FJ, Nuévalos M, Lalchandani J, Martín Galiano AJ, Fernández-Ruiz M, Aguado JM, García-Ríos E, Pérez-Romero P.Antiviral Res. 2024 Jul;227:105914. doi: 10.1016/j.antiviral.2024.105914. Epub 2024 May 15.PMID: 38759930

Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.

Miller E, Michel A, Singh P, Limaye R.Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024.06.058. Online ahead of print.PMID: 38997850

Prophylactic vaccination inducing anti-Env antibodies can result in protection against HTLV-1 challenge in macaques.
Nakamura-Hoshi M, Ishii H, Nomura T, Nishizawa M, Hau TTT, Kuse N, Okazaki M, Ainai A, Suzuki T, Hasegawa H, Yoshida T, Yonemitsu K, Suzaki Y, Ami Y, Yamamoto H, Matano T.Mol Ther. 2024 Jul 3;32(7):2328-2339. doi: 10.1016/j.ymthe.2024.05.020. Epub 2024 May 11.PMID: 38734900

No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
Lee BR, Brostek AR, Kaffenberger BH.J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.PMID: 38490372

Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
Bang JY, Kim YJ, Seo YJ, Hong SH.Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.07.017. Online ahead of print.PMID: 38981742

mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
Soe P, Wong H, Naus M, Muller MP, Vanderkooi OG, Kellner JD, Top KA, Sadarangani M, Isenor JE, Marty K, De Serres G, Valiquette L, McGeer A, Bettinger JA; Canadian Immunization Research Network.Vaccine. 2024 Jul 11;42(18):3819-3829. doi: 10.1016/j.vaccine.2024.04.096. Epub 2024 May 6.PMID: 38714447

Physical Activity at Different Life Stages and Its Consequence on the Initial Immunization and Inflammatory Response Against COVID-19.
Rossi PAQ, Gomes R, Nascimento Salazar TCD, Lustosa Barros EM, Vasconcelos S, da Silva AS, Pereira EM, Melo VB, Fonseca MHG, Teixeira CR, Furtado GP, Pontes LQ, Khouri R, Vasconcelos B, Almeida SS, Werneck GL, Rossi FE, Santos MAPD.J Phys Act Health. 2024 Apr 24;21(7):717-725. doi: 10.1123/jpah.2023-0370. Print 2024 Jul 1.PMID: 38663845

Immune reactivity of two biological models to vaccination with inactivated vaccine QazVac against coronavirus infection COVID-19.
Myrzakhmetova BS, Zhapparova GA, Bisenbayeva KB, Toytanova AS, Tuyskanova MS, Zhugunissov KD, Kutumbetov LB.Vopr Virusol. 2024 Jul 5;69(3):219-230. doi: 10.36233/0507-4088-222.PMID: 38996371

Language barriers during vaccination practice, the point of view of healthcare providers.
Bianconi A, Zanutto G, Castagna G, Coa AA, De Gioia ER, Longo G, Sicari G, Tomaiuolo G, Todeschini R, Pandolfi P, Gori D.Ann Ig. 2024 Jul-Aug;36(4):462-475. doi: 10.7416/ai.2024.2624.PMID: 38747080

Global burden of vaccine-associated hepatobiliary and gastrointestinal adverse drug reactions, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.
Lee S, Lee K, Park J, Jeong YD, Jo H, Kim S, Woo S, Son Y, Kim HJ, Lee K, Ha Y, Oh NE, Lee J, Rhee SY, Smith L, Kang J, Rahmati M, Lee H, Yon DK.J Med Virol. 2024 Jul;96(7):e29792. doi: 10.1002/jmv.29792.PMID: 38993028

Bergenin potentiates BCG efficacy by enriching mycobacteria-specific adaptive memory responses via the Akt-Foxo-Stat4 axis.
Mukhopadhyay S, Pahuja I, Okieh AA, Pandey D, Yadav V, Bhaskar A, Dwivedi VP.Tuberculosis (Edinb). 2024 Jul;147:102517. doi: 10.1016/j.tube.2024.102517. Epub 2024 May 8.PMID: 38733881

Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth.
Hou Y, Wang Z, Chen Z, Shuai L, Pei Y, Sun B, Jiang Y, Wang H.ACS Biomater Sci Eng. 2024 Jul 8;10(7):4587-4600. doi: 10.1021/acsbiomaterials.4c00426. Epub 2024 Jun 13.PMID: 38869192

Influenza vaccination-associated cryoglobulinemic vasculitis.
Taki E, Wirtshafter S, Geara AS.Clin Nephrol. 2024 Jul 12. doi: 10.5414/CN111383. Online ahead of print.PMID: 38994595

Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
Li J, Gong L, Li J, Gong Z, Wang X, Yan H, Zhang Y, Mao H, Chen K.Vaccine. 2024 Jul 11;42(18):3751-3755. doi: 10.1016/j.vaccine.2024.04.093. Epub 2024 May 6.PMID: 38714449

Light-Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy.
An X, Chen Z, Luo Y, Yang P, Yang Z, Ji T, Chi Y, Wang S, Zhang R, Wang Z, Li J.Adv Sci (Weinh). 2024 Jul 2:e2403158. doi: 10.1002/advs.202403158. Online ahead of print.PMID: 38953329

Trust in information sources during the COVID-19 pandemic and its association with vaccine trust among a sample of Hispanic adults.
Morales-Cortés PM, Rivera-Gastón FA, Rivera-Santiago T, Pérez-Cardona CM, Colón-López V, Ortiz AP.J Am Pharm Assoc (2003). 2024 Jul 9:102184. doi: 10.1016/j.japh.2024.102184. Online ahead of print.PMID: 38992740

Evaluation of protective immunity induced by a DNA vaccine encoding SAG2 and SRS2 against Toxoplasma gondii infection in mice.
Guo XD, Zhou CX, Cui LL, Qiu HJ, Wang YL, Fu M, Liu DA, Han B, Zhou HY, Zhou DH.Acta Trop. 2024 Jul 2;257:107302. doi: 10.1016/j.actatropica.2024.107302. Online ahead of print.PMID: 38959992

Assessing the modification impact of vaccination on the relationship of the Discomfort Index with hand, foot, and mouth disease in Guizhou: A multicounty study.
Sun J, Zhang W, Yao G, Gu J, Wu W, Wang D, Du Z, Hao Y.PLoS Negl Trop Dis. 2024 Jul 1;18(7):e0012008. doi: 10.1371/journal.pntd.0012008. eCollection 2024 Jul.PMID: 38949988

Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine.
Buerger V, Maurer G, Kosulin K, Hochreiter R, Larcher-Senn J, Dubischar K, Eder-Lingelbach S.J Travel Med. 2024 Jul 3:taae084. doi: 10.1093/jtm/taae084. Online ahead of print.PMID: 38959854

Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.

Urquidi C, Sepúlveda-Peñaloza A, Valenzuela MT, Ponce A, Menares V, Cortes CP, Benítez R, Santelices E, Anfossi R, Moller A, Santolaya ME.Vaccine. 2024 Jul 11;42(18):3851-3856. doi: 10.1016/j.vaccine.2024.05.002. Epub 2024 May 15.PMID: 38749822

Estimation of the poliovirus type 2 immunity gap in South Africa.
Brown L, Bingham J, Pulliam J, Mthombothi Z, Sereo T, Kamupira M, Botha S, Molema K, Maseti E, Schönfeldt M, Mabhena N, Prabdial-Sing N, von Gottberg A, McCarthy K, van Schalkwyk C.Vaccine. 2024 Jul 4:S0264-410X(24)00703-5. doi: 10.1016/j.vaccine.2024.06.029. Online ahead of print.PMID: 38969540

Monoclonal antibody based solid phase competition ELISA to detect FMDV serotype A specific antibodies.
Hema Sayee R, Hosamani M, Krishnaswamy N, Shanmuganathan S, Nagasupreeta SR, Sri Sai Charan M, Sheshagiri G, Gairola V, Basagoudanavar SH, Sreenivasa BP, Bhanuprakash V.J Virol Methods. 2024 Jul;328:114959. doi: 10.1016/j.jviromet.2024.114959. Epub 2024 May 23.PMID: 38788979

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.
Zhang Y, Chamblee M, Xu J, Qu P, Shamseldin MM, Yoo SJ, Misny J, Thongpan I, Kc M, Hall JM, Gupta YA, Evans JP, Lu M, Ye C, Hsu CC, Liang X, Martinez-Sobrido L, Yount JS, Boyaka PN, Liu SL, Dubey P, Peeples ME, Li J.Nat Commun. 2024 Jul 3;15(1):5589. doi: 10.1038/s41467-024-49443-2.PMID: 38961063

Novel Personalized Cancer Vaccine Using Tumor Extracellular Vesicles with Attenuated Tumorigenicity and Enhanced Immunogenicity.
Han J, Kim S, Hwang YH, Kim SA, Lee Y, Kim J, Cho S, Woo J, Jeong C, Kwon M, Nam GH, Kim IS.Adv Sci (Weinh). 2024 Jul;11(25):e2308662. doi: 10.1002/advs.202308662. Epub 2024 Apr 26.PMID: 38666427

Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
Wynne C, Balgos A, Li J, Hamilton P, Tirador L, Jaen AM, Mo C, Yue Z, Ma Y, Wang Q, Wen R, Yao Z, Yu J, Yao W, Zhang J, Zheng H, Hong K, Zhu F, Liu Y.Infect Dis Ther. 2024 Jul;13(7):1723-1724. doi: 10.1007/s40121-024-00998-z.PMID: 38874695

COVID-19 Vaccines #ForYou: Analyzing COVID-19 Vaccine Videos on TikTok During the Early Phase of the Vaccine Rollout in the U.S.
Yang B, Li Y, Terán L, Choi E, Choi Y.Health Commun. 2024 Jul;39(8):1594-1605. doi: 10.1080/10410236.2023.2227431. Epub 2023 Jun 22.PMID: 37345468

SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, Antinori A; Vax ICONA ORCHESTRA Study group.Int J Infect Dis. 2024 Jul;144:107065. doi: 10.1016/j.ijid.2024.107065. Epub 2024 Apr 19.PMID: 38643867

Cerebellar encephalitis and peripheral neuropathy with an atypical clinical and neuroimaging signature following Covid-19 vaccine: a report of two cases.

Sicard M, Shor N, Davy V, Rouby JJ, Oquendo B, Maisonobe T, Puybasset L, Lehericy S, Lecarpentier A, Donadio C, Oasi C, Belmin J, Lubetzki C, Corvol JC, Grabli D, Saracino D.J Neurol. 2024 Jul;271(7):4680-4684. doi: 10.1007/s00415-024-12390-5. Epub 2024 May 4.PMID: 38704487

Combined vaccines against angiotensin II receptor type 1 and alpha 1D-adrenergic receptor for hypertension.
Wu J, Wu Z, Kuang W, Shi D, Yang Y, Li X, Huang J, Li X, Liao Y, Zhou Z, Qiu Z.J Hypertens. 2024 Jul 1;42(7):1184-1196. doi: 10.1097/HJH.0000000000003710. Epub 2024 Mar 8.PMID: 38690916

Effectiveness of self-financed rotavirus vaccines on acute gastroenteritis primary care episodes using real-world data in Spain: a propensity score-matched analysis of cohort study.
López-Lacort M, Muñoz-Quiles C, Díez-Domingo J, Orrico-Sánchez A.Eur J Pediatr. 2024 Jul;183(7):2843-2853. doi: 10.1007/s00431-024-05536-0. Epub 2024 Apr 7.PMID: 38584228

A Nanoparticle Vaccine Displaying Conserved Epitopes of the Preexisting Neutralizing Antibody Confers Broad Protection against SARS-CoV-2 Variants.
Wu X, Li W, Rong H, Pan J, Zhang X, Hu Q, Shi ZL, Zhang XE, Cui Z.ACS Nano. 2024 Jul 9;18(27):17749-17763. doi: 10.1021/acsnano.4c03075. Epub 2024 Jun 27.PMID: 38935412

Immunogenicity of a bivalent BA.1 COVID-19 booster vaccine in people with HIV in the Netherlands.
Jongkees MJ, Tan NH, Geers D, de Vries RD, GeurtsvanKessel CH, Hensley KS, Sablerolles RSG, Bogers S, Gommers L, Blakaj B, Miranda Afonso P, Hansen BE, Rijnders BJA, Brinkman K, van der Kuy PHM, Roukens AHE, Rokx C.AIDS. 2024 Jul 15;38(9):1355-1365. doi: 10.1097/QAD.0000000000003933. Epub 2024 May 28.PMID: 38788210

Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
Fisman DN, Simmons AE, Tuite AR.Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.07.035. Online ahead of print.PMID: 39004528

Orchestrated Codelivery of Peptide Antigen and Adjuvant to Antigen-Presenting Cells by Using an Engineered Chimeric Peptide Enhances Antitumor T-Cell Immunity.
Pan H, Yu S, Zhuang H, Yang H, Jiang J, Yang H, Ren S, Luo G, Yu X, Chen S, Lin Y, Sheng R, Zhang S, Yuan Q, Huang C, Zhang T, Li T, Ge S, Zhang J, Xia N.Cancer Immunol Res. 2024 Jul 2;12(7):905-920. doi: 10.1158/2326-6066.CIR-23-0926.PMID: 38631019

"This was never about a virus": Perceptions of Vaccination Hazards and Pandemic Risk in #Covid19NZ Tweets.
Long M, Calude A, Burnette J.J Med Humanit. 2024 Jul 10. doi: 10.1007/s10912-024-09859-9. Online ahead of print.PMID: 38985255

Optimal vaccination strategies for imperfect vaccines and variable host susceptibility.
Kisdi E.J Theor Biol. 2024 Jul 6:111899. doi: 10.1016/j.jtbi.2024.111899. Online ahead of print.PMID: 38977125

Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.

Meshram R, Kolte B, Gacche R.Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.07.007. Online ahead of print.PMID: 38971664

Development of α-Tocopherol Loaded PLGA Nanoparticles and Its Evaluation as a Novel Immune Adjuvant.
Zhang H, Song M, Zhuang S, Wang Z, Shi H, Song Z, Song C, Cen L.Macromol Rapid Commun. 2024 Jul 9:e2400400. doi: 10.1002/marc.202400400. Online ahead of print.PMID: 38981020

COVID-19 Immunity in the Cohort of IRCCS San Raffaele Hospital Employees after BNT162b2 Vaccination: A Retrospective Observational Study.
Stocchi M, Melodia P, Lucini A, De Lorenzo R, Pozzi C, Rovere-Querini P, Odone A, Renzi C, Signorelli C.Ann Ig. 2024 Jul-Aug;36(4):432-445. doi: 10.7416/ai.2024.2615. Epub 2024 Feb 22.PMID: 38386027

Field efficacy of a novel porcine reproductive and respiratory syndrome modified-live virus vaccine with an emphasis on growth performance.
Ham S, Lee H, Suh J, Kim C, Kwon WJ, Park GS, Chae C.Vet Med Sci. 2024 Jul;10(4):e1540. doi: 10.1002/vms3.1540.PMID: 38967727

Disparities in Influenza, Pneumococcal, COVID-19 Vaccine Coverage in High-Risk Adults Aged 19 to 64 Years in Southeastern Minnesota, 2010-2021.
Felzer JR, Montgomery AJ, LeMahieu AM, Finney Rutten LJ, Juhn YJ, Wi CI, Jacobson RM, Kennedy CC.Chest. 2024 Jul;166(1):49-60. doi: 10.1016/j.chest.2024.01.049. Epub 2024 Feb 9.PMID: 38342164

Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
Dull PM, Achilles SL, Ahmed R, Barnabas RV, Campos NG, Chirgwin K, Cohen JA, de Sanjosé S, Doorbar J, Einstein MH, Emerson CI, Gottlieb SL, Hildesheim A, Qiao Y, Ruff P, Sampson JN, Sasieni P, Schiffman M, Shin H, Stanley MA, Trimble CL, Wentzensen N, Riemer AB, Schiller JT, Kreimer AR.Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024.07.001. Online ahead of print.PMID: 39004526

Primary care providers' views of discussing COVID-19 vaccination with vaccine hesitant patients: A qualitative study.
Fisher KA, Singh S, Stone RT, Nguyen N, Crawford S, Mazor KM.Patient Educ Couns. 2024 Jul 1;127:108369. doi: 10.1016/j.pec.2024.108369. Online ahead of print.PMID: 38996575

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients.
Kyr M, Mudry P, Polaskova K, Dubska LZ, Demlova R, Kubatova J, Hlavackova E, Pilatova KC, Mazanek P, Vejmelkova K, Dusek V, Tinka P, Balaz M, Merta T, Kuttnerova Z, Turekova T, Pavelka Z, Pokorna P, Palova H, Mlnarikova M, Jezova M, Kellnerova R, Kozakova S, Slaby O, Valik D, Sterba J.Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35062. Online ahead of print.PMID: 38958237

Representations of lipid nanoparticles using large language models for transfection efficiency prediction.
Moayedpour S, Broadbent J, Riahi S, Bailey M, V Thu H, Dobchev D, Balsubramani A, N D Santos R, Kogler-Anele L, Corrochano-Navarro A, Li S, U Montoya F, Agarwal V, Bar-Joseph Z, Jager S.Bioinformatics. 2024 Jul 1;40(7):btae342. doi: 10.1093/bioinformatics/btae342.PMID: 38810107

A Comparison of COVID-19 Associated Hospitalization Rates Among Unvaccinated Versus Vaccinated Residents in Rhode Island, September 2022 to March 2024.
Caron G, McMahon J, Lape-Newman B.R I Med J (2013). 2024 Jul 1;107(7):39-43.PMID: 38917315

Effectiveness of Vaccination Against Tick-Borne Encephalitis in the Czech Republic, 2018-2022.
Kyncl J, Angulo FJ, Orlikova H, Zhang P, Vlckova I, Maly M, Krivohlavkova D, Harper LR, Edwards J, Bender C, Pilz A, Erber W, Madhava H, Moïsi JC.Vector Borne Zoonotic Dis. 2024 Jul 1. doi: 10.1089/vbz.2023.0166. Online ahead of print.PMID: 38946629

Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
Prosper P, Rodríguez Puertas R, Guérin DMA, Branda MM.Vaccine. 2024 Jul 11;42(18):3916-3929. doi: 10.1016/j.vaccine.2024.05.025. Epub 2024 May 22.PMID: 38782665

Vexing Vaccine Ethics: Denying ICU Care to Vaccine Refusers.
Fleck LM.Am J Bioeth. 2024 Jul;24(7):92-94. doi: 10.1080/15265161.2024.2353801. Epub 2024 Jun 24.PMID: 38913481

Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
Nowalk MP, Smith KJ, Raviotta JM, Wateska A, Zimmerman RK.Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.07.008. Online ahead of print.PMID: 38971665

Water-in-oil adjuvant challenges in fish vaccination: An experimental inactivated adjuvanted vaccine against betanodavirus infection in Senegalese sole.
Valero Y, Souto S, Olveira JG, López-Vázquez C, Dopazo CP, Bandín I.J Fish Dis. 2024 Jul;47(7):e13945. doi: 10.1111/jfd.13945. Epub 2024 Mar 24.PMID: 38523313

Hypothesis: the generation of T cells directed against neoepitopes employing immune-mediating agents other than neoepitope vaccines.
Schlom J, Donahue RN, Palena C, Gameiro SR, Hodge JW, Hamilton DH, Gulley JL.J Immunother Cancer. 2024 Jul 8;12(7):e009595. doi: 10.1136/jitc-2024-009595.PMID: 38977329

Human T-cell activation with *Toxoplasma gondii* antigens loaded in maltodextrin nanoparticles.
García-López L, Zamora-Vélez A, Vargas-Montes M, Sanchez-Arcila JC, Fasquelle F, Betbeder D, Gómez-Marín JE.Life Sci Alliance. 2024 May 9;7(7):e202302486. doi: 10.26508/lsa.202302486. Print 2024 Jul.PMID: 38724195

A low-endotoxic Salmonella enterica Gallinarum serovar delivers infectious bronchitis virus immunogens via a dual-promoter vector system that drives protective immune responses through MHC class-I and -II activation in chickens.
Hewawaduge C, Kwon J, Park JY, Lee JH.Poult Sci. 2024 Jul;103(7):103844. doi: 10.1016/j.psj.2024.103844. Epub 2024 May 24.PMID: 38795516

Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.

Verani JR, Omondi D, Odoyo A, Odiembo H, Ouma A, Ngambi J, Aol G, Audi A, Kiplangat S, Agumba N, Munywoki PK, Onyango C, Hunsperger E, Farrar JL, Kim L, Kobayashi M, Breiman RF, Pimenta FC, da Gloria Carvalho M, Lessa FC, Whitney CG, Bigogo G.Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024.07.021. Online ahead of print.PMID: 39004525

T cell epitope based vaccine design while targeting outer capsid proteins of rotavirus strains infecting neonates: an immunoinformatics approach.
Sharma AD, Grewal RK, Gorle S, Cuspoca AF, Kaushik V, Rajjak Shaikh A, Cavallo L, Chawla M.J Biomol Struct Dyn. 2024 Jul;42(10):4937-4955. doi: 10.1080/07391102.2023.2226721. Epub 2023 Jun 29.PMID: 37382214

Preparation and characterization of mouse-derived monoclonal antibodies against the hemagglutinin of the H1N1 influenza virus.
Lin X, Yang F, Yan S, Wu H, Wang P, Zhao Y, Shi D, Yao H, Wu H, Li L.Virus Res. 2024 Jul;345:199402. doi: 10.1016/j.virusres.2024.199402. Epub 2024 May 21.PMID: 38772446

Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents.
Lee ES, Choe YJ, Choe SA, Gwak ES, Kwon D.Pediatr Infect Dis J. 2024 Jul 3. doi: 10.1097/INF.0000000000004463. Online ahead of print.PMID: 38985994

Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.
Eviatar T, Pappo A, Freund T, Friedlander Y, Elkayam O, Hagin D, Heshin-Bekenstein M.Clin Exp Immunol. 2024 Jul 12;217(2):167-172. doi: 10.1093/cei/uxae044.PMID: 38767466

Post-Vaccination Delivery of CpG ODNs Enhances the Th2-Associated Protective Immunity of the Smallpox DNA Vaccine.
Lee MH, Choi HS, Kim NY, Sim E, Choi JY, Hong S, Shin YK, Yu CH, Gu SH, Song DH, Hur GH, Shin S.Mol Biotechnol. 2024 Jul;66(7):1718-1726. doi: 10.1007/s12033-023-00800-4. Epub 2023 Jul 10.PMID: 37428433

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation.
Xie D, Han C, Chen C, Liao Z, Campos de Souza S, Niu Y, Mano JF, Dong L, Wang C.Bioact Mater. 2024 Apr 23;37:315-330. doi: 10.1016/j.bioactmat.2024.03.035. eCollection 2024 Jul.PMID: 38694764

The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in England 2022/23.
Andrews N, Osuntoki I, Stowe J, Kirsebom FCM, Allen A, Bernal JL.J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221. Online ahead of print.PMID: 38996819

A depiction of poliomyelitis in a 17th -century Piedmontese fresco?
Mazzarello P, Varotto E, Galassi FM.Neurol Sci. 2024 Jul;45(7):3517-3519. doi: 10.1007/s10072-024-07531-7. Epub 2024 Apr 25.PMID: 38662105

Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.

Ji J, Tang T, Zhu M, Wu Z, Zhang J, Shi D, Zhu L, Zhang X, Lu X, Chen L, Yao H.Antiviral Res. 2024 Jul 2:105954. doi: 10.1016/j.antiviral.2024.105954. Online ahead of print.PMID: 38964615

Immunological Activity of Vaccine Systems Containing Liposomal Nanocarriers against Protozoan-Induced Diseases: A Systematic Review.
Lourenço FD, Teixeira JVL, Acacio de Moura G, Rocha YM, Rodrigues JPV, Oliveira JR, Pinheiro CV, Nicolete LDF, Nicolete R.Curr Med Chem. 2024 Jul 4. doi: 10.2174/0109298673306158240620071438. Online ahead of print.PMID: 38967082

Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.
Zeng S, Xing S, Zhang Y, Wang H, Liu Q.J Zhejiang Univ Sci B. 2024 Jul 9:1-11. doi: 10.1631/jzus.B2300392. Online ahead of print.PMID: 38993057

Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine.
Kolla HB, Dutt M, Kumar A, Hebbandi Nanjunadappa R, Karakach T, Singh KP, Kelvin D, Clement Mertens PP, Umeshappa CS.Front Immunol. 2024 Jul 1;15:1424307. doi: 10.3389/fimmu.2024.1424307. eCollection 2024.PMID: 39011043

'We were having a rather long conversation about the uproar': memorable messages about COVID-19 vaccinations in a mostly young, white sample.
Bates BR, Finkelshteyn S, Odunsi IA.J Commun Healthc. 2024 Jul;17(2):143-153. doi: 10.1080/17538068.2023.2223437. Epub 2023 Jun 16.PMID: 37326437

HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS): Study protocol for a hybrid 1 stepped-wedge cluster randomized trial.
Christy SM, Patel L, Arevalo M, Fuzzell L, Whitmer A, Turner K, Gore LR, Chung-Bridges K, Parras D, Endemano EY, Brownstein NC, Vadaparampil ST.Contemp Clin Trials. 2024 Jul;142:107576. doi: 10.1016/j.cct.2024.107576. Epub 2024 May 17.PMID: 38763306

IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial.
Low JG, Oh HM, Leo YS, Kalimuddin S, Wijaya L, Pang J, Lee TH, Moss KJ, Brose M, Tricou V.Am J Trop Med Hyg. 2024 May 28;111(1):102-106. doi: 10.4269/ajtmh.23-0549. Print 2024 Jul 3.PMID: 38806045

Natural carriage of Streptococcus pneumoniae is associated with increased experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a human challenge model.
Galafa B, Chikaonda T, Kudowa E, Sichone S, Sibale L, Thole F, Mkandawire C, Dula D, Nsomba E, Tembo G, Chaponda M, Chirwa AE, Nkhoma V, Ngoliwa C, Kamng'ona R, Toto N, Makhaza L, Muyaya A, Howard A, Nyazika TK, Ndaferankhande J, Chimgoneko L, Banda NPK, Chiwala G, Rylance J, Ferreira D, Jambo KC, Morton B, Henrion MYR, Gordon SB.J Infect Dis. 2024 Jul 10:jiae341. doi: 10.1093/infdis/jiae341. Online ahead of print.PMID: 38984706

Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.

Kim KH, Bhatnagar N, Subbiah J, Liu R, Pal SS, Raha JR, Grovenstein P, Shin CH, Wang BZ, Kang SM.Virology. 2024 Jul;595:110097. doi: 10.1016/j.virol.2024.110097. Epub 2024 Apr 25.PMID: 38685171

A natural human cell-adapted dengue type 3 virus strain.
Ng WC, Lin L, Siriphanitchakorn T, Jiang MKX, Tan HC, Ooi EE.Microbiol Spectr. 2024 Jul 2;12(7):e0070124. doi: 10.1128/spectrum.00701-24. Epub 2024 Jun 7.PMID: 38847546

Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
Xu Y, Sun F, Chuai Z, Wang J, Bai Z, Bian C, Wang X, Zhao Z, Liu Y, Yang P.Antiviral Res. 2024 Jul 8:105960. doi: 10.1016/j.antiviral.2024.105960. Online ahead of print.PMID: 38986872

Immunization with a Mu-class glutathione transferase from Echinococcus granulosus induces efficient antibody responses and confers long-term protection against secondary cystic echinococcosis.
Arbildi P, Muniz-Lagos AC, Fernández E, Giorgi R, Wiater K, Mourglia-Ettlin G, Fernández V.Microbes Infect. 2024 Jul-Aug;26(5-6):105364. doi: 10.1016/j.micinf.2024.105364. Epub 2024 May 21.PMID: 38777107

Negativity in online news coverage of vaccination rates in Serbia: a content analysis.
Lazić A, Žeželj I.Psychol Health. 2024 Jul;39(7):895-913. doi: 10.1080/08870446.2022.2121962. Epub 2022 Sep 13.PMID: 36097724

A Dialogue about Vaccine Side Effects: Understanding Difficult Pandemic Experiences.
Hammarlin MM, Dellson P.J Med Humanit. 2024 Jul 1. doi: 10.1007/s10912-024-09850-4. Online ahead of print.PMID: 38951319

Characteristics Associated With Homebound Vaccination Against COVID-19.
Ren J, Kumar A, Zhao D, Ornstein KA, Gliatto P.J Am Med Dir Assoc. 2024 Jul 11:105147. doi: 10.1016/j.jamda.2024.105147. Online ahead of print.PMID: 39004101

Physicians' Human Papillomavirus Vaccine Communication With Parents of Different Skin Color: Feasibility of Measuring Indicators of Implicit Bias With Virtual Reality.
Popler E, Rosen BL, Meisman AR, Lee MR, Kahn JA, Chandler EL, Klein MD, Real FJ.J Adolesc Health. 2024 Jul;75(1):192-195. doi: 10.1016/j.jadohealth.2024.02.017. Epub 2024 Mar 16.PMID: 38493391

Multiplex Assay to Determine Acute Phase Proteins in Modified Live PRRSV Vaccinated Pigs.
Tor M, Fraile L, Vilaró F, Pena RN.J Proteome Res. 2024 Jul 15. doi: 10.1021/acs.jproteome.4c00154. Online ahead of print.PMID: 39007742

The COVID-19 Uninsured Program: Nearly 39 Million Vaccine Doses Were Funded, 2020-22.
Tsai Y, Singleton JA, Lindley MC, Jatlaoui TC.Health Aff (Millwood). 2024 Jul;43(7):979-984. doi: 10.1377/hlthaff.2023.00977.PMID: 38950301

Immersion immunization with recombinant Saccharomyces cerevisiae displaying ORF25 induced protective immunity against cyprinid herpesvirus 2.
Yang M, Luo S, Zhou Q, Lu J, Chen J.J Fish Dis. 2024 Jul 7:e13996. doi: 10.1111/jfd.13996. Online ahead of print.PMID: 38973170

Bacterial glycoengineering: Cell-based and cell-free routes for producing biopharmaceuticals with customized glycosylation.
Palma JA, Bunyatov MI, Hulbert SW, Jewett MC, DeLisa MP.Curr Opin Chem Biol. 2024 Jul 10;81:102500. doi: 10.1016/j.cbpa.2024.102500. Online ahead of print.PMID: 38991462

The impact of the COVID-19 pandemic and the free vaccination policy on seasonal influenza vaccination uptake among older adults in Ningbo, Eastern China.
Ye L, Chen J, Mei Q, Sun Y, Yang T.Hum Vaccin Immunother. 2024 Dec 31;20(1):2370999. doi: 10.1080/21645515.2024.2370999. Epub 2024 Jul 3.PMID: 38957901

Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: a systematic review and meta-analysis.
Imran M, Ali S, Ibrahim AA, Amjad A, Tanveer A, Khalil S, Ali M, Abuelazm M.Clin Rheumatol. 2024 Jul;43(7):2203-2214. doi: 10.1007/s10067-024-07013-3. Epub 2024 May 27.PMID: 38802670

Cold-adapted influenza-vectored RSV vaccine protects BALB/c mice and cotton rats from RSV challenge.
Xu Y, Sun F, Bai Z, Bian C, Wang X, Zhao Z, Yang P.J Med Virol. 2024 Jul;96(7):e29308. doi: 10.1002/jmv.29308.PMID: 39007405

A ferritin-based nanoparticle displaying a neutralizing epitope for foot-and-mouth disease virus (FMDV) confers partial protection in guinea pigs.
Lu B, Ru Y, Hao R, Yang Y, Liu H, Li Y, Zhang Y, Mao Y, Yang R, Pan Y, Yu S, Zheng H, Cui Y.BMC Vet Res. 2024 Jul 6;20(1):301. doi: 10.1186/s12917-024-04159-9.PMID: 38971791

STEPS (Study To Examine Parent, Patient/Dental Provider Systems) to Prevent Human Papillomavirus (HPV)-Related Cancers: A Piloted Dental Patient and Provider Evaluation of Current and Future HPV Education.
Jordan KH, Stephens JA, Niles K, Hoffmeyer N, Pennell ML, Oliveri JM, Paskett ED.J Cancer Educ. 2024 Jul 4. doi: 10.1007/s13187-024-02465-2. Online ahead of print.PMID: 38963602

The contributions of vaccination and natural infection to the production of neutralizing antibodies against the SARS-CoV-2 prototype strain and variants.
Xie H, Zhang J, Bai S, Lv M, Li J, Chen W, Suo L, Chen M, Zhao W, Zhou S, Wang J, Zhang A, Ma J, Wang F, Yan L, Li D, Wu J.Int J Infect Dis. 2024 Jul;144:107060. doi: 10.1016/j.ijid.2024.107060. Epub 2024 Apr 25.PMID: 38670482

A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma.
Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, Gafoor Z, Heery C, Pico-Navarro C, Adams T.Cancer. 2024 Jul 10. doi: 10.1002/cncr.35477. Online ahead of print.PMID: 38985843

Respiratory infection- and asthma-prone, low vaccine responder children demonstrate distinct mononuclear cell DNA methylation pathways.

Martino D, Schultz N, Kaur R, van Haren SD, Kresoje N, Hoch A, Diray-Arce J, Su JL, Levy O, Pichichero M; in association with the IDEAL Consortium.Clin Epigenetics. 2024 Jul 3;16(1):85. doi: 10.1186/s13148-024-01703-0.PMID: 38961479

Development of Interoperable Computable Phenotype Algorithms for Adverse Events of Special Interest to Be Used for Biologics Safety Surveillance: Validation Study.
Holdefer AA, Pizarro J, Saunders-Hastings P, Beers J, Sang A, Hettinger AZ, Blumenthal J, Martinez E, Jones LD, Deady M, Ezzeldin H, Anderson SA.JMIR Public Health Surveill. 2024 Jul 15;10:e49811. doi: 10.2196/49811.PMID: 39008361

Hepatitis B Vaccine Refusal Trends in Washington, DC, Newborns, 2017-2022.
Yang YT, Leslie TF, Delamater PL.JAMA Netw Open. 2024 Jul 1;7(7):e2421202. doi: 10.1001/jamanetworkopen.2024.21202.PMID: 38990574

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis.
Soung J, Laquer V, Merola JF, Moore A, Elmaraghy H, Hu C, Piruzeli MLB, Pierce E, Garcia Gil E, Jarell AD.Dermatol Ther (Heidelb). 2024 Jul 15. doi: 10.1007/s13555-024-01217-w. Online ahead of print.PMID: 39009804

Establishing a Framework for Evaluating the Effectiveness of Vaccines Targeting National Vaccination Programs.
Kang CR, Choe YJ, Shin J, Jeong HJ, Kwon S, Lee H.J Korean Med Sci. 2024 Jul 1;39(25):e193. doi: 10.3346/jkms.2024.39.e193.PMID: 38952346

Influenza and Covid-19 Vaccination in 2023: a descriptive analysis in two Italian Research and Teaching Hospitals. Is the On-Site strategy effective?
Perrone PM, Villa S, Raciti GM, Clementoni L, Vegro V, Scovenna F, Altavilla A, Tomoiaga AM, Beltrami V, Bruno I, Vaccargiu M, Astorri E, Tiwana N, Letzgus M, Schulz PJ, Pregliasco FE, Castaldi S.Ann Ig. 2024 Jul-Aug;36(4):421-431. doi: 10.7416/ai.2024.2606. Epub 2024 Mar 21.PMID: 38525974

Assessing the impacts of vaccination and viral evolution in contact networks.
Blanco-Rodríguez R, Tetteh JNA, Hernández-Vargas E.Sci Rep. 2024 Jul 8;14(1):15753. doi: 10.1038/s41598-024-66070-5.PMID: 38977773

Quasi-experimental methods for pharmacoepidemiology: difference-in-differences and synthetic control methods with case studies for vaccine evaluation.
Kennedy-Shaffer L.Am J Epidemiol. 2024 Jul 8;193(7):1050-1058. doi: 10.1093/aje/kwae019.PMID: 38456774

Incidence and risk factors of cutaneous reactions to the first COVID-19 booster vaccine.
Smith LR, Shah RJ, King AJ, Shenoy ES, Landman AB, Hashimoto DM, Blumenthal K.Allergy. 2024 Jul 9. doi: 10.1111/all.16223. Online ahead of print.PMID: 38979795

Willingness to receive mpox vaccine among men who have sex with men: a systematic review and meta-analysis.
Liu J, Liu S, Yu S, Du X, Hao J, Hui R, Buh A, Chen W, Chen J.BMC Public Health. 2024 Jul 15;24(1):1878. doi: 10.1186/s12889-024-19260-9.PMID: 39010029

Models for predicting the risk of illness in leprosy contacts in Brazil: Leprosy prediction models in Brazilian contacts.
de Alecrin ES, Martins MAP, de Oliveira ALG, Lyon S, Lages ATC, Reis IA, Pereira FH, Oliveira D, Goulart IMB, da Costa Rocha MO.Trop Med Int Health. 2024 Jul 4. doi: 10.1111/tmi.14020. Online ahead of print.PMID: 38961761

Interdependency or submission to authority? The impacts of horizontal and vertical collectivist orientation on vaccine attitudes in mainland China.
Jin Y, Bai S, Han T, Li L, Xie T, Guo Y, Zhang RJ.Int J Psychol. 2024 Jul 4. doi: 10.1002/ijop.13217. Online ahead of print.PMID: 38961732

A Single-Dose mRNA Vaccine Employing Porous Silica Nanoparticles Induces Robust Immune Responses Against the Zika Virus.
Shin H, Kang S, Won C, Min DH.Adv Sci (Weinh). 2024 Jul 15:e2404590. doi: 10.1002/advs.202404590. Online ahead of print.PMID: 39010673

Bacterially expressed full length Hemagglutinin of Avian Influenza Virus H5N1 forms oligomers and exhibits hemagglutination.
Panwar P, Jhala D, Tamrakar A, Joshi C, Patel A.Protein Expr Purif. 2024 Jul 4:106541. doi: 10.1016/j.pep.2024.106541. Online ahead of print.PMID: 38971212

Total synthesis of the hexasaccharide arabinan domain of mycobacterial arabinogalactan.
Fang S, Huang C, Ao J, Xiao Q, Zhou S, Deng W, Cai H, Ding F.Carbohydr Res. 2024 Jul 4;542:109204. doi: 10.1016/j.carres.2024.109204. Online ahead of print.PMID: 38981322

Cost-Effectiveness of the Recombinant Zoster Vaccine Among People Living With HIV in Japan.
Sato S, Konishi T, Ohbe H, Yasunaga H.Value Health Reg Issues. 2024 Jul 5;44:101025. doi: 10.1016/j.vhri.2024.101025. Online ahead of print.PMID: 38970854

Single dose of Dengvaxia vaccine: is it a cause for alarm?
Buerano CC, Morita K.Lancet Infect Dis. 2024 Jul;24(7):670-671. doi: 10.1016/S1473-3099(24)00181-6. Epub 2024 Mar 22.PMID: 38527473

Assessment of an in-house IgG ELISA targeting SARS-CoV-2 RBD: Applications in infected and vaccinated individuals.
da Costa HHM, Silva VO, Amorim GC, Guereschi MG, Sergio LM, Gomes CHR, Hong MA, de Oliveira EL, Brígido LFM, Lindoso JAL, Prudencio CR.J Immunol Methods. 2024 Jul;530:113683. doi: 10.1016/j.jim.2024.113683. Epub 2024 May 15.PMID: 38759864

Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States.

Yi Z, Johnson KD, Owusu-Edusei K.Infect Dis Ther. 2024 Jul;13(7):1501-1514. doi: 10.1007/s40121-024-00988-1. Epub 2024 May 25.PMID: 38796565

A quadrivalent norovirus vaccine based on a chimpanzee adenovirus vector induces potent immunity in mice.
Jiang Y, Sun L, Qiao N, Wang X, Zhu C, Xing M, Liu H, Zhou P, Zhou D.Virol Sin. 2024 Jul 10:S1995-820X(24)00112-3. doi: 10.1016/j.virs.2024.07.002. Online ahead of print.PMID: 38997087

Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2-Dominant Period, Japan.
Ogata T, Tanaka H, Kon A, Sakaibori N, Tanaka E.Emerg Infect Dis. 2024 Jul;30(7):1430-1433. doi: 10.3201/eid3007.230968.PMID: 38916601

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity.
Mandal S, Ghosh JS, Lohani SC, Zhao M, Cheng Y, Burrack R, Luo M, Li Q.Emerg Microbes Infect. 2024 Jul 9:2377606. doi: 10.1080/22221751.2024.2377606. Online ahead of print.PMID: 38979723

Breast Milk-Derived Antibodies Impair Vaccine Immunity in Suckling Mice.
Dangi T, Sanchez S, Awakoaiye B, Lew MH, Irani N, Penaloza-MacMaster P.J Immunol. 2024 Jul 15:ji2400277. doi: 10.4049/jimmunol.2400277. Online ahead of print.PMID: 39007643

Self-Assembling Nanoparticle Hemagglutinin Influenza Vaccines Induce High Antibody Response.
Ren H, Zhang B, Zhang X, Wang T, Hou X, Lan X, Pan C, Wu J, Liu B.Int J Mol Sci. 2024 Jul 1;25(13):7259. doi: 10.3390/ijms25137259.PMID: 39000366

The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI.
Ganelin-Cohen E, Buxbaum C, Bosak N, Sobol S, Vaknin-Dembinsky A, Hellmann MA, Wilf-Yarkoni A, Regev K, Pustovoyt E, Shifrin A, Wexler Y, Rozenberg A.Brain Behav. 2024 Jul;14(7):e3587. doi: 10.1002/brb3.3587.PMID: 38940313

Genetic analysis of the circumsporozoite gene in Plasmodium falciparum isolates from Cameroon: Implications for efficacy and deployment of RTS,S/AS01 vaccine.
Kojom Foko LP, Hawadak J, Eboumbou Moukoko CE, Das A, Singh V.Gene. 2024 Jul 2;927:148744. doi: 10.1016/j.gene.2024.148744. Online ahead of print.PMID: 38964492

Effectiveness of mRNA COVID-19 Vaccines as First Booster Doses in England: An Observational Study in OpenSAFELY-TPP.
Horne EMF, Hulme WJ, Parker EPK, Keogh RH, Williamson EJ, Walker VM, Palmer TM, Denholm R, Knight R, Curtis HJ, Walker AJ, Andrews CD, Mehrkar A, Morley J, MacKenna B, Bacon SCJ, Goldacre B, Hernán MA, Sterne JAC; and the OpenSAFELY collaborative.Epidemiology. 2024 Jul 1;35(4):568-578. doi: 10.1097/EDE.0000000000001747. Epub 2024 Jun 24.PMID: 38912714

Trailblazing in adjuvant research: succinate's uncharted territory with neutrophils.

Wang Y, Xiu Z, Qu K, Wang L, Wang H, Yu Y.Am J Physiol Cell Physiol. 2024 Jul 1;327(1):C1-C10. doi: 10.1152/ajpcell.00129.2024. Epub 2024 May 6.PMID: 38708521

Age-Related Differences in Neutralizing Antibody Responses against SARS-CoV-2 Delta and Omicron Variants in 151 SARS-CoV-2-Naïve Metropolitan Residents Boosted with BNT162b2.
Lee B, Bae GE, Jeong IH, Kim JH, Kwon MJ, Kim J, Kim B, Lee JW, Nam JH, Huh HJ, Kang ES.J Appl Lab Med. 2024 Jul 1;9(4):741-751. doi: 10.1093/jalm/jfae014.PMID: 38531067

Determinants of Intention to Uptake COVID-19 Vaccination Among Saudi Adults: Application of the Health Belief Model.
Alshagrawi SS.Risk Manag Healthc Policy. 2024 Jul 8;17:1803-1814. doi: 10.2147/RMHP.S432153. eCollection 2024.PMID: 39007107

School children's perceptions about being offered the HPV vaccination - A focus group study.
Enskär I, Fransson E, Enskär K, Nevéus T, Grandahl M.Acta Paediatr. 2024 Jul;113(7):1672-1678. doi: 10.1111/apa.17225. Epub 2024 Mar 29.PMID: 38551330

Exploring the genetic diversity pattern of PvEBP/DBP2: A promising candidate for an effective Plasmodium vivax vaccine.
Hernández-Zambrano LJ, Alfonso-González H, Buitrago SP, Castro-Cavadía CJ, Garzón-Ospina D.Acta Trop. 2024 Jul;255:107231. doi: 10.1016/j.actatropica.2024.107231. Epub 2024 Apr 27.PMID: 38685340

Estimating vaccine effectiveness against COVID-19 using cause-specific sick leave as an indicator: a nationwide population-based cohort study, Norway, July 2021 - December 2022.
Meijerink H, Veneti L, Kristoffersen AB, Danielsen AS, Stecher M, Starrfelt J.BMC Public Health. 2024 Jul 11;24(1):1861. doi: 10.1186/s12889-024-19374-0.PMID: 38992631

Acquired immune thrombotic thrombocytopenic purpura (TTP) associated with inactivated COVID-19 vaccine CoronaVac.
Long Z, Jiang S, Xin H, Zhang L, Lu R, Liu F, Xu Y, Wang L, Wang J, Zhang X, Liao H, Shi J, Yan X, Zhu X, Shao R, Li Z, Zhu Y, Yan H, Wu J, Fang C, Xi X, Shi X.Front Med. 2024 Jul 3. doi: 10.1007/s11684-023-1054-2. Online ahead of print.PMID: 38958922

Immunogenicity of 4-dose Essen intramuscular regimen for rabies post-exposure prophylaxis: A multi-center cross-sectional study in China.
Hou Q, Liu S, Liu C, Wang X, Shi J, Chen Q, Lv X, Zhu Z, Wang C, Yin W.Travel Med Infect Dis. 2024 Jul 9;60:102735. doi: 10.1016/j.tmaid.2024.102735. Online ahead of print.PMID: 38992484

Against a New Wave of Vaccine Apartheid: Reconceptualizing Justice in Vaccine-Sensitive Rationing.
Pondugula N, Garcia Hernandez C, Sirvent R.Am J Bioeth. 2024 Jul;24(7):111-114. doi: 10.1080/15265161.2024.2353806. Epub 2024 Jun 24.PMID: 38913488

Estimation of self-funded human papillomavirus vaccine recipients from Japan's previously assumed "unvaccinated generation".
Kobayashi M, Nakagawa S, Ueda Y, Yagi A, Kakuda M, Hiramatsu K, Kimura T.Cancer Sci. 2024 Jul 11. doi: 10.1111/cas.16272. Online ahead of print.PMID: 38992919

Omission of alcohol skin cleansing and risk of adverse events in long-term care residents undergoing COVID-19 vaccination: A cohort study.
Lafleur B, Fung J, Verschoor CP, Dubois S, MacDonald NE, Taddio A.Hum Vaccin Immunother. 2024 Dec 31;20(1):2368681. doi: 10.1080/21645515.2024.2368681. Epub 2024 Jul 2.PMID: 38953297

A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity.
Vergara EJ, Tran AC, Paul MJ, Harrison T, Cooper A, Reljic R.NPJ Vaccines. 2024 Jul 2;9(1):123. doi: 10.1038/s41541-024-00906-z.PMID: 38956057

Lack of detection of aluminium-reactive T-lymphocytes in patients with SCIT-induced granulomas.
Hoffmann SS, Elberling J, Johansen JD, Blom LH.Clin Transl Allergy. 2024 Jul;14(7):e12378. doi: 10.1002/clt2.12378.PMID: 38952207

Age dependent discrepancy between SARS-CoV-2 anti-nucleoprotein antibody and anti-RBD spike protein antibody in children reflects vaccine coverage.
Fujii Y, Ishigaki H, Miyairi I, Niizeki N, Nagura O, Yamashita K, Maekawa M, Furuhashi K.J Infect Chemother. 2024 Jul;30(7):646-650. doi: 10.1016/j.jiac.2024.01.020. Epub 2024 Feb 1.PMID: 38309499

Evaluation of immunogenicity and protective efficacy of outer membrane vesicles from Salmonella Typhimurium and Salmonella Choleraesuis.
Tian Y, Huang S, Zhou G, Fei X, Li YA, Li Q, Wang S, Shi H.Vet Microbiol. 2024 Jul;294:110131. doi: 10.1016/j.vetmic.2024.110131. Epub 2024 May 23.PMID: 38805917

Chikungunya virus release is reduced by TIM-1 receptors through binding of envelope phosphatidylserine.
Reyes Ballista JM, Hoover AJ, Noble JT, Acciani MD, Miazgowicz KL, Harrison SA, Tabscott GAL, Duncan A, Barnes DN, Jimenez AR, Brindley MA.J Virol. 2024 Jul 15:e0077524. doi: 10.1128/jvi.00775-24. Online ahead of print.PMID: 39007616

Determinants of Intention to Uptake COVID-19 Vaccination Among Saudi Adults: Application of the Health Belief Model.
Alshagrawi SS.Risk Manag Healthc Policy. 2024 Jul 8;17:1803-1814. doi: 10.2147/RMHP.S432153. eCollection 2024.PMID: 39007107

Malaria transmission blocking activity of Anopheles stephensi alanyl aminopeptidase N antigen formulated with MPL, CpG, and QS21 adjuvants.
Pourhashem Z, Nourani L, Pirahmadi S, Yousefi H, J Sani J, Raz A, Zakeri S, Dinparast Djadid N, Abouie Mehrizi A.PLoS One. 2024 Jul 5;19(7):e0306664. doi: 10.1371/journal.pone.0306664. eCollection 2024.PMID: 38968270

A case of biopsy-proven inflammatory dilated cardiomyopathy following heterologous mRNA-1273 third-dose immunization.
Hashimoto K, Yamamoto H, Ikeda Y, Isogai J, Hashimoto T.ESC Heart Fail. 2024 Jul 1. doi: 10.1002/ehf2.14924. Online ahead of print.PMID: 38946583

Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency.
McGee JE, Kirsch JR, Kenney D, Cerbo F, Chavez EC, Shih TY, Douam F, Wong WW, Grinstaff MW.Nat Biotechnol. 2024 Jul 8. doi: 10.1038/s41587-024-02306-z. Online ahead of print.PMID: 38977924

Do pregnant persons want influenza vaccines? Knowledge, attitudes, perceptions, and practices toward influenza vaccines in 8 low- and middle-income countries.
McCarron M, Yau TS, Griffin C, Marcenac P, Ebama MS, Lafond KE, Igboh LS, Duca LM, Bino S, Bettaieb J, Dhaouadi S, Sahakyan G, Cherkaoui I, Alj L, Coulibaly D, Lutwama JJ, Douba A, N'Gattia A, Khanthamaly V, Tengbriacheu C, Patthammavong C, Lambach P, Otorbaeva D, Azziz-Baumgartner E, Bresee JS.J Infect Dis. 2024 Jul 2:jiae340. doi: 10.1093/infdis/jiae340. Online ahead of print.PMID: 38954648

Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials.
Zhang Y, Zhuang X, Hu Y, Chen J, Hao K, Tang Z, Tian M, Tian H, Jin N, Chen X.Biomacromolecules. 2024 Jul 8;25(7):4281-4291. doi: 10.1021/acs.biomac.4c00365. Epub 2024 Jun 6.PMID: 38843459

Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets.
Graaf-Rau A, Schmies K, Breithaupt A, Ciminski K, Zimmer G, Summerfield A, Sehl-Ewert J, Lillie-Jaschniski K, Helmer C, Bielenberg W, Grosse Beilage E, Schwemmle M, Beer M, Harder T.NPJ Vaccines. 2024 Jul 13;9(1):127. doi: 10.1038/s41541-024-00916-x.PMID: 39003272

Drug repositioning identifies salvinorin A and deacetylgedunin (DCG) enriched plant extracts as novel inhibitors of Mpro, RBD-ACE2 and TMPRRS2 proteins.
Shayo MJ, Samwel B, Shadrack DM, Cassel J, Salvino JM, Montaner LJ, Deogratias G, Tietjen I, Kiruri L, Hilonga S, Innocent E.RSC Adv. 2024 Jul 4;14(29):21203-21212. doi: 10.1039/d4ra02593h. eCollection 2024 Jun 27.PMID: 38966817

Growth and replication of infectious bursal disease virus in the fish cell line as an experimental vaccine.
Ghermezian B, Namavari M, Abdi-Hachesoo B, Mohammadi A, Hayati M, Bootorabi Z, Khabazan Z, Dabiri F, Rajablou H.Res Vet Sci. 2024 Jul;174:105293. doi: 10.1016/j.rvsc.2024.105293. Epub 2024 May 10.PMID: 38754221

Financial hindrances to introducing higher-valent pediatric combination vaccines.
Amimo F.Hum Vaccin Immunother. 2024 Dec 31;20(1):2364497. doi: 10.1080/21645515.2024.2364497. Epub 2024 Jul 8.PMID: 38976756

miR-214-PTEN pathway is a potential mechanism for stress-induced immunosuppression affecting chicken immune response to avian influenza virus vaccine.
Ma X, Wang Q, Xu X, Zhang W, Zhang R, Jiang Y, Wang X, Man C.Virology. 2024 Jul;595:110094. doi: 10.1016/j.virol.2024.110094. Epub 2024 Apr 25.PMID: 38692133

Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.

Buchhorn de Freitas S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, Drawanz Hartwig D.Vaccine. 2024 Jul 11;42(18):3802-3810. doi: 10.1016/j.vaccine.2024.04.094. Epub 2024 May 7.PMID: 38719690

CpG adjuvant enhances humoral and cellular immunity against OVA in different degrees in BALB/c, C57BL/6J, and C57BL/6N mice.
Chu Y, He Y, Zhai W, Huang Y, Tao C, Pang Z, Wang Z, Zhang D, Li H, Jia H.Int Immunopharmacol. 2024 Jul 6;138:112593. doi: 10.1016/j.intimp.2024.112593. Online ahead of print.PMID: 38972210

Recurrent Skin Rash, Epigastralgia, and Arthralgia After SARS-CoV-2 mRNA Immunization and Breakthrough Infection.
Katsube K, Nagai T, Watanabe T.Gastroenterology. 2024 Jul;167(2):e5-e8. doi: 10.1053/j.gastro.2023.12.024. Epub 2024 Jan 8.PMID: 38199589

A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
Zhang D, Jiang Y, Wang M, Zhao J, Wan J, Li Z, Huang D, Yu J, Li J, Liu J, Huang F, Hao S.Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024.06.064. Online ahead of print.PMID: 38960787

Experiences of community pharmacists in the United Kingdom on the provision of travel health services and associated educational requirements.
Goodyer L, Evans D, Wilson A, Palit P, Ma C, Lister HR, Poletti T.Int J Pharm Pract. 2024 Jul 4;32(4):287-293. doi: 10.1093/ijpp/riae024.PMID: 38810219

Stability and expression of K-ras mimotopes in freeze-dried recombinant Lactococcus lactis NZ3900-fermented milk powder during storage in vacuum packaging.
How YH, Teo MYM, In LLA, Yeo SK, Bhandari B, Yusof YA, Pui LP.J Appl Microbiol. 2024 Jul 2;135(7):lxae162. doi: 10.1093/jambio/lxae162.PMID: 38955370

Randomised controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine.
Lee WS, Audsley J, Trieu MC, Reynaldi A, Aurelia LC, Mehta PH, Patterson J, Kent HE, Nguyen J, Amarasena T, Esterbauer R, Haycroft ER, Ramanathan P, Davenport MP, Schlub TE, Sasadeusz J, Wheatley AK, Chung AW, Juno JA, Selva KJ, Kent SJ.J Clin Invest. 2024 Jul 11:e181244. doi: 10.1172/JCI181244. Online ahead of print.PMID: 38990644

Six adenoviral vectored African swine fever virus genes protect against fatal disease caused by genotype I challenge.
Portugal R, Goldswain H, Moore R, Tully M, Harris K, Corla A, Flannery J, Dixon LK, Netherton CL.J Virol. 2024 Jul 2:e0062224. doi: 10.1128/jvi.00622-24. Online ahead of print.PMID: 38953377

How mRNA is powering a personalized vaccine revolution.
May M.Nat Med. 2024 Jul 15. doi: 10.1038/d41591-024-00052-y. Online ahead of print.PMID: 39009892

A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice.

Luo J, Zhang M, Ye Q, Gao F, Xu W, Li B, Wang Q, Zhao L, Tan WS.Arch Virol. 2024 Jul 11;169(8):163. doi: 10.1007/s00705-024-06082-8.PMID: 38990396

Target screening using RNA interference in the sheep abomasal nematode parasite Haemonchus contortus.
Bouchet C, Umair S, Stasiuk S, Grant W, Green P, Knight J.Mol Biochem Parasitol. 2024 Jul 12:111648. doi: 10.1016/j.molbiopara.2024.111648. Online ahead of print.PMID: 39004228

Proteome profile of Leishmania donovani Centrin1$^{-/-}$ parasite-infected human macrophage cell line and its implications in determining possible mechanisms of protective immunity.
Reyaz E, Tandon R, Beg MA, Dey R, Puri N, Salotra P, Nakhasi HL, Selvapandiyan A.Microbes Infect. 2024 Jul-Aug;26(5-6):105340. doi: 10.1016/j.micinf.2024.105340. Epub 2024 Apr 23.PMID: 38663721

Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice.
Prajeeth CK, Zdora I, Saletti G, Friese J, Gerlach T, Wilken L, Beicht J, Kubinski M, Puff C, Baumgärtner W, Kortekaas J, Wichgers Schreur PJ, Osterhaus ADME, Rimmelzwaan GF.Emerg Microbes Infect. 2024 Dec;13(1):2373313. doi: 10.1080/22221751.2024.2373313. Epub 2024 Jul 10.PMID: 38946528

Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV: Erratum.
[No authors listed]AIDS. 2024 Jul 1;38(8):1279. doi: 10.1097/01.aids.0001010204.00856.15. Epub 2024 May 30.PMID: 38814720

Chitosan-alginate/R8 ternary polyelectrolyte complex as an oral protein-based vaccine candidate induce effective mucosal immune responses.
Liu Y, Long M, Wang Y, Liang Z, Dong Y, Qu M, Ge X, Nan Y, Chen Y, Zhou X.Int J Biol Macromol. 2024 Jul 5;275(Pt 2):133671. doi: 10.1016/j.ijbiomac.2024.133671. Online ahead of print.PMID: 38971274

COVID-19 vaccinated children, adolescents, and young adults with acute lymphoblastic leukemia show spike reactive antibodies and multifunctional T-cells.
Parker RS, Le J, Villa M, Luong A, Lin TY, Lee Y, Doan A, Aguayo-Hiraldo P, Pannaraj PS, Yoon SJ, Wallace WD, Armstrong A, O'Gorman MR, Bard JD, Parekh C.Int J Cancer. 2024 Jul 15. doi: 10.1002/ijc.35096. Online ahead of print.PMID: 39005114

Expression of dengue capsid-like particles in silkworm and display of envelope domain III of dengue virus serotype 2.
Muthuraman KR, Utomo DIS, Matsuda M, Suzuki R, Park EY.Protein Expr Purif. 2024 Oct;222:106543. doi: 10.1016/j.pep.2024.106543. Epub 2024 Jul 4.PMID: 38971211

Identifying a Level of Neutralizing Antibody That Correlates With Protection From Clinical Mumps Disease During a 2017 Mumps Outbreak Among Military Service Members.
Sowers SB, Clemmons NS, Mercader S, Nielsen L, Colley H, Jordan NN, Bettger CC, Masters NB, Markelz AE, Hickman CJ.Open Forum Infect Dis. 2024 Jun 17;11(7):ofae329. doi: 10.1093/ofid/ofae329. eCollection 2024 Jul.PMID: 38975246

Exploring Barriers and Facilitators to COVID-19 Vaccination in People Planning Pregnancy, Trying to Conceive, Pregnant, and Postpartum: A Mixed-Methods Study.

Guarna G, Bauer-Maison N, Malik M, D'Souza R, Sharma S.J Obstet Gynaecol Can. 2024 Jul;46(7):102548. doi: 10.1016/j.jogc.2024.102548. Epub 2024 May 8.PMID: 38723865

Decomposition Analysis of Socioeconomic Inequalities in Vaccination Dropout in Remote and Underserved Settings in Ethiopia.
Shiferie F, Gebremedhin S, Andargie G, Tsegaye DA, Alemayehu WA, Fenta TG.Am J Trop Med Hyg. 2024 Jun 4;111(1):196-204. doi: 10.4269/ajtmh.23-0816. Print 2024 Jul 3.PMID: 38834055

Expression of immuno-transcriptome response in red hybrid tilapia (Oreochromis sp.) hindgut following vaccination with feed-based bivalent vaccine.
Ali NSM, Ngalimat MS, Saad MZ, Azmai MNA, Salleh A, Zulperi Z, Md Yasin IS.J Fish Dis. 2024 Jul;47(7):e13943. doi: 10.1111/jfd.13943. Epub 2024 Mar 13.PMID: 38481095

Prevention of vertical transmission of hepatitis B: A retrospective review of a 5-year maternal-infant cohort in London.
O'Mahony E, Raghunanan S, Brown A, Foster C.J Paediatr Child Health. 2024 Jul 2. doi: 10.1111/jpc.16609. Online ahead of print.PMID: 38953228

Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans, vaccine deficient in chitosan.
Specht CA, Wang R, Oliveira LVN, Hester MM, Gomez C, Mou Z, Carlson D, Lee CK, Hole CR, Lam WC, Upadhya R, Lodge JK, Levitz SM.mBio. 2024 Jul 9:e0174624. doi: 10.1128/mbio.01746-24. Online ahead of print.PMID: 38980038

Applying two approaches to detect unmeasured confounding due to time-varying variables in a self-controlled risk interval design evaluating COVID-19 vaccine safety signals, using myocarditis as a case example.
Bots SH, Belitser S, Groenwold RHH, Durán CE, Riera-Arnau J, Schultze A, Messina D, Segundo E, Douglas I, Carreras JJ, Garcia-Poza P, Gini R, Huerta C, Martín-Pérez M, Martin I, Paoletti O, Bissacco CA, Correcher-Martínez E, Souverein P, Urchuequía A, Villalobos F, Sturkenboom MCJM, Klungel OH.Am J Epidemiol. 2024 Jul 3:kwae172. doi: 10.1093/aje/kwae172. Online ahead of print.PMID: 38960670

Reassortment incompetent live attenuated and replicon influenza vaccines provide improved protection against influenza in piglets.
Graaf-Rau A, Schmies K, Breithaupt A, Ciminski K, Zimmer G, Summerfield A, Sehl-Ewert J, Lillie-Jaschniski K, Helmer C, Bielenberg W, Grosse Beilage E, Schwemmle M, Beer M, Harder T.NPJ Vaccines. 2024 Jul 13;9(1):127. doi: 10.1038/s41541-024-00916-x.PMID: 39003272

Author Correction: A computational approach to design a polyvalent vaccine against human respiratory syncytial virus.
Moin AT, Ullah MA, Patil RB, Faruqui NA, Araf Y, Das S, Uddin KMK, Hossain MS, Miah MF, Moni MA, Chowdhury DUS, Islam S.Sci Rep. 2024 Jul 8;14(1):15721. doi: 10.1038/s41598-024-66721-7.PMID: 38977863

[Can citizenship help analyze the risk of underimmunization in the foreign population?].
Primieri C, Bietta C.Recenti Prog Med. 2024 Jul-Aug;115(7):323-324. doi: 10.1701/4314.42984.PMID: 39011912

Standardizing routine vaccination of dermatologists with occupational exposure to human papillomavirus in clinical settings.
Rypka KJ, Farah RS, Mansh M.J Am Acad Dermatol. 2024 Jul;91(1):178-179. doi: 10.1016/j.jaad.2023.04.053. Epub 2023 May 13.PMID: 37187428

Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study.
Kirsebom FCM, Stowe J, Lopez Bernal J, Allen A, Andrews N.J Infect. 2024 Jul;89(1):106177. doi: 10.1016/j.jinf.2024.106177. Epub 2024 May 7.PMID: 38719110

Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designs.
Diaz-Quijano FA, Siqueira de Carvalho D, Raboni SM, Shimakura SE, Maron de Mello A, Vieira da Costa-Ribeiro MC, Silva L, da Cruz Magalhães Buffon M, Cesario Pereira Maluf EM, Graeff G, Almeida G, Preto C, Luhm KR.Lancet Reg Health Am. 2024 May 21;35:100777. doi: 10.1016/j.lana.2024.100777. eCollection 2024 Jul.PMID: 38807985

Variation in incidence rates of outcomes relevant to vaccine safety monitoring in a US commercially insured population by case identification algorithm.
Crowe CL, Dreyfus J, Lanes S, Chung H, Watson W.Vaccine. 2024 Jul 11;42(18):3811-3818. doi: 10.1016/j.vaccine.2024.04.095. Epub 2024 May 6.PMID: 38714442

Interleukin-10 as a marker for response to dendritic cells-dribbles immunotherapy in hepatocellular carcinoma, a mice model.
El Shahawy AA, Gawish AA, Meawed TE, Ahmed NM, Ahmed AA, Abdelhadi AA.Egypt J Immunol. 2024 Jul;31(3):123-130.PMID: 38995717

New in the tropics: Safety concerns of the novel Butantan-Dengue vaccine for dengue prevention in tropical countries.
Ng IKS, Goh WGW, Teo DB.Trop Doct. 2024 Jul;54(3):235-236. doi: 10.1177/00494755241250083. Epub 2024 Apr 28.PMID: 38679746

Reply to "Financial hindrances to introducing higher-valent pediatric combination vaccines".
Huang A, Xu X, Tang L, Wang F.Hum Vaccin Immunother. 2024 Dec 31;20(1):2364509. doi: 10.1080/21645515.2024.2364509. Epub 2024 Jul 8.PMID: 38976763

Vaccine design and development: Exploring the interface with computational biology and AI.
Ananya, Panchariya DC, Karthic A, Singh SP, Mani A, Chawade A, Kushwaha S.Int Rev Immunol. 2024 Jul 10:1-20. doi: 10.1080/08830185.2024.2374546. Online ahead of print.PMID: 38982912

Spray vaccination with a Newcastle disease virus (NDV)-vectored infectious laryngotracheitis (ILT) vaccine protects commercial chickens from ILT in the presence of maternally-derived antibodies.
Zeng Z, Wang Z, Wang X, Yao L, Shang Y, Feng H, Wang H, Shao H, Luo Q, Wen G.Avian Pathol. 2024 Jul 11:1-7. doi: 10.1080/03079457.2024.2356676. Online ahead of print.PMID: 38836447

Comparative safety and efficacy of autogenous vaccine administrated by different routes against furunculosis caused by Aeromonas salmonicida sub. salmonicida in large Rainbow trout (Oncorhynchus mykiss).
Moreau E, Marie S, Bachelet F, Pineau L, Calvez S.Fish Shellfish Immunol. 2024 Jul 11:109757. doi: 10.1016/j.fsi.2024.109757. Online ahead of print.PMID: 39002556

Viral-vectored boosting of OmcB- or CPAF-specific T-cell responses fail to enhance protection from Chlamydia muridarum in infection-immune mice and elicits a non-protective CD8-dominant response in naïve mice.
Poston TB, Girardi J, Polson AG, Bhardwaj A, Yount KS, Jaras Salas I, Trim LK, Li Y, O'Connell CM, Leahy D, Harris JM, Beagley KW, Goonetilleke N, Darville T.Mucosal Immunol. 2024 Jul 3:S1933-0219(24)00066-7. doi: 10.1016/j.mucimm.2024.06.012. Online ahead of print.PMID: 38969067

Augmented humoral response to third and fourth dose of SARS-CoV-2 mRNA vaccines in lung transplant recipients.
Kawana S, Sugimoto S, Matsubara K, Choshi H, Tanaka S, Ishihara M, Habu T, Hashimoto K, Suzawa K, Shien K, Miyoshi K, Okazaki M, Nakayama M, Toyooka S.Respir Investig. 2024 Jul 12;62(5):804-810. doi: 10.1016/j.resinv.2024.07.004. Online ahead of print.PMID: 39002293

COVID-19 Vaccine Acceptance and Hesitancy among People Living with HIV: Review and Meta-Analysis.
Pereira M, Santos Aleluia IR, de Castro CT, de Almeida Oliveira T, Cunha MS, Magno L, Dourado I, Barreto F, Natividade M, Appiah SCY, Abade E, Paixao ES, de Souza MLT.AIDS Behav. 2024 Jul;28(7):2193-2204. doi: 10.1007/s10461-024-04351-w. Epub 2024 May 7.PMID: 38713281

SARS-CoV-2-Spike T-cell response after receiving one or two Wuhan-Hu-1-based mRNA COVID-19 vaccine booster doses in elderly nursing home residents.
Carretero D, Giménez E, Albert E, Colomer E, Torres I, Olea B, Sánchez-Simarro Á, Navarro D.J Med Virol. 2024 Jul;96(7):e29790. doi: 10.1002/jmv.29790.PMID: 38994662

COVID-19 Surge During Summer 2024: The Phantom Menace?
Davido B, Mégarbane B, Loubet P.Clin Microbiol Infect. 2024 Jul 11:S1198-743X(24)00338-0. doi: 10.1016/j.cmi.2024.07.009. Online ahead of print.PMID: 39002663

Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study.
López-Lacort M, Corberán-Vallet A, Santonja FJ, Muñoz-Quiles C, Díez-Domingo J, Orrico-Sánchez A.J Infect Public Health. 2024 Jul 8;17(8):102492. doi: 10.1016/j.jiph.2024.102492. Online ahead of print.PMID: 39002465

The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials.
Skaarup KG, Lassen MCH, Modin D, Johansen ND, Loiacono MM, Harris RC, Lee JKH, Dufournet M, Vardeny O, Peikert A, Claggett B, Solomon SD, Jensen JUS, Biering-Sørensen T.J Infect. 2024 Jul;89(1):106187. doi: 10.1016/j.jinf.2024.106187. Epub 2024 May 23.PMID: 38795774

Measles in the vaccinated host.

Stout R, Muir D, Sriskandan S.BMJ Case Rep. 2024 Jul 2;17(7):e259429. doi: 10.1136/bcr-2023-259429.PMID: 38960425

Pre-graft vaccination or infection do not decrease COVID-19 infections in recipients of allogeneic stem cell transplantation vaccinated and/or protected by immunotherapy after transplant.
Letailleur V, Le Bourgeois A, Guillaume T, Garnier A, Peterlin P, Jullien M, Antier C, Béné MC, Chevallier P.Hum Vaccin Immunother. 2024 Dec 31;20(1):2370970. doi: 10.1080/21645515.2024.2370970. Epub 2024 Jul 8.PMID: 38977418

Human papillomavirus vaccination coverage among young women in the three sub-Saharan African countries using Demographic and Health Surveys data.
Wassie M, Zegeye AF, Mekonen EG, Tekeba B, Ali MS, Gonete AT, Kassie AT, Workneh BS, Alemu TG, Tamir TT.Hum Vaccin Immunother. 2024 Dec 31;20(1):2370111. doi: 10.1080/21645515.2024.2370111. Epub 2024 Jul 1.PMID: 38946555

[Determinants of human papillomavirus vaccine amongst boys in Reunion Island: survey of parents and general practitioners.].
Rouglan C, Bertolotti A, Balaya V, France Malcher M, Khettab M, Boukerrou M, Lien Tran P.Gynecol Obstet Fertil Senol. 2024 Jul 11:S2468-7189(24)00258-7. doi: 10.1016/j.gofs.2024.07.002. Online ahead of print.PMID: 39002861

Motivating COVID-19 Vaccination through Persuasive Communication: A Systematic Review of Randomized Controlled Trials.
Xia S, Nan X.Health Commun. 2024 Jul;39(8):1455-1478. doi: 10.1080/10410236.2023.2218145. Epub 2023 May 31.PMID: 37254940

Does COVID-19 vaccination increase the risk of interstitial lung disease at a population level?
Kim T, Lee H, Jeong CY, Yeom SW, Kim BG, Park TS, Park DW, Moon JY, Kim TH, Sohn JW, Yoon HJ, Kim SH, Kim JS.ERJ Open Res. 2024 Jul 1;10(4):00690-2023. doi: 10.1183/23120541.00690-2023. eCollection 2024 Jul.PMID: 38957166

Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
Huang WT, Law B, Tran H, Schönborn L, Huang WI, Buttery J, Chen VMY, Greinacher A, Pavord S.Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.07.032. Online ahead of print.PMID: 39003103

Association Between the United States Department of Health and Human Services' COVID-19 Public Education Campaign and Initial Adult COVID-19 Vaccination Uptake by Race and Ethnicity in the United States, 2020-2022.
Luchman JN, Nighbor T, Kranzler EC, Denison B, Dahlen H, Kim JC, Williams C, Trigger S, Bennett M, Hoffman L, Peck J.Health Promot Pract. 2024 Jul;25(4):602-611. doi: 10.1177/15248399231221159. Epub 2023 Dec 30.PMID: 38158812

Monoclonal Antibody chP3R99 Reduces Subendothelial Retention of Atherogenic Lipoproteins in Insulin-Resistant Rats: Acute Treatment Versus Long-Term Protection as an Idiotypic Vaccine for Atherosclerosis.

Soto Y, Hernández A, Sarduy R, Brito V, Marleau S, Vine DF, Vázquez AM, Proctor SD.J Am Heart Assoc. 2024 Jul 2;13(13):e032419. doi: 10.1161/JAHA.123.032419. Epub 2024 Jun 27.PMID: 38934863

Interleukin-1 beta (IL-1beta) as adjuvant enhances the immune effects of Aeromonas veronii inactivated vaccine in largemouth bass (Micropterus salmoides).
Zhang ZS, Ren HC, Gu X, Liang QR, Fei H, Yang YH, Yang S, He LY, Liu LL.Int J Biol Macromol. 2024 Jul;273(Pt 2):133135. doi: 10.1016/j.ijbiomac.2024.133135. Epub 2024 Jun 13.PMID: 38876231

Programming of in Situ Tumor Vaccines via Supramolecular Nanodrug/Hydrogel Composite and Deformable Nanoadjuvant for Cancer Immunotherapy.
Shao S, Cao Z, Xiao Z, Yu B, Hu L, Du XJ, Yang X.Nano Lett. 2024 Jul 15. doi: 10.1021/acs.nanolett.4c02113. Online ahead of print.PMID: 39007530

PIKfyve controls dendritic cell function and tumor immunity.
Choi JE, Qiao Y, Kryczek I, Yu J, Gurkan J, Bao Y, Gondal M, Tien JC, Maj T, Yazdani S, Parolia A, Xia H, Zhou J, Wei S, Grove S, Vatan L, Lin H, Li G, Zheng Y, Zhang Y, Cao X, Su F, Wang R, He T, Cieslik M, Green MD, Zou W, Chinnaiyan AM.bioRxiv [Preprint]. 2024 Jul 1:2024.02.28.582543. doi: 10.1101/2024.02.28.582543.PMID: 38464258

Acceptability of a Future HIV Vaccine: A Rapid Scoping Review.
Choi J, May SB, Dang BN, Markham C, McGlone M, Cuccaro PM.J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):197-207. doi: 10.1097/QAI.0000000000003416.PMID: 38905472

Global prevalence and correlates of mpox vaccine acceptance and uptake: a systematic review and meta-analysis.
Sulaiman SK, Isma'il Tsiga-Ahmed F, Musa MS, Makama BT, Sulaiman AK, Abdulaziz TB.Commun Med (Lond). 2024 Jul 9;4(1):136. doi: 10.1038/s43856-024-00564-1.PMID: 38977752

Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease.
Shook LM, Rosen BL, Mara CA, Mosley C, Thompson AA, Smith-Whitley K, Schwartz L, Barriteau C, King A, Oke E, Jallow F, Murphy B, Crosby L.J Pediatr Hematol Oncol. 2024 Jul 1;46(5):e305-e312. doi: 10.1097/MPH.0000000000002877. Epub 2024 May 20.PMID: 38775380

Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024).
Koul PA, Vora AC, Jindal SK, Ramasubramanian V, Narayanan V, Tripathi SK, Bahera D, Chandrashekhar HB, Mehta R, Raval N, Dorairaj P, Chhajed P, Balki A, Aurangabadwalla RK, Khandelwal A, Kawedia M, Rai SP, Grover A, Sachdev M, Chatterjee S, Ramanaprasad VV, Das A, Modi MM.Lung India. 2024 Jul 1;41(4):307-317. doi: 10.4103/lungindia.lungindia_8_24. Epub 2024 Jun 28.PMID: 38953196

Public health audit of vaccine cold chain management in general practice and community pharmacy in Western Australia.
Hillan A, Pung L, Ridderhof S, Ramsay J, Vinogradov R, Westphal D, Foong M, Leeb A, Scalley B, Phillips A.Aust N Z J Public Health. 2024 Jul 13;48(4):100168. doi: 10.1016/j.anzjph.2024.100168. Online ahead of print.PMID: 39003884

COVID-19 and Influenza Vaccine Coadministration Among Older U.S. Adults.
Harris DA, Chachlani P, Hayes KN, McCarthy EP, Wen KJ, Deng Y, Zullo AR, Djibo DA, McMahill-Walraven CN, Smith-Ray RL, Gravenstein S, Mor V.Am J Prev Med. 2024 Jul;67(1):67-78. doi: 10.1016/j.amepre.2024.02.013. Epub 2024 Feb 23.PMID: 38401746

Addressing the re-emergence and resurgence of vaccine-preventable diseases in Africa: A health equity perspective.
Lubanga AF, Bwanali AN, Kangoma M, Matola Y, Moyo C, Kaonga B, Ssebibubbu S, Makole TJ, Kambili F, Chumbi GD, Munthali L, Mwale A, Kaphesi F, Simfukwe R, Mphepo M, Kapatsa T, Harawa G, Mpinganjira SL.Hum Vaccin Immunother. 2024 Dec 31;20(1):2375081. doi: 10.1080/21645515.2024.2375081. Epub 2024 Jul 9.PMID: 38982713

Recent Surge in Mumps Cases in India: Will the Introduction of the MMR Vaccine Prevent Future Outbreaks?
Kumar P, Vashishtha VM.Indian Pediatr. 2024 Jul 15;61(7):695.PMID: 38973685

Development and qualification of 3 L scale-down model for large scale vaccine process on vero cell culture using microcarriers.
Huang R, Wang K, Flamm MH, Vazquez J, Gercke C, Ton C, Whitmer T, Mathis PK, Ploeger KJM, Rameez S.Biotechnol Bioeng. 2024 Jul 11. doi: 10.1002/bit.28785. Online ahead of print.PMID: 38993032

Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
Araujo-Chaveron L, Olivier C, Pellissier G, Bouvet E, Mueller JE.Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.07.004. Online ahead of print.PMID: 38972764

Edwardsiella tarda Attenuates Virulence upon Oxytetracycline Resistance.
Liu YL, Chen XW, Tian SQ, Tan XH, Peng B.J Proteome Res. 2024 Jul 5;23(7):2576-2586. doi: 10.1021/acs.jproteome.4c00303. Epub 2024 Jun 11.PMID: 38860290

Factors influencing COVID-19 vaccine uptake among Latinos: A cross-sectional study.
Smith DG, Smith CD, DeLeon JA, Sandoz JL, Ochoa CO, Pearson MP, Macena RHM.PLoS One. 2024 Jul 5;19(7):e0302332. doi: 10.1371/journal.pone.0302332. eCollection 2024.PMID: 38968176

Effectiveness of financial incentives on influenza vaccination among older adults in China: a randomized clinical trial.
Shen Y, Wang J, Wang J, Nicholas S, Maitland E, Lv M, Yin T, Zhu D.Clin Microbiol Infect. 2024 Jul;30(7):911-916. doi: 10.1016/j.cmi.2024.02.004. Epub 2024 Feb 8.PMID: 38341143

Robust immunity conferred by combining COVID-19 vaccine platforms in older adults.
van de Sandt CE, Kedzierska K.Nat Aging. 2024 Jul 12. doi: 10.1038/s43587-024-00668-2. Online ahead of print.PMID: 38997423

The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.

Danelian G, Burton L, Bayley T, Sanchez-Marroquin A, Park J, Manley H, Choi Y, Andrews N, Ladhani S, Earnshaw A, Gritzfeld JF, Trotter C, Panovska-Griffiths J.Vaccine. 2024 Jul 11;42(18):3838-3850. doi: 10.1016/j.vaccine.2024.05.001. Epub 2024 May 18.PMID: 38763851

Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization.
Becker W, Olkhanud PB, Seishima N, Moreno PA, Goldfarbmuren KC, Maeng HM, Berzofsky JA.J Immunother Cancer. 2024 Jul 1;12(7):e008970. doi: 10.1136/jitc-2024-008970.PMID: 38955422

Geographical migration and fitness dynamics of Streptococcus pneumoniae.
Belman S, Lefrancq N, Nzenze S, Downs S, du Plessis M, Lo SW; Global Pneumococcal Sequencing Consortium; McGee L, Madhi SA, von Gottberg A, Bentley SD, Salje H.Nature. 2024 Jul;631(8020):386-392. doi: 10.1038/s41586-024-07626-3. Epub 2024 Jul 3.PMID: 38961295

Factors influencing Jordanian parents' COVID-19 vaccination decision for children: A cross-sectional study.
Alosta MR, Alsadi M, Othman EH, Khalifeh AH, Atiyeh H.J Pediatr Nurs. 2024 Jul-Aug;77:45-52. doi: 10.1016/j.pedn.2024.03.017. Epub 2024 Mar 12.PMID: 38479062

Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec.
Dionne M, Étienne D, Witteman HO, Sauvageau C, Dubé È.Vaccine. 2024 Jul 11;42(18):3768-3773. doi: 10.1016/j.vaccine.2024.04.089. Epub 2024 May 6.PMID: 38714451

Test-Negative Study Designs for Evaluating Vaccine Effectiveness.
Dean N, Amin AB.JAMA. 2024 Jul 9;332(2):163-164. doi: 10.1001/jama.2024.5633.PMID: 38865112

The negative impact of misinformation and vaccine conspiracy on COVID-19 vaccine uptake and attitudes among the general public in Iraq.
Sallam M, Kareem N, Alkurtas M.Prev Med Rep. 2024 Jun 7;43:102791. doi: 10.1016/j.pmedr.2024.102791. eCollection 2024 Jul.PMID: 38947232

Application of plant-derived products as adjuvants for immune activation and vaccine development.
Zou M, Lei C, Huang D, Liu L, Han Y.Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024.07.016. Online ahead of print.PMID: 38987109

Willingness to get vaccinated initially and yearly against COVID-19 and its association with vaccine hesitancy, vaccine knowledge and psychological well-being: a cross-sectional study in UK adults.
Kale D, Shoesmith E, Herbec A, Shahab L.BMJ Open. 2024 Jul 5;14(7):e080778. doi: 10.1136/bmjopen-2023-080778.PMID: 38969372

Acceptability, facilitators, and barriers to a hypothetical HIV vaccine in the pre-exposure prophylaxis era.
Richterman A, O'Brien C, Ghadimi F, Sumners E, Ford A, Houston N, Tate S, Aitcheson N, Nkwihoreze H, Jemmott JB 3rd, Momplaisir F.AIDS Care. 2024 Jul 4:1-7. doi: 10.1080/09540121.2024.2372715. Online ahead of print.PMID: 38961850

SMS-based interventions for improving child and adolescent vaccine coverage and timeliness: a systematic review.
Currie GE, McLeod C, Waddington C, Snelling TL.BMC Public Health. 2024 Jul 2;24(1):1753. doi: 10.1186/s12889-024-18900-4.PMID: 38956527

Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
Arango-Luque A, Yucumá D, Castañeda CE, Espin J, Becerra-Posada F.Value Health Reg Issues. 2024 Jul;42:100981. doi: 10.1016/j.vhri.2024.01.003. Epub 2024 Apr 27.PMID: 38677063

Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
Wachinger J, Reñosa MDC, Endoma V, Landicho-Guevarra J, McMahon SA.Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.06.062. Online ahead of print.PMID: 38972765

Development, Implementation, and Evaluation of Three Outreach Events to Improve COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Communities in Houston, Texas, 2022.
Munoz-Lavanderos C, Oluyomi A, Rosales O, Hernandez N, Mensah-Bonsu N, Badr H.Public Health Rep. 2024 Jul-Aug;139(1_suppl):71S-80S. doi: 10.1177/00333549231213848. Epub 2023 Dec 23.PMID: 38140821

Knowledge of hepatitis B infection, hepatitis B vaccine, and vaccination status with its associated factors among healthcare workers in Kampot and Kep Provinces, Cambodia.
Sok S, Chhoung C, Sun B, Ko K, Sugiyama A, Akita T, Fukuma S, Tanaka J.BMC Infect Dis. 2024 Jul 1;24(1):658. doi: 10.1186/s12879-024-09571-y.PMID: 38956495

Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
Gharpure R, Longley AT, Takamiya M, Hidle A, Munyanyi M, Chawurura T, Maxwell L, Mamire G, Chaora G, Chakauya J, Rupfutse M, Poncin M, Gasasira A, Date K, Manangazira P, Sreenivasan N.Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024.06.053. Online ahead of print.PMID: 38991917

Perceptions and Acceptance of a Prophylactic Vaccine for Human Immunodeficiency Virus (HIV): A Qualitative Study.
Aldhouse NVJ, Chan EKH, Al-Zubeidi T, McKee S, Oriol Mathieu V, El Khoury AC, Kitchen H.Patient. 2024 Jul;17(4):457-469. doi: 10.1007/s40271-024-00686-7. Epub 2024 Apr 6.PMID: 38581599

Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.
Wang W, Zhou J, Kong X, Wang Y, Wu Q, Gong X, Tai J, Pan Y, Huang H, Zhao Z, Jiang M, Liu J.Orphanet J Rare Dis. 2024 Jul 3;19(1):247. doi: 10.1186/s13023-024-03260-4.PMID: 38956624

Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
Houle SKD, Waite NM, Vernon-Wilson E, Dolovich L, Yang M.Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.06.063. Online ahead of print.PMID: 38955590

Expectations Versus Fantasies and Vaccine Hesitancy: How Suffering From COVID-19 Versus Suffering From Vaccines Interact.
Kim S, Gollwitzer PM, Oettingen G.Ann Behav Med. 2024 Jul 11;58(8):563-577. doi: 10.1093/abm/kaae034.PMID: 38944699

Predictors of COVID-19 vaccine acceptability among refugees and other migrant populations: A systematic scoping review.
Yazdani Y, Pai P, Sayfi S, Mohammadi A, Perdes S, Spitzer D, Fabreau GE, Pottie K.PLoS One. 2024 Jul 5;19(7):e0292143. doi: 10.1371/journal.pone.0292143. eCollection 2024.PMID: 38968187

Herpes Zoster Vaccine and Herpes Zoster Ophthalmicus Recurrence-Reply.
Acharya NR.JAMA Ophthalmol. 2024 Jul 3. doi: 10.1001/jamaophthalmol.2024.2267. Online ahead of print.PMID: 38958938

Herpes Zoster Vaccine and Herpes Zoster Ophthalmicus Recurrence.
Shen LT, Chen HL.JAMA Ophthalmol. 2024 Jul 3. doi: 10.1001/jamaophthalmol.2024.2262. Online ahead of print.PMID: 38958935

Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles.
Lingemann M, Amaro-Carambot E, Lamirande EW, Pierson TC, Whitehead SS.J Virol. 2024 Jul 2:e0068124. doi: 10.1128/jvi.00681-24. Online ahead of print.PMID: 38953379

Important role of Bacillus subtilis as a probiotic and vaccine carrier in animal health maintenance.
Yuan C, Ji X, Zhang Y, Liu X, Ding L, Li J, Ren S, Liu F, Chen Z, Zhang L, Zhu W, Yu J, Wu J.World J Microbiol Biotechnol. 2024 Jul 15;40(9):268. doi: 10.1007/s11274-024-04065-0.PMID: 39007987

"Do not inject our babies": a social listening analysis of public opinion about authorizing pediatric COVID-19 vaccines.
Golos AM, Guntuku SC, Buttenheim AM.Health Aff Sch. 2024 Jul 8;2(7):qxae082. doi: 10.1093/haschl/qxae082. eCollection 2024 Jul.PMID: 38979103

Prediction of the 3D conformation of a small peptide vaccine targeting Abeta42 oligomers.
Guan Y, Mei J, Gao X, Wang C, Jia M, Ahmad S, Muhammad FN, Ai H.Phys Chem Chem Phys. 2024 Jul 15. doi: 10.1039/d4cp02078b. Online ahead of print.PMID: 39007924

Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
Pan X, Guo X, Shi J.Vaccine. 2024 Jul 11;42(18):3883-3898. doi: 10.1016/j.vaccine.2024.04.098. Epub 2024 May 21.PMID: 38777697

Influences on male college students' patient-provider communications and uptake behaviors related to the human papillomavirus vaccine.
Koskan AM, Stecher C, Helitzer DL.J Am Coll Health. 2024 Jul;72(5):1568-1574. doi: 10.1080/07448481.2022.2086004. Epub 2022 Jun 21.PMID: 35728081

Covid-19 vaccine hesitancy and its predictors among diabetic patients on follow-up at public hospitals in Nekemte Town, Western Ethiopia.
Olani Kuta A, Dida N.PLoS One. 2024 Jul 8;19(7):e0305200. doi: 10.1371/journal.pone.0305200. eCollection 2024.PMID: 38976683

Concerns about vaccines and vaccination behavior among Japanese budget travelers to India.
Yamakawa M, Tanaka Y, Tokinobu A, Tsuda T.J Infect Chemother. 2024 Jul 12:S1341-321X(24)00189-2. doi: 10.1016/j.jiac.2024.07.011. Online ahead of print.PMID: 39004400

Unmasking vaccine hesitancy and refusal: a deep dive into Anti-vaxxer perspectives on COVID-19 in Spain.
Prieto-Campo Á, Vázquez-Cancela O, Roque F, Herdeiro MT, Figueiras A, Zapata-Cachafeiro M.BMC Public Health. 2024 Jul 1;24(1):1751. doi: 10.1186/s12889-024-18864-5.PMID: 38951819

The R21 malaria vaccine: Spotlight on policy goals and pathways to African vaccine manufacturing.
Adeyi O, Yadav P, Panjabi R, Mbacham W.PLOS Glob Public Health. 2024 Jul 8;4(7):e0003412. doi: 10.1371/journal.pgph.0003412. eCollection 2024.PMID: 38976675

Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the EU's Regulation on HTA for Vaccines.
Largeron N, D'Agostino P, Chapman R, Danko D, Eskola J, Godfroid P, Feldmajer G, Hanley R, de Pouvourville G, Postma M, Puig-Barberà J, Schaible K, Sabale U, Schmitt J, de Waure C, Vicere A, Beck E.Value Health. 2024 Jul 6:S1098-3015(24)02750-5. doi: 10.1016/j.jval.2024.06.011. Online ahead of print.PMID: 38977187

Knowledge, attitudes, and intentions regarding COVID-19 vaccination in the general population and the effect of different framing messages for a brief video on intentions to get vaccinated among unvaccinated individuals in the United States during July 2021.
Zapf AJ, Schuh HB, Dudley MZ, Rimal RN, Harvey SA, Shaw J, Balgobin K, Salmon DA.Patient Educ Couns. 2024 Jul;124:108258. doi: 10.1016/j.pec.2024.108258. Epub 2024 Mar 26.PMID: 38608538

Corrigendum to "Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
Lambach P, Silal S, Sbarra AN, Koh M, Aggarwal R, Farooqui HH, Flasche S, Hogan AB, Kim SY, Leung K, Moss WJ, Munywoki PK, Portnoy A, Sheel M, Wang XY.Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024.07.003. Online ahead of print.PMID: 38991915

Understanding HPV Vaccine Hesitancy and What Helped Hesitant Adopter Parents Have Their Children Vaccinated Despite Their Hesitancy.
Purvis RS, Moore R, Willis DE, Li J, Kraleti S, Imran T, McElfish PA.J Pediatr Health Care. 2024 Jul-Aug;38(4):468-479. doi: 10.1016/j.pedhc.2023.11.013. Epub 2023 Dec 19.PMID: 38127043

Immune-enhancing activity of compound polysaccharide on the inactivated influenza vaccine.

Zhang Y, Wang D, Tan D, Zou A, Wang Z, Gong H, Yang Y, Sun L, Lin X, Liang M, Yu Y, He X, Yu G, Wang W, Cai C.Carbohydr Polym. 2024 Jul 15;336:122080. doi: 10.1016/j.carbpol.2024.122080. Epub 2024 Mar 26.PMID: 38670772

Identification of novel T-cell epitopes on monkeypox virus and development of multi-epitopes vaccine using immunoinformatics approaches.
Ezzemani W, Ouladlahsen A, Altawalah H, Saile R, Sarih M, Kettani A, Ezzikouri S.J Biomol Struct Dyn. 2024 Jul;42(10):5349-5364. doi: 10.1080/07391102.2023.2226733. Epub 2023 Jun 24.PMID: 37354141

Evaluation of the cross-protection of the Vero cell-derived attenuated influenza vaccines with compound adjuvant, through intranasal immunization.
Ze L, Shaohui S, Jinhai H, Hui G.APMIS. 2024 Jul 3. doi: 10.1111/apm.13448. Online ahead of print.PMID: 38961516

Enhanced efficacy of BCG vaccine formulated in adjuvant is dependent on IL-17A expression.
Derrick SC, Yang A, Cowley S.Tuberculosis (Edinb). 2024 Jul 6;148:102540. doi: 10.1016/j.tube.2024.102540. Online ahead of print.PMID: 39002310

mRNA vaccine technology for infectious diseases and beyond.
Hao P, Li X, Li X, Zhong W.Sci China Life Sci. 2024 Jul 1. doi: 10.1007/s11427-024-2639-3. Online ahead of print.PMID: 38965140

Pentavalent Rotavirus Vaccine Coverage and Trends in Rotavirus Detection Before and After This Vaccination in Chengdu, China.
Xiao G, Zhu T, Wang Z, Xie X, Shu M, Gao S, Wang L, Zhou W, Deng J, Xie Y, Yu F.Pediatr Infect Dis J. 2024 Jul 2. doi: 10.1097/INF.0000000000004441. Online ahead of print.PMID: 38985999

Update on the research on the antigens of anti-sperm antibodies over the last decade.
Chen Y, Hasegawa A, Wakimoto Y, Shibahara H.J Reprod Immunol. 2024 Jul 1;164:104292. doi: 10.1016/j.jri.2024.104292. Online ahead of print.PMID: 38964133

An immuno-informatics approach for annotation of hypothetical proteins and multi-epitope vaccine designed against the Mpox virus.
Ahmed MH, Samia NSN, Singh G, Gupta V, Mishal MFM, Hossain A, Suman KH, Raza A, Dutta AK, Labony MA, Sultana J, Faysal EH, Alnasser SM, Alam P, Azam F.J Biomol Struct Dyn. 2024 Jul;42(10):5288-5307. doi: 10.1080/07391102.2023.2239921. Epub 2023 Jul 31.PMID: 37519185

Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group.Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024.06.056. Online ahead of print.PMID: 38971666

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.
Ishiwada N, Akaishi R, Kobayashi Y, Togo K, Yonemoto N, Matsuo M, Kaneko S, Law AW, Kamei K.Infect Dis Ther. 2024 Jul;13(7):1665-1682. doi: 10.1007/s40121-024-01000-6. Epub 2024 Jun 5.PMID: 38834858

Development a high-sensitivity sandwich ELISA for determining antigen content of porcine circovirus type 2 vaccines.
Xu L, Chen Z, Gong H, Pei X, Zhu Y, Lu Y, Wang Y, Nan S, Yin Y, Zhao Q, Fan Y, Sun Y, Xiao S.J Virol Methods. 2024 Jul;328:114954. doi: 10.1016/j.jviromet.2024.114954. Epub 2024 May 17.PMID: 38763359

The Association Between the We Can Do This Campaign and Vaccination Beliefs in the United States, January 2021-March 2022.
Kim JC, Kranzler EC, Yu K, Denison B, Dahlen HM, Luchman JN, Ihongbe TO, Marshall MC, Hoffman B, Moffett K, Dupervil D, Margolis KA, Hoffman L.J Health Commun. 2024 Jul 3:1-12. doi: 10.1080/10810730.2024.2373159. Online ahead of print.PMID: 38958603

Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
Kannan R.Oral Oncol. 2024 Jul 4;156:106936. doi: 10.1016/j.oraloncology.2024.106936. Online ahead of print.PMID: 38968721

Immunization adherence among children with sickle cell disease and sickle cell trait: Results of a population-based study.
Shi JS, Sutaria A, Lakshmanan S, Attell B, Zhou M, Tang A, Eckman J, Snyder A.Pediatr Blood Cancer. 2024 Jul;71(7):e31042. doi: 10.1002/pbc.31042. Epub 2024 May 3.PMID: 38702922

A laponite-based immunologically active gel delivery system for long-acting tumor vaccine.
Zhang J, Fu C, Luo Q, Qin X, Batur S, Xie Q, Kong L, Yang C, Zhang Z.J Control Release. 2024 Jul 12:S0168-3659(24)00461-9. doi: 10.1016/j.jconrel.2024.07.030. Online ahead of print.PMID: 39004104

Highlight of 2023: Advances in germinal centers.
Pankhurst TE, Linterman MA.Immunol Cell Biol. 2024 Jul;102(6):463-466. doi: 10.1111/imcb.12800. Epub 2024 Jun 30.PMID: 38946158

Protease shaving of Mycobacterium tuberculosis facilitates vaccine antigen discovery and delivery of novel cargoes to the Mtb surface.
Lepe BA, Zheng CR, Leddy OK, Allsup BL, Solomon SL, Bryson BD.bioRxiv [Preprint]. 2024 Jul 2:2024.07.02.601718. doi: 10.1101/2024.07.02.601718.PMID: 39005324

Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group.
Borja-Tabora C, Fernando L, Lopez Medina E, Reynales H, Rivera L, Saez-Llorens X, Sirivichayakul C, Yu D, Folschweiller N, Moss KJ, Rauscher M, Tricou V, Zhao Y, Biswal S.Clin Infect Dis. 2024 Jul 12:ciae369. doi: 10.1093/cid/ciae369. Online ahead of print.PMID: 38995684

Los Angeles County dentists' opinions on discussing human papilloma virus-related oral health issues and recommending vaccine to patients.
Bhoopathi V, Fellows JL, Glenn B, Bastani R, Atchison KA.Hum Vaccin Immunother. 2024 Dec 31;20(1):2371671. doi: 10.1080/21645515.2024.2371671. Epub 2024 Jul 3.PMID: 38958386

A Cross-Sectional Analysis of Community Perceptions of Flu and COVID-19 Vaccines at Turtle Creek Primary Care Center.
Murali A, Sojati J, Levochkina M, Pressimone C, Griffith K, Fan E, Dakroub A.Community Health Equity Res Policy. 2024 Jul;44(4):439-451. doi: 10.1177/2752535X231205665. Epub 2023 Oct 14.PMID: 37837451

Lipid Nanoparticle with 1,2-Di-O-octadecenyl-3-trimethylammonium-propane as a Component Lipid Confers Potent Responses of Th1 Cells and Antibody against Vaccine Antigen.
Kawai A, Noda M, Hirata H, Munakata L, Matsuda T, Omata D, Takemura N, Onoe S, Hirose M, Kato T, Saitoh T, Hirai T, Suzuki R, Yoshioka Y.ACS Nano. 2024 Jul 2;18(26):16589-16609. doi: 10.1021/acsnano.4c00278. Epub 2024 Jun 17.PMID: 38885198

Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
Pham-Huy A, Bowes J, Russell K, Amira A, Lai L.Vaccine. 2024 Jul 12:S0264-410X(24)00731-X. doi: 10.1016/j.vaccine.2024.06.057. Online ahead of print.PMID: 39003104

Social Determinants of Health and Satisfaction With Sources of Information About COVID-19 Related to Vaccine Uptake in a Safety Net Healthcare System.
Blake N, Siddiq H, Brecht ML, Warda U, Villacorte F, Banawa J.Nurs Res. 2024 Jul-Aug 01;73(4):261-269. doi: 10.1097/NNR.0000000000000732. Epub 2024 Mar 12.PMID: 38498855

AACR 2024 presents advancements in pancreatic and gastric cancers: Promising evidence has been found for the therapeutic potential of a neoantigen-based cancer vaccine used in the adjuvant setting.
Nierengarten MB.Cancer. 2024 Jul 1;130(13):2244. doi: 10.1002/cncr.35371.PMID: 38849706

COVID-19 mRNA Vaccination Responses in Individuals With Sickle Cell Disease: ASH RC Sickle Cell Research Network Study.
Anderson AR, Strouse JJ, Manwani D, Brandow AM, Vichinsky EP, Campbell A, Leavey PJ, Nero A, Ibrahim IF, Field JJ, Baer A, Soto-Calderon H, Vincent L, Zhao Y, Santos JJS, Hensley SE, Mortier N, Lanzkron S, Neuberg DS, Abrams CS.Blood Adv. 2024 Jul 11:bloodadvances.2024013878. doi: 10.1182/bloodadvances.2024013878. Online ahead of print.PMID: 38991137

Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals.
La Rosa C, Park Y, Yang D, Zhou Q, Kaltcheva T, Karras N, Cheng J, Sun W, Diamond DJ, Pawlowska A.Haematologica. 2024 Jul 1;109(7):2303-2308. doi: 10.3324/haematol.2023.284256.PMID: 38426277

Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.

Garcia S, Shin M, Gill M, He Z, Dang E, Kast WM, Unger JB, Baezconde-Garbanati L, Tsui J.Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.07.030. Online ahead of print.PMID: 38997849

Impact of COVID-19 vaccines in patients on hemodialysis: an Italian multicentre cohort study.
De Masi S, Da Cas R, Ippolito FM, Baglio G, Zoccali C, Chiarotti F, Fabiani M, Colavita F, Castilletti C, Salomone M, Mele A, Messa P; COVIDVaxDia Study Group.J Nephrol. 2024 Jul 12. doi: 10.1007/s40620-024-02007-5. Online ahead of print.PMID: 38995613

Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.
Weitzman ER, Pierce SE, Blakemore LM, Murdock A, Angelidou A, Dowling DJ, Levy O, Levy S.Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024.06.049. Online ahead of print.PMID: 38991914

COVID-19 severity, breakthrough infections and vaccine safety in young individuals with autoimmune diseases: insights from the COVAD study.
Alunno A, Carubbi F, Tan AL, Sen P, Cavagna L, Joshi M, Day J, Saha S, Gutiérrez CET, Caballero-Uribe CV, Distler O, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD Study Group.Rheumatol Int. 2024 Jul 13. doi: 10.1007/s00296-024-05654-w. Online ahead of print.PMID: 39003346

Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41) (2023) 6105-6111].
Sánchez-González G, Luna-Casas G, Mascareñas C, Macina D, Vargas-Zambrano JC.Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024.06.052. Online ahead of print.PMID: 38981744

Novel structure of secreted small molecular weight antigen Mtb12 from Mycobacterium tuberculosis.
Han JH, Kim DY, Lee SY, Park HH.Biochem Biophys Res Commun. 2024 Jul 12;717:150040. doi: 10.1016/j.bbrc.2024.150040. Epub 2024 May 4.PMID: 38718566

Recent efforts in the development of glycoconjugate vaccine and available treatment for tuberculosis.
Banoo S, Yadav Y, Tyagi R, Manna A, Sagar R.Bioorg Chem. 2024 Jul 1;150:107610. doi: 10.1016/j.bioorg.2024.107610. Online ahead of print.PMID: 38991488

Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
[No authors listed]J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093/infdis/jiae336. Online ahead of print.PMID: 38959419

The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.
Marron L, Mateo-Urdiales A, O'Donnell J, Robinson E, Domegan L.Euro Surveill. 2024 Jul;29(28):2300697. doi: 10.2807/1560-7917.ES.2024.29.28.2300697.PMID: 38994604

A case of renal limited myeloperoxidase anti-neutrophil cytoplasmic antibody-positive vasculitis treated with maintenance avacopan monotherapy.

Ubara Y, Oba Y, Kurihara S, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Kono K, Ohashi K, Wada T, Sawa N.CEN Case Rep. 2024 Jul 2. doi: 10.1007/s13730-024-00910-1. Online ahead of print.PMID: 38955948

Coincidence or association: Adult-onset Still's disease following HPV vaccine.
Ahmed M, Husain K, Husain A, Syed S, Haque MZ, Meysami A.Clin Case Rep. 2024 Jul 5;12(7):e9030. doi: 10.1002/ccr3.9030. eCollection 2024 Jul.PMID: 38974183

Effect of Vaccination on Seroprevalence of COVID-19 among Blood donors - A cross-sectional Analytic Study from South India.
Sahoo D, Karnesh SJ, Abhishekh B.Indian J Hematol Blood Transfus. 2024 Jul;40(3):443-447. doi: 10.1007/s12288-023-01716-4. Epub 2023 Dec 16.PMID: 39011267

fim3-24/ptxP-3 genotype is associated to whooping cough outbreak in Brazilian Midwest: The selection of Bordetella pertussis strains driven by vaccine immunization.
de Paula VG, de Sousa RS, da Silva RCMR, Alves EG, Caetano AR, Ianella P, de Campos TA.Infect Genet Evol. 2024 Jul;121:105599. doi: 10.1016/j.meegid.2024.105599. Epub 2024 Apr 26.PMID: 38679113

Role of vaccinia virus growth factor in stimulating the mTORC1-CAD axis of the *de novo* pyrimidine pathway under different nutritional cues.
Dsouza L, Pant A, Pope B, Yang Z.bioRxiv [Preprint]. 2024 Jul 2:2024.07.02.601567. doi: 10.1101/2024.07.02.601567.PMID: 39005450

A Study of Humoral Immune Response to Inactivated COVID-19 Vaccine in Patients with Psoriasis Receiving Biologics and Small Molecules.
Zou Y, Peng Y, Xu J, Chen A, Huang K, Wang P.Clin Cosmet Investig Dermatol. 2024 Jul 3;17:1565-1568. doi: 10.2147/CCID.S467889. eCollection 2024.PMID: 38974704

A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
Miao Q, Nguyen W, Zhu J, Liu G, van Oers MM, Tang B, Yan K, Larcher T, Suhrbier A, Pijlman GP.Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024.07.037. Online ahead of print.PMID: 39004524

Corrigendum to: COVID-19 Vaccine Hesitancy: Umbrella Review of Systematic Reviews and Meta-Analysis.
Leung T, Sanchez T, Eysenbach G.JMIR Public Health Surveill. 2024 Jul 10;10:e64080. doi: 10.2196/64080.PMID: 38986125

Reduced risk for Omicron SARS-CoV-2 infection observed in older adults with hybrid immunity.
Pallett SJC, Heskin J, Keating F, Tuck J, Mazzella A, Randell P, Rayment M, Jones R, Mughal N, Davies GW, O'Shea MK, Moore LSP.Age Ageing. 2024 Jul 2;53(7):afae145. doi: 10.1093/ageing/afae145.PMID: 39003235

Exploring the impact of gut microbial metabolites on inactivated SARS-CoV-2 vaccine efficacy during pregnancy and mother-to-infant antibody transfer.

Fu X, Du B, Chen PA, Shama A, Chen B, Zhang X, Han X, Xu Y, Gong Y, Zeng X, Sun C, Yang W, Xing X, Li Z, Fu Y, Ke D, Wang N, Xia Y, Sun Y, Chen Q.Gut. 2024 Jul 11;73(8):1397-1400. doi: 10.1136/gutjnl-2023-330497.PMID: 37739779

Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
[No authors listed]J Infect Dis. 2024 Jul 1:jiae334. doi: 10.1093/infdis/jiae334. Online ahead of print.PMID: 38949967

Author Correction: Mucosal bivalent live attenuated vaccine protects against human metapneumovirus and respiratory syncytial virus in mice.
Ogonczyk-Makowska D, Brun P, Vacher C, Chupin C, Droillard C, Carbonneau J, Laurent E, Dulière V, Traversier A, Terrier O, Julien T, Galloux M, Paul S, Eléouët JF, Fouret J, Hamelin ME, Pizzorno A, Boivin G, Rosa-Calatrava M, Dubois J.NPJ Vaccines. 2024 Jul 9;9(1):125. doi: 10.1038/s41541-024-00917-w.PMID: 38982077

Differential polyvalent passive immune protection of egg yolk antibodies (IgY) against live and inactivated Vibrio fluvialis in fish.
Liu X, Xiao H, Cui P, Chen J, Chao J, Wu X, Lu J, Zhang X, Xu G, Liu Y.Fish Shellfish Immunol. 2024 Jul 4;151:109751. doi: 10.1016/j.fsi.2024.109751. Online ahead of print.PMID: 38971349

Ag85B with c-di-AMP as mucosal adjuvant showed immunotherapeutic effects on persistent Mycobacterium tuberculosis infection in mice.
Liang X, Cui R, Li X, Ning H, Kang J, Lu Y, Zhou S, Huang X, Peng Y, Zhang J, Li S, Ma Y, Bai Y.Braz J Med Biol Res. 2024 Jul 1;57:e13409. doi: 10.1590/1414-431X2024e13409. eCollection 2024.PMID: 38958367

Surface display of the COE antigen of porcine epidemic diarrhoea virus on Bacillus subtilis spores.
Tian Y, Wang Z, Sun J, Gu J, Xu X, Cai X.Microb Biotechnol. 2024 Jul;17(7):e14518. doi: 10.1111/1751-7915.14518.PMID: 38953907

Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.
Hu Z, López-Muñoz AD, Kosik I, Li T, Callahan V, Brooks K, Yee DS, Holly J, Santos JJS, Castro Brant A, Johnson RF, Takeda K, Zheng ZM, Brenchley JM, Yewdell JW, Fox JM.Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.PMID: 38976733

Structural biology of flavivirus NS1 protein and its antibody complexes.
Alvin Chew BL, Pan Q, Hu H, Luo D.Antiviral Res. 2024 Jul;227:105915. doi: 10.1016/j.antiviral.2024.105915. Epub 2024 May 20.PMID: 38777094

Identification of risk factors on rabies vaccine efficacy from censored data: Pre-travel tests for dogs and cats from Yaounde (2005-2015).
Ntsama F, Noh SM, Tizzani P, Ayangma Ntsama CF, Nteme Ella GS, Awada L, Djatche Tidjou GS.Res Vet Sci. 2024 Jul;174:105278. doi: 10.1016/j.rvsc.2024.105278. Epub 2024 May 1.PMID: 38759348

Breakthrough Mpox Outbreak Investigation, the Delicate Balance Between Host Immune Response and Viral Immune Escape.
Moretti M, Meuwissen A, Rezende AM, Zange S, Van Nedervelde E, de Block T, Vercauteren K, Demuyser T, Allard SD.Sex Transm Dis. 2024 Jul 1;51(7):499-503. doi: 10.1097/OLQ.0000000000001974. Epub 2024 Apr 19.PMID: 38647249

Investigating the importance of selected surface-exposed loops in HpuB for hemoglobin binding and utilization by *Neisseria gonorrhoeae*.
Awate OA, Ng D, Stoudenmire JL, Moraes TF, Cornelissen CN.Infect Immun. 2024 Jul 11;92(7):e0021124. doi: 10.1128/iai.00211-24. Epub 2024 Jun 12.PMID: 38864605

Long COVID among US adults from a population-based study: Association with vaccination, cigarette smoking, and the modifying effect of chronic obstructive pulmonary disease (COPD).
Erinoso O, Osibogun O, Balakrishnan S, Yang W.Prev Med. 2024 Jul;184:108004. doi: 10.1016/j.ypmed.2024.108004. Epub 2024 May 14.PMID: 38754738

MIL-53(Al)-oil/water emulsion composite as an adjuvant promotes immune responses to an inactivated pseudorabies virus vaccine in mice and pigs.
Yang B, Nie J, Guo A, Xie N, Cui Y, Sun W, Li Y, Li X, Wu Y, Liu Y.Acta Biomater. 2024 Jul 15;183:330-340. doi: 10.1016/j.actbio.2024.05.050. Epub 2024 Jun 3.PMID: 38838909

A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma.
Makino T, Miyata H, Yasuda T, Kitagawa Y, Muro K, Park JH, Hikichi T, Hasegawa T, Igarashi K, Iguchi M, Masaoka Y, Yano M, Doki Y.Esophagus. 2024 Jul 11. doi: 10.1007/s10388-024-01072-w. Online ahead of print.PMID: 38990441

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.
Platt HL, Bruno C, Buntinx E, Pelayo E, Garcia-Huidobro D, Barranco-Santana EA, Sjoberg F, Song JY, Grijalva CG, Orenstein WA, Morgan L, Fernsler D, Xu W, Waleed M, Li J, Buchwald UK; STRIDE-3 Study Group.Lancet Infect Dis. 2024 Jul 1:S1473-3099(24)00344-X. doi: 10.1016/S1473-3099(24)00344-X. Online ahead of print.PMID: 38964361

Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
Mahdi AGM.Oral Oncol. 2024 Jul 10;156:106939. doi: 10.1016/j.oraloncology.2024.106939. Online ahead of print.PMID: 38991396

An MCDM approach for Reverse vaccinology model to predict bacterial protective antigens.
Angaitkar P, Ram Janghel R, Prasad Sahu T.Vaccine. 2024 Jul 11;42(18):3874-3882. doi: 10.1016/j.vaccine.2024.04.078. Epub 2024 May 3.PMID: 38704249

Seasonal variation in BCG-induced trained immunity.

Kilic G, Debisarun PA, Alaswad A, Baltissen MP, Lamers LA, de Bree LCJ, Benn CS, Aaby P, Dijkstra H, Lemmers H, Martens JHA, Domínguez-Andrés J, van Crevel R, Li Y, Xu CJ, Netea MG.Vaccine. 2024 Jul 8:S0264-410X(24)00751-5. doi: 10.1016/j.vaccine.2024.07.010. Online ahead of print.PMID: 38981740

A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
Arconada Nuin E, Vilken T, Xavier BB, Doua J, Morrow B, Geurtsen J, Go O, Spiessens B, Sarnecki M, Poolman J, Bonten M, Ekkelenkamp M, Lammens C, Goossens H, Glupczynski Y, Van Puyvelde S; COMBACTE-NET Consortium/EXPECT Study Group.J Antimicrob Chemother. 2024 Jul 13:dkae182. doi: 10.1093/jac/dkae182. Online ahead of print.PMID: 39001716

Evolution of Pyrrolysyl-tRNA Synthetase: From Methanogenesis to Genetic Code Expansion.
Koch NG, Budisa N.Chem Rev. 2024 Jul 2. doi: 10.1021/acs.chemrev.4c00031. Online ahead of print.PMID: 38953775

Social Media Authentication and Users' Assessments of Health Information: Random Assignment Survey Experiment.
Neely S, Witkowski K.JMIR Form Res. 2024 Jul 9;8:e52503. doi: 10.2196/52503.PMID: 38980714

Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies.
Zhang J, Terreni M, Liu F, Sollogoub M, Zhang Y.Biomed Pharmacother. 2024 Jul;176:116824. doi: 10.1016/j.biopha.2024.116824. Epub 2024 May 30.PMID: 38820973

Quality Control of mRNA Vaccines by Synthetic Ribonucleases: Analysis of the Poly-A-Tail.
Zellmann F, Schmauk N, Murmann N, Böhm M, Schwenger A, Göbel MW.Chembiochem. 2024 Jul 2;25(13):e202400347. doi: 10.1002/cbic.202400347. Epub 2024 Jun 21.PMID: 38742914

Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prospective, population-based cohort study.
Ylade M, Crisostomo MV, Daag JV, Agrupis KA, Cuachin AM, Sy AK, Kim DR, Ahn HS, Escoto AC, Katzelnick LC, Adams C, White L, de Silva AM, Deen J, Lopez AL.Lancet Infect Dis. 2024 Jul;24(7):737-745. doi: 10.1016/S1473-3099(24)00099-9. Epub 2024 Mar 22.PMID: 38527474

The GE296_RS03820 and GE296_RS03830 genes are involved in capsular polysaccharide biosynthesis in Riemerella anatipestifer.
Wu X, Ge J, Song G, Liu Y, Gao P, Tian T, Li X, Xu J, Chu Y, Zheng F.FASEB J. 2024 Jul 15;38(13):e23763. doi: 10.1096/fj.202302694RR.PMID: 38954404

An educational approach to develop intercultural nursing care for refugees from Ukraine: A qualitative study.
Larson KL, Choufani MR, Płaszewska-Żywko L.Int Nurs Rev. 2024 Jul 2. doi: 10.1111/inr.13016. Online ahead of print.PMID: 38953501

Protective efficacy of Eimeria maxima EmLPL and EmTregIM-1 against homologous challenge in chickens.
Xiang Q, Wan Y, Pu X, Lu M, Xu L, Yan R, Li X, Song X.Poult Sci. 2024 Jul;103(7):103865. doi: 10.1016/j.psj.2024.103865. Epub 2024 May 16.PMID: 38810564

Vocal Fold Paralysis Following COVID-19 Vaccination: Query of VAERS Database.
Hamdi OA, Jonas RH, Daniero JJ.J Voice. 2024 Jul;38(4):936-939. doi: 10.1016/j.jvoice.2022.01.016. Epub 2022 Jan 24.PMID: 35193788

Laboratory approach for vaccine-induced thrombotic thrombocytopenia diagnosis in the Netherlands.
Meier RT, Porcelijn L, Hofstede-van Egmond S, Henskens YMC, Coutinho JM, Kruip MJHA, Stroobants AK, Zwaginga JJ, van der Bom JG, van der Schoot CE, de Haas M, Kapur R.Vox Sang. 2024 Jul;119(7):728-736. doi: 10.1111/vox.13633. Epub 2024 Apr 10.PMID: 38597072

Recent increase in infant pertussis cases in Europe and the critical importance of antenatal immunisations: we must do better…now.
Khalil A, Samara A, Campbell H, Ladhani SN, Amirthalingam G.Int J Infect Dis. 2024 Jul 1:107148. doi: 10.1016/j.ijid.2024.107148. Online ahead of print.PMID: 38960028

Temporary Declines and Demand Resurgence: Gender-Affirming Surgery Volume and Complication Trends During and After the COVID-19 Pandemic.
Miller AS, Beagles CB, Kaur MN, Marano AA, Hu S, Ghoshal S, Dey T, Coon D, Succi MD.Aesthetic Plast Surg. 2024 Jul 11. doi: 10.1007/s00266-024-04243-3. Online ahead of print.PMID: 38992249

Per- and polyfluoroalkyl substances and human health outcomes: An umbrella review of systematic reviews with meta-analyses of observational studies.
Xing WY, Sun JN, Liu FH, Shan LS, Yin JL, Li YZ, Xu HL, Wei YF, Liu JX, Zheng WR, Zhang YY, Song XJ, Liu KX, Liu JC, Wang JY, Jia MQ, Chen X, Li XY, Liu C, Gong TT, Wu QJ.J Hazard Mater. 2024 Jul 5;472:134556. doi: 10.1016/j.jhazmat.2024.134556. Epub 2024 May 8.PMID: 38735187

Partners in vaccination: A community-based intervention to promote COVID-19 vaccination among low-income homebound and disabled adults.
Kim SE, Turner BJ, Steinberg J, Solano L, Hoffman E, Saluja S.Disabil Health J. 2024 Jul;17(3):101589. doi: 10.1016/j.dhjo.2024.101589. Epub 2024 Feb 5.PMID: 38341354

Evaluation of the COVID-19 Vaccination Campaign *¡Ándale! ¿Qué Esperas?* in Latinx Communities in California, June 2021-May 2022.
Nawaz S, Moon KJ, Anagbonu F, Trinh A, Escobedo L, Montiel GI.Public Health Rep. 2024 Jul-Aug;139(1_suppl):44S-52S. doi: 10.1177/00333549231204043. Epub 2023 Nov 13.PMID: 37957827

COVID-19 vaccination status in people with spinal cord injury: Results from a cross-sectional study in Thailand.
Chotiyarnwong C, Pattanakuhar S, Srisuppaphon D, Komaratat N, Insook S, Tunwattanapong P, Kammuang-Lue P, Laohasinnarong P, Potiart T, Kaewma A, Thoowadaratrakool T, Potiruk P, Mahisanan T, Wangchumthong A, Kaewtong A, Kittiwarawut J, Dissaneewate T, Kovindha A.J Spinal Cord Med. 2024 Jul;47(4):573-583. doi: 10.1080/10790268.2022.2154733. Epub 2023 Mar 29.PMID: 36988422

Neonatal BCG Vaccination for Prevention of Allergy in Infants: The MIS BAIR Randomised Controlled Trial.
Messina NL, Gardiner K, Pittet LF, Forbes EK, Francis KL, Freyne B, Zufferey C, Abruzzo V, Morison C, Turner H, Allen KJ, Flanagan KL, Ponsonby AL, Robins-Browne R, Shann F, Vuillermin P, Donath S, Casalaz

D, Curtis N; Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR) Group.Clin Exp Allergy. 2024 Jul 14. doi: 10.1111/cea.14537. Online ahead of print.PMID: 39004434

The association between emotional and physical intimate partner violence and COVID-19 vaccine uptake in a community-based U.S. Cohort.
Penrose K, Abraham A, Robertson M, Berry A, Xi Jasmine Chan B, Shen Y, Srivastava A, Balasubramanian S, Yadav S, Piltch-Loeb R, Nash D, Parcesepe AM.Prev Med Rep. 2024 Jun 8;43:102784. doi: 10.1016/j.pmedr.2024.102784. eCollection 2024 Jul.PMID: 38938628

Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study.
Zhu Y, Sun L, Wang Y, Wang J, Wang Y, Li J, Wang L, Guo Y.Hum Vaccin Immunother. 2024 Dec 31;20(1):2372884. doi: 10.1080/21645515.2024.2372884. Epub 2024 Jul 3.PMID: 38957938

Combating Disparities in a Pandemic: Increasing Dissemination of Coronavirus Disease 2019 Resources in Spanish.
Barral RL, Clark NA, Zapata F, Vargas Collado LM, Cuevas JJ, Fernandez C.Pediatr Qual Saf. 2024 Jul 10;9(4):e744. doi: 10.1097/pq9.0000000000000744. eCollection 2024 Jul-Aug.PMID: 38993272

RNA vaccines for cancer: Principles to practice.
Guasp P, Reiche C, Sethna Z, Balachandran VP.Cancer Cell. 2024 Jul 8;42(7):1163-1184. doi: 10.1016/j.ccell.2024.05.005. Epub 2024 Jun 6.PMID: 38848720

Undesirable effects of COVID-19 vaccination on Saudi population: A descriptive study, Winter 2022.
AlGhamdi SA, AlGhamdi AS, Al-Ogailan AA, Ghazwani AH, Redhwan EZ, Alkinani KB, Hasaballah NH.Int J Health Sci (Qassim). 2024 Jul-Aug;18(4):32-45.PMID: 38974645

Bergenin inhibits growth of human cervical cancer cells by decreasing Galectin-3 and MMP-9 expression.
Chauhan R, Malhotra L, Gupta A, Dagar G, Mendiratta M, Masoodi T, Hashem S, Al Marzooqi S, Das D, Uddin S, Ethayathulla AS, Macha MA, Akil AA, Sahoo RK, Rai E, Bhat AA, Singh M.Sci Rep. 2024 Jul 3;14(1):15287. doi: 10.1038/s41598-024-64781-3.PMID: 38961106

Molecular epidemiology of enteroviruses from Guatemalan wastewater isolated from human lung fibroblasts.
Sayyad L, Harrington C, Castro CJ, Belgasmi-Allen H, Jeffries Miles S, Hill J, Mendoza Prillwitz ML, Gobern L, Gaitán E, Delgado AP, Castillo Signor L, Rondy M, Rey-Benito G, Gerloff N.PLoS One. 2024 Jul 3;19(7):e0305108. doi: 10.1371/journal.pone.0305108. eCollection 2024.PMID: 38959255

SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Ameratunga R, Jordan A, Lehnert K, Leung E, Mears ER, Snell R, Steele R, Woon ST.Antiviral Res. 2024 Jul;227:105894. doi: 10.1016/j.antiviral.2024.105894. Epub 2024 Apr 25.PMID: 38677595

Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
Yoshifuji A, Toda M, Oyama E, Nakayama T, Mise-Omata S, Kikuchi K, Yoshizawa M, Kato N, Wakai H, Koibuchi K, Morimoto K, Uwamino Y, Namkoong H, Shibata A, Wakabayashi K, Fujino M, Komatsu M,

Mochizuki N, Kondo N, Yoshimura A, Hasegawa N, Ryuzaki M.Clin Exp Nephrol. 2024 Jul;28(7):674-682. doi: 10.1007/s10157-024-02477-8. Epub 2024 Mar 8.PMID: 38457030

Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
Duncan MC, Omondi FH, Kinloch NN, Lapointe HR, Speckmaier S, Moran-Garcia N, Lawson T, DeMarco ML, Simons J, Holmes DT, Lowe CF, Bacani N, Sereda P, Barrios R, Harris M, Romney MG, Montaner JSG, Brumme CJ, Brockman MA, Brumme ZL.AIDS. 2024 Jul 1;38(8):1120-1130. doi: 10.1097/QAD.0000000000003841. Epub 2024 Jan 22.PMID: 38224350

Evaluating the cost and operational context for national human papillomavirus (HPV) vaccine delivery in three regions of Ethiopia.
Mvundura M, Bayeh A, Zelalem M, Lakew Y, Dhufera A, Dagnew B, Slavkovsky R, Lamontagne DS.PLOS Glob Public Health. 2024 Jul 15;4(7):e0003357. doi: 10.1371/journal.pgph.0003357. eCollection 2024.PMID: 39008460

Measles outbreak in 2019: a warning for the post-COVID-19 pandemic period.
Salimović-Bešić I, Musa S, Kotorić-Keser Š, Zahirović E, Mutevelić S, Dedeić-Ljubović A.J Med Microbiol. 2024 Jul;73(7). doi: 10.1099/jmm.0.001855.PMID: 38995847

Comparative safety of monovalent and bivalent mRNA COVID-19 booster vaccines in adolescents aged 12 to 17 years in the Republic of Korea.
Ko M, Kim S, Choi SK, Shin SH, Lee YK, Kwon Y.Osong Public Health Res Perspect. 2024 Jul 9. doi: 10.24171/j.phrp.2024.0081. Online ahead of print.PMID: 38988090

Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases.
Teles MS, Brundage J, Chiang TP, Alejo JL, Henriquez N, Wallwork R, Christopher Stine L, Massie A, Segev DL, Connolly CM, Paik JJ, Werbel WA.J Rheumatol. 2024 Jul 1:jrheum.2023-1212. doi: 10.3899/jrheum.2023-1212. Online ahead of print.PMID: 38950954

Retention rate of vaccination card and its associated factors among vaccinated children aged 12—23 months in Ethiopia: Multilevel logistic regression analysis.
Tareke AA, Tewabe Ayelign A, Yewodiaw TK, Shiferaw EW, Eshetu HB, Enyew EB.PLoS One. 2024 Jul 11;19(7):e0306421. doi: 10.1371/journal.pone.0306421. eCollection 2024.PMID: 38990882

Long-term changes in the phenotype and cytokine production of monocytes in COVID-19 recovered and vaccinated individuals.
Ostapchuk YO, Lushova AV, Kan SA, Abdolla N, Kali A, Tleulieva R, Perfilyeva AV, Perfilyeva YV.Infect Immun. 2024 Jul 11;92(7):e0021624. doi: 10.1128/iai.00216-24. Epub 2024 Jun 14.PMID: 38874358

Validation of self-reported human papillomavirus vaccination in young adult men who have sex with men.
Chow EPF, Fairley CK, Atkinson S, Bradshaw CS, Chen MY.Hum Vaccin Immunother. 2024 Dec 31;20(1):2371179. doi: 10.1080/21645515.2024.2371179. Epub 2024 Jul 7.PMID: 38972858

Inter- and intra-individual differences regarding SARS-CoV-2 and influenza vaccination in pediatric kidney transplant recipients: An observational study.

Kanai T, Ito T, Saito T, Aoyagi J, Kurosaki M, Betsui H, Maru T, Ono M, Tajima T.Medicine (Baltimore). 2024 Jul 5;103(27):e38809. doi: 10.1097/MD.0000000000038809.PMID: 38968522

Increased adherence to influenza vaccination among Palermo family pediatricians: a study on safety and compliance of qLAIV vaccination.
Costantino C, Tramuto F, Bonaccorso N, Giudice MCL, Balsamo F, Carubia A, D'Azzo L, Fruscione S, Sciortino M, Vitello T, Zagra L, Pieri A, Rizzari R, Serra G, Palermo M, Randazzo MA, Palmeri S, Asciutto R, Corsello G, Graziano G, Maida CM, Mazzucco W, Vitale F.Ital J Pediatr. 2024 Jul 11;50(1):126. doi: 10.1186/s13052-024-01693-y.PMID: 38987808

Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A, Bennett R, Ali K, Griffin C, Clifford RA, Turner M, Poston R, Hautzinger K, Yeakey A, Girard B, Zhou W, Deng W, Zhou H, Schnyder Ghamloush S, Kuter BJ, Slobod K, Miller JM, Priddy F, Das R; ROVER Study Investigators.Lancet Infect Dis. 2024 Jul;24(7):687-697. doi: 10.1016/S1473-3099(24)00101-4. Epub 2024 Mar 19.PMID: 38518789

Injectable Hydrogels: A Paradigm Tailored with Design, Characterization, and Multifaceted Approaches.
Singhal R, Sarangi MK, Rath G.Macromol Biosci. 2024 Jul;24(7):e2400049. doi: 10.1002/mabi.202400049. Epub 2024 Apr 19.PMID: 38577905

Understanding the Regulatory Pathways Used to Develop, Evaluate, Authorize, and Approve New Drugs and Vaccines in the United States.
Domachowske JB.J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S93-S102. doi: 10.1093/jpids/piae036.PMID: 38995086

Glycoconjugates: Advances in modern medicines and human health.
Chettri D, Chirania M, Boro D, Verma AK.Life Sci. 2024 Jul 1;348:122689. doi: 10.1016/j.lfs.2024.122689. Epub 2024 May 4.PMID: 38710281

SEMA 2.0: web-platform for B-cell conformational epitopes prediction using artificial intelligence.
Ivanisenko NV, Shashkova TI, Shevtsov A, Sindeeva M, Umerenkov D, Kardymon O.Nucleic Acids Res. 2024 Jul 5;52(W1):W533-W539. doi: 10.1093/nar/gkae386.PMID: 38742639

Pathogenicity and virulence of African swine fever virus.
Ruedas-Torres I, Thi To Nga B, Salguero FJ.Virulence. 2024 Dec;15(1):2375550. doi: 10.1080/21505594.2024.2375550. Epub 2024 Jul 7.PMID: 38973077

Transition transferases prime bacterial capsule polymerization.
Litschko C, Di Domenico V, Schulze J, Li S, Ovchinnikova OG, Voskuilen T, Bethe A, Cifuente JO, Marina A, Budde I, Mast TA, Sulewska M, Berger M, Buettner FFR, Lowary TL, Whitfield C, Codée JDC, Schubert M, Guerin ME, Fiebig T.Nat Chem Biol. 2024 Jul 1. doi: 10.1038/s41589-024-01664-8. Online ahead of print.PMID: 38951648

Proscan: a structure-based proline design web server.

Felbinger N, Ribeiro-Filho HV, Pierce BG.Nucleic Acids Res. 2024 Jul 5;52(W1):W280-W286. doi: 10.1093/nar/gkae408.PMID: 38769060

Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.
Zhao G, Wang S, Nie G, Li N.Med. 2024 Jul 12;5(7):660-688. doi: 10.1016/j.medj.2024.03.012. Epub 2024 Apr 5.PMID: 38582088

20 years of herpes simplex virus type 2 (HSV-2) research in low-income and middle-income countries: systematic evaluation of progress made in addressing WHO priorities for research in HSV-2/HIV interactions, HSV-2 control and mathematical modelling.
Owen EM, Jama M, Nahal B, Clarke E, Obasi A.BMJ Glob Health. 2024 Jul 4;9(7):e015167. doi: 10.1136/bmjgh-2024-015167.PMID: 38964882

Cross-sectional study: mindset towards Coronavirus in developing countries and lessons learned: the case of Sudan.
Omer Z, Khalid Y, Zakaria G, Sabir S, MohamedAbdallah A.Ann Med Surg (Lond). 2024 May 1;86(7):3900-3908. doi: 10.1097/MS9.0000000000002056. eCollection 2024 Jul.PMID: 38989223

Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study.
Choi YJ, Lim J, Bea S, Lee J, Choi JY, Rho SY, Lee DI, Na JO, Kim HK.Eur Heart J. 2024 Jul 12:ehae335. doi: 10.1093/eurheartj/ehae335. Online ahead of print.PMID: 38993069

Identification of immune- and oxidative stress-related signature genes as potential targets for mRNA vaccines for pancreatic cancer patients.
Li J, Han Y, Zhao N, Lv L, Ma P, Zhang Y, Li M, Sun H, Deng J, Zhang Y.Medicine (Baltimore). 2024 Jul 5;103(27):e38666. doi: 10.1097/MD.0000000000038666.PMID: 38968513

Predicting COVID-19 vaccine uptake: Comparing the health belief model and theory of planned behavior.
Alshagrawi SS.Hum Vaccin Immunother. 2024 Dec 31;20(1):2361503. doi: 10.1080/21645515.2024.2361503. Epub 2024 Jul 15.PMID: 39007826

Characterizing zero-dose and under-vaccinated children among refugees and internally displaced persons in the Democratic Republic of Congo.
Nimpa MM, Cikomola Mwana-Wabene A, Otomba J, Mukendi JC, Danovaro-Holliday MC, Mboussou FF, Mwamba D, Kambala L, Ngwanga D, Mwanga C, Etapelong SG, Compaoré I, Yapi MD, Ishoso DK.Trop Dis Travel Med Vaccines. 2024 Jul 15;10(1):17. doi: 10.1186/s40794-024-00225-0.PMID: 39004758

Fighting against Clostridioides difficile infection: Current medications.
Quan M, Zhang X, Fang Q, Lv X, Wang X, Zong Z.Int J Antimicrob Agents. 2024 Jul;64(1):107198. doi: 10.1016/j.ijantimicag.2024.107198. Epub 2024 May 10.PMID: 38734214

Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38.

Shin OS, Monticelli SR, Hjorth CK, Hornet V, Doyle M, Abelson D, Kuehne AI, Wang A, Bakken RR, Mishra AK, Middlecamp M, Champney E, Stuart L, Maurer DP, Li J, Berrigan J, Barajas J, Balinandi S, Lutwama JJ, Lobel L, Zeitlin L, Walker LM, Dye JM, Chandran K, Herbert AS, Pauli NT, McLellan JS.Cell Rep. 2024 Jul 12;43(7):114502. doi: 10.1016/j.celrep.2024.114502. Online ahead of print.PMID: 39002130

Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
Korchinski I, Marquez C, McClymont E, Av-Gay G, Andrade J, Elwood C, Jassem A, Krajden M, Morshed M, Sadarangani M, Tanunliong G, Sekirov I, Money D.Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.07.024. Online ahead of print.PMID: 38981741

COVID-19 vaccine: recent advancements and future prospects.
Xu L, Li M, He W.MedComm (2020). 2024 Jul 5;5(7):e646. doi: 10.1002/mco2.646. eCollection 2024 Jul.PMID: 38974715

The Psychosocial, Organizational, and Environmental Stressors Experienced by Food Service Workers in a Hospital Setting During the COVID-19 Pandemic.
Kent KB, Zhang Y, Roemer EC, Davis MF, Safeer R, Mojica A, Goetzel RZ.J Occup Environ Med. 2024 Jul 1;66(7):556-563. doi: 10.1097/JOM.0000000000003108. Epub 2024 Apr 10.PMID: 38595305

Looking Beyond the Lens of Crimean-Congo Hemorrhagic Fever in Africa.
Okesanya OJ, Olatunji GD, Kokori E, Olaleke NO, Adigun OA, Manirambona E, Lucero-Prisno DE 3rd.Emerg Infect Dis. 2024 Jul;30(7):1319-1325. doi: 10.3201/eid3007.230810.PMID: 38916548

SARS-CoV-2 humoral immunity in people living with HIV-1.
Motsoeneng BM, Bhiman JN, Richardson SI, Moore PL.Trends Immunol. 2024 Jul;45(7):511-522. doi: 10.1016/j.it.2024.05.005. Epub 2024 Jun 17.PMID: 38890026

Enhancing in situ cancer vaccines using delivery technologies.
Gong N, Alameh MG, El-Mayta R, Xue L, Weissman D, Mitchell MJ.Nat Rev Drug Discov. 2024 Jul 1. doi: 10.1038/s41573-024-00974-9. Online ahead of print.PMID: 38951662

Components, Formulations, Deliveries, and Combinations of Tumor Vaccines.
Liu T, Yao W, Sun W, Yuan Y, Liu C, Liu X, Wang X, Jiang H.ACS Nano. 2024 Jul 9. doi: 10.1021/acsnano.4c05065. Online ahead of print.PMID: 38979917

Characteristics and factors of repeated influenza vaccination among elderly individuals in Shanghai, China from 2020 to 2022.
Niu D, Xu J, Liu J, Gong R, Shi J, Wu Q.Hum Vaccin Immunother. 2024 Dec 31;20(1):2364480. doi: 10.1080/21645515.2024.2364480. Epub 2024 Jul 7.PMID: 38972854

N-glycosylation on hemagglutinin head reveals inter-branch antigenic variability of avian influenza virus H5-subtypes.
Shi K, Feng S, Zhao L, Chen J, Song W, Jia Y, Qu X, Liu Z, Jia W, Du S, Liao M.Int J Biol Macromol. 2024 Jul;273(Pt 2):132901. doi: 10.1016/j.ijbiomac.2024.132901. Epub 2024 Jun 5.PMID: 38848854

Myocarditis in children 2024, new themes and continued questions.
Goldberg JF, Spinner JA, Soslow JH.Curr Opin Cardiol. 2024 Jul 1;39(4):315-322. doi: 10.1097/HCO.0000000000001151. Epub 2024 Apr 24.PMID: 38661130

INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes.
Pedersen IB, Kjolby M, Hjelholt AJ, Madsen M, Christensen AR, Adolfsen D, Hjelle JS, Kremke B, Støvring H, Jessen N, Vestergaard ET, Kristensen K, Frobert O.BMJ Open. 2024 Jul 1;14(6):e084808. doi: 10.1136/bmjopen-2024-084808.PMID: 38950997

Genomic characterization of circulating human respiratory syncytial viruses A and B in Kuwait using whole-genome sequencing.
Madi N, Safar HA, Al-Adwani A, Sadeq M, Al-Turab M.Microbiol Spectr. 2024 Jul 2;12(7):e0015924. doi: 10.1128/spectrum.00159-24. Epub 2024 May 29.PMID: 38808977

An open-label, phase IV randomised controlled trial of two schedules of a four-component meningococcal B vaccine in UK preterm infants.
Calvert A, Andrews N, Barlow S, Borrow R, Black C, Bromage B, Carr J, Clarke P, Collinson AC, Few K, Hayward N, Jones CE, Le Doare K, Ladhani SN, Louth J, Papadopoulou G, Pople M, Scorrer T, Snape MD, Heath PT.Arch Dis Child. 2024 Jul 8:archdischild-2024-327040. doi: 10.1136/archdischild-2024-327040. Online ahead of print.PMID: 38977298

Spatial distribution and determinants of measles vaccination dropout among under-five children in Ethiopia: A spatial and multilevel analysis of 2019 Ethiopian demographic and health survey.
Zegeye AF, Mekonen EG, Tekeba B, Alemu TG, Ali MS, Gonete AT, Kassie AT, Workneh BS, Tamir TT, Wassie M.PLoS One. 2024 Jul 8;19(7):e0305393. doi: 10.1371/journal.pone.0305393. eCollection 2024.PMID: 38976660

Primary health care utilisation and delivery in remote Australian clinics during the COVID-19 pandemic.
Mathew S, Fitts MS, Liddle Z, Bourke L, Campbell N, Murakami-Gold L, Russell DJ, Humphreys JS, Rossingh B, Zhao Y, Jones MP, Boffa J, Ramjan M, Tangey A, Schultz R, Mulholland E, Wakerman J.BMC Prim Care. 2024 Jul 5;25(1):240. doi: 10.1186/s12875-024-02485-3.PMID: 38969977

Assessment of $CD8^+$ T-cell mediated immunity in an influenza A(H3N2) human challenge model in Belgium: a single centre, randomised, double-blind phase 2 study.
Evans TG, Castellino F, Kowalik Dobczyk M, Tucker G, Walley AM, Van Leuven K, Klein J, Rutkowski K, Ellis C, Eagling-Vose E, Treanor J, van Baalen C, Filkov E, Laurent C, Thacker J, Asher J, Donabedian A.Lancet Microbe. 2024 Jul;5(7):645-654. doi: 10.1016/S2666-5247(24)00024-7. Epub 2024 May 7.PMID: 38729196

Transient reemergence of *Bordetella parapertussis* in France in 2022.
Bouchez V, Toubiana J, Guillot S, Parapertussis Study Group, El Belghiti FA, Landier A, Armatys N, Trombert-Paolantoni S, Soares A, Rodrigues C, Brisse S.J Med Microbiol. 2024 Jul;73(7). doi: 10.1099/jmm.0.001843.PMID: 38995835

The inhibitory effect of swine TAB1 on the replication of pseudorabies virus.

Xia X, Wu X, Jiang D, Hu Y, Cong X, Li J, Dai M, Du Y, Qi J.Vet Microbiol. 2024 Jul 2;296:110172. doi: 10.1016/j.vetmic.2024.110172. Online ahead of print.PMID: 38971118

Display of FliC131 on the Surface of Lactococcus lactis as a Strategy to Increase its Adjuvanticity for Mucosal Immunization.
Silvestre D, Moreno G, Argüelles MH, Tomás Fariña J, Biedma ME, Peri Ibáñez ES, Mandile MG, Glikmann G, Rumbo M, Castello AA, Temprana CF.J Pharm Sci. 2024 Jul;113(7):1794-1803. doi: 10.1016/j.xphs.2024.03.013. Epub 2024 Mar 22.PMID: 38522753

A safe, effective and adaptable live-attenuated SARS-CoV-2 vaccine to reduce disease and transmission using one-to-stop genome modifications.
Schön J, Barut GT, Trüeb BS, Halwe NJ, Berenguer Veiga I, Kratzel A, Ulrich L, Kelly JN, Brügger M, Wylezich C, Taddeo A, Aguiar Moreira E, Túrós D, Grau-Roma L, Ahrens AK, Schlottau K, Britzke T, Breithaupt A, Corleis B, Kochmann J, Oliveira Esteves BI, Almeida L, Thomann L, Devisme C, Stalder H, Steiner S, Ochsenbein S, Schmied K, Labroussaa F, Jores J, V'kovski P, Cmiljanovic V, Alves MP, Benarafa C, Ebert N, Hoffmann D, Beer M, Thiel V.Nat Microbiol. 2024 Jul 12. doi: 10.1038/s41564-024-01755-1. Online ahead of print.PMID: 38997518

SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.
Carreño JM, Wagner AL, Monahan B, Singh G, Floda D, Gonzalez-Reiche AS, Tcheou J, Raskin A, Bielak D, Morris S, Fried M, Yellin T, Sullivan L; PARIS study group; Sordillo EM, Gordon A, van Bakel H, Simon V, Krammer F.Nat Commun. 2024 Jul 11;15(1):5847. doi: 10.1038/s41467-024-50052-2.PMID: 38992013

Unveiling the immune dynamics of *Neisseria* persistent oral colonization.
Alles M, Gunasena M, Zia T, D'Mello A, Bhattarai S, Mulhern W, Terry L, Scherger T, Wijeratne S, Singh S, Wijeratne AJ, Kasturiratna D, Tettelin H, Weyand NJ, Liyanage NPM.Infect Immun. 2024 Jul 11;92(7):e0004824. doi: 10.1128/iai.00048-24. Epub 2024 May 30.PMID: 38814083

Evaluation of candidate International Standards for meningococcal capsular polysaccharide groups W and Y.
Chan H, Beresford N, Rudd TR, Rigsby P, Vipond C, Gao F, Matejtschuk P, Malik K, Duru C, Atkinson E, Burkin K, De Benedetto G, Lockyer K, Bolgiano B; MenW/MenY IS Working Group.Biologicals. 2024 Jul 5;87:101780. doi: 10.1016/j.biologicals.2024.101780. Online ahead of print.PMID: 38970883

Cancer mRNA vaccines: clinical advances and future opportunities.
Sayour EJ, Boczkowski D, Mitchell DA, Nair SK.Nat Rev Clin Oncol. 2024 Jul;21(7):489-500. doi: 10.1038/s41571-024-00902-1. Epub 2024 May 17.PMID: 38760500

Leptospiral LipL45 lipoprotein undergoes processing and shares structural similarities with bacterial sigma regulators.
de Assis Noman G, Lacerda de Moura BE, Vieira ML.Biochem Biophys Res Commun. 2024 Jul 12;717:150057. doi: 10.1016/j.bbrc.2024.150057. Epub 2024 May 4.PMID: 38718568

Graduate Student Literature Review: Role of antioxidants in calf immunity, growth, and health.
Carlson H, Abuelo A.J Dairy Sci. 2024 Jul;107(7):4844-4854. doi: 10.3168/jds.2023-23988. Epub 2024 Apr 25.PMID: 38670342

Semiautomated design and soluble expression of a chimeric antigen TbpAB01 from Glaesserella parasuis.
Chen JP, Zhou L, Gong JS, Wang NK, Miao FF, Su C, Gao XL, Xu GQ, Shi JS, Xu ZH.Biotechnol Bioeng. 2024 Jul;121(7):2163-2174. doi: 10.1002/bit.28710. Epub 2024 Apr 10.PMID: 38595326

Applications and advancements in animal models for antiviral research on mosquito-borne arboviruses.
Tang MC, Wong KH, Azman AS, Lani R.Animal Model Exp Med. 2024 Jul 10. doi: 10.1002/ame2.12471. Online ahead of print.PMID: 38987937

Neutralizing the threat: harnessing broadly neutralizing antibodies against HIV-1 for treatment and prevention.
Becerra JC, Hitchcock L, Vu K, Gach JS.Microb Cell. 2024 Jul 3;11:207-220. doi: 10.15698/mic2024.07.826. eCollection 2024.PMID: 38975023

Modeling and analysis of a human papilloma virus transmission model with impact of media.
Liu H, Lin X, Zhu X, Zhang Q, Wei Y, Ma G.Math Biosci. 2024 Jul 3:109247. doi: 10.1016/j.mbs.2024.109247. Online ahead of print.PMID: 38969058

Mammalian cell display with automated oligo design and library assembly allows for rapid residue level conformational epitope mapping.
Thalén NB, Karlander M, Lundqvist M, Persson H, Hofström C, Turunen SP, Godzwon M, Volk AL, Malm M, Ohlin M, Rockberg J.Commun Biol. 2024 Jul 3;7(1):805. doi: 10.1038/s42003-024-06508-8.PMID: 38961245

Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2.
Liang Y, Xiao W, Peng Y, Zhang S, Dong J, Zhao J, Wang Y, Zhang M, Liu Z, Yu B.Antiviral Res. 2024 Jul;227:105917. doi: 10.1016/j.antiviral.2024.105917. Epub 2024 May 21.PMID: 38782067

Evaluation of immunoregulation and immunoprotective efficacy of Glaesserella parasuis histidine kinase QseC.
Yan X, Gu C, Xiao W, Zhou Y, Xiang X, Yu Z, He M, Yang Q, Zhao M, He L.Microb Pathog. 2024 Jul;192:106685. doi: 10.1016/j.micpath.2024.106685. Epub 2024 May 13.PMID: 38750774

DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants.
Yu B, Chen Y, Yan Y, Lu X, Zhu B.Nucleic Acids Res. 2024 Jul 9:gkae593. doi: 10.1093/nar/gkae593. Online ahead of print.PMID: 38979568

Metformin as a therapeutic agent for obesity-associated immune dysfunction.
Rajeev D, MacIver NJ.J Nutr. 2024 Jul 5:S0022-3166(24)00381-X. doi: 10.1016/j.tjnut.2024.07.001. Online ahead of print.PMID: 38972391

Job analysis of vaccination health workers at public health centers and sub-centers.
Park NY, Cho CM, Lee EH, Park JM, Lee YR, Hong JI, Kwon GY.Public Health Nurs. 2024 Jul-Aug;41(4):723-735. doi: 10.1111/phn.13325. Epub 2024 Apr 8.PMID: 38588062

Association Between Influenza Vaccination and SARS-CoV-2 Infection.

Ma'ayeh M, de Voest JA, Hughes BL, Grobman WA, Saade GR, Manuck TA, Longo M, Simhan HN, Rouse DJ, Mendez-Figueroa H, Gyamfi-Bannerman C, Bailit JL, Costantine MM, Sehdev HM, Tita ATN, Metz TD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network.Am J Reprod Immunol. 2024 Jul;92(1):e13896. doi: 10.1111/aji.13896.PMID: 38994889

Awareness of cervical cancer risk factors and preventive approaches, and perceived causes of cervical cancer among secondary school girls: a cross-sectional study in Northern Uganda.
Oringtho S, Mwaka AD, Garimoi Orach C, Wabinga H.Ann Med. 2024 Dec;56(1):2374860. doi: 10.1080/07853890.2024.2374860. Epub 2024 Jul 8.PMID: 38975806

Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case-control study.
Saukkoriipi A, Silmon de Monerri NC, Toropainen M, Lindholm L, Veijola R, Toppari J, Knip M, Radley D, Gomme E, Jongihlati B, Anderson AS, Palmu AA, Simon R.Lancet Microbe. 2024 Jul;5(7):689-696. doi: 10.1016/S2666-5247(24)00038-7. Epub 2024 Apr 26.PMID: 38679040

The effect of matrine and glycyrrhizic acid on porcine reproductive and respiratory syndrome virus in Vitro and in vivo.
Zhang Z, Wu W, Li Q, Du F, Wang X, Yang M, Zhang H.Virol J. 2024 Jul 4;21(1):150. doi: 10.1186/s12985-024-02415-w.PMID: 38965549

Dynamics of Antibody Response to Covishield Vaccine after 6 Months: A Longitudinal Prospective Study.
Chavhan SS, Dhikale PT, Adsul BB, Kinge KV, Ingale AR, Gokhale CN, Jadhav N.J Assoc Physicians India. 2024 Jul;72(7):22-24. doi: 10.59556/japi.72.0590.PMID: 38990582

Sequence variants associated with resilient responses in growing pigs.
Laghouaouta H, Laplana M, Ros-Freixedes R, Fraile LJ, Pena RN.J Anim Breed Genet. 2024 Jul 5. doi: 10.1111/jbg.12886. Online ahead of print.PMID: 38967062

Advances in engineered nanosystems: immunomodulatory interactions for therapeutic applications.
Khatua R, Bhar B, Dey S, Jaiswal C, J V, Mandal BB.Nanoscale. 2024 Jul 11;16(27):12820-12856. doi: 10.1039/d4nr00680a.PMID: 38888201

Platform establishment of the Cre-loxP recombination system for genetic manipulation of the Lumpy skin disease virus.
Ren S, Zhang Y, Gao X, Wang X, Tong L, Wang S, Sun Y, Yin X, Chen H.Vet Microbiol. 2024 Jul;294:110122. doi: 10.1016/j.vetmic.2024.110122. Epub 2024 May 18.PMID: 38772074

From hit to vial: Precision discovery and development of an imidazopyrimidine TLR7/8 agonist adjuvant formulation.
Soni D, Borriello F, Scott DA, Feru F, DeLeon M, Brightman SE, Cheng WK, Melhem G, Smith JA, Ramirez JC, Barman S, Cameron M, Kelly A, Walker K, Nanishi E, van Haren SD, Phan T, Qi Y, Kinsey R, Raczy MM, Ozonoff A, Pettengill MA, Hubbell JA, Fox CB, Dowling DJ, Levy O.Sci Adv. 2024 Jul 5;10(27):eadg3747. doi: 10.1126/sciadv.adg3747. Epub 2024 Jul 3.PMID: 38959314

Anti-LGI-1 Limbic Encephalitis and Autoimmune Epilepsy Following a Third Dose of COVID-19 Vaccination: A Case Report.
Mullan G, Kinney M.Neurohospitalist. 2024 Jul;14(3):332-335. doi: 10.1177/19418744241234100. Epub 2024 Feb 20.PMID: 38895001

Effects of fish-human transmission and different life stages of fish on Clonorchiasis: A novel mathematical model.
Wang W, Huang X, Wang H.Math Biosci. 2024 Jul;373:109209. doi: 10.1016/j.mbs.2024.109209. Epub 2024 May 15.PMID: 38754625

Facile Generation of Heterotelechelic Poly(2-Oxazoline)s Towards Accelerated Exploration of Poly(2-Oxazoline)-Based Nanomedicine.
Van Guyse JFR, Abbasi S, Toh K, Nagorna Z, Li J, Dirisala A, Quader S, Uchida S, Kataoka K.Angew Chem Int Ed Engl. 2024 Jul 1;63(27):e202404972. doi: 10.1002/anie.202404972. Epub 2024 Jun 3.PMID: 38651732

Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.
Gordillo-Marañón M, Candore G, Hedenmalm K, Browne K, Flynn R, Piccolo L, Santoro A, Zaccaria C, Kurz X.Drug Saf. 2024 Jul;47(7):607-615. doi: 10.1007/s40264-024-01422-8. Epub 2024 Apr 9.PMID: 38592665

COVID-19 ethics: unique aspects and a review as of early 2024.
Shandera WX.Monash Bioeth Rev. 2024 Jul 13. doi: 10.1007/s40592-024-00199-x. Online ahead of print.PMID: 39003388

Deciphering the Thermal Stability of Bacteriophage MS2-Derived Virus-like Particle and Its Engineered Variant.
Vishwakarma P, Puri S, Banerjee M, Chang CY, Chang CC, Chaudhuri TK.ACS Biomater Sci Eng. 2024 Jul 8. doi: 10.1021/acsbiomaterials.4c00770. Online ahead of print.PMID: 38976823

Splenic marginal zone B cells restrict Mycobacterium tuberculosis infection by shaping the cytokine pattern and cell-mediated immunity.
Tsai CY, Oo M, Peh JH, Yeo BCM, Aptekmann A, Lee B, Liu JJJ, Tsao WS, Dick T, Fink K, Gengenbacher M.Cell Rep. 2024 Jul 2;43(7):114426. doi: 10.1016/j.celrep.2024.114426. Online ahead of print.PMID: 38959109

Spider minor ampullate silk protein nanoparticles: an effective protein delivery system capable of enhancing systemic immune responses.
Yu H, Chen G, Li L, Wei G, Li Y, Xiong S, Qi X.MedComm (2020). 2024 Jun 15;5(7):e573. doi: 10.1002/mco2.573. eCollection 2024 Jul.PMID: 38882211

Survivin: A key apoptosis inhibitor in COVID-19 infection and its implication for treatment protocol.
Q B Alenzi F.Saudi J Biol Sci. 2024 Jul;31(7):104021. doi: 10.1016/j.sjbs.2024.104021. Epub 2024 May 12.PMID: 38831893

Hydrogel activation of Mincle receptors for tumor cell processing: A novel approach in cancer immunotherapy.
Lin J, Zhou Y, Li C, Li B, Hao H, Tian F, Li H, Liu Z, Wang G, Shen XC, Tang R, Wang X.Biomaterials. 2024 Jul 8;311:122703. doi: 10.1016/j.biomaterials.2024.122703. Online ahead of print.PMID: 39002516

Fish Iridoviridae: infection, vaccination and immune response.
Leiva-Rebollo R, Labella AM, Gémez-Mata J, Castro D, Borrego JJ.Vet Res. 2024 Jul 15;55(1):88. doi: 10.1186/s13567-024-01347-1.PMID: 39010235

Shar-Pei autoinflammatory disease with skin necrosis due to neutrophilic vasculitis: a case report.
Alamán Trigo L, Ortiz Gutiérrez J, Alonso-Miguel D, García San José P, García Martín P, Cuvertoret Sanz M, Lorente Méndez C.Vet Res Commun. 2024 Jul 2. doi: 10.1007/s11259-024-10454-5. Online ahead of print.PMID: 38954258

Mucoadhesive chitosan-catechol as an efficient vaccine delivery system for intranasal immunization.
Deng K, Huang Z, Jing B, Zhu L, Feng Y, Jiang Q, Xu Z, Wan H, Zhao X.Int J Biol Macromol. 2024 Jul;273(Pt 1):133008. doi: 10.1016/j.ijbiomac.2024.133008. Epub 2024 Jun 7.PMID: 38852736

Highly efficient strategy of lipopolysaccharide (LPS) decontamination from rHBsAg: synergistic effect of enhanced magnetic nanoparticles (MNPs) as an LPS affinity adsorbent (LAA) and surfactant as a dissociation factor.
Kavianpour A, Hosseini SN, Ashjari M, Khatami M, Hosseini T, Soleimani H.Prep Biochem Biotechnol. 2024 Jul 13:1-10. doi: 10.1080/10826068.2024.2377326. Online ahead of print.PMID: 39002143

Dermotoscope assisted diagnosis of adolescent bullous pilomatricoma: six case reports.
Liu J, Liu X, Qu Y, Zhang S.BMC Pediatr. 2024 Jul 9;24(1):437. doi: 10.1186/s12887-024-04914-9.PMID: 38982398

SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
Richardson SI, Mzindle N, Motlou T, Manamela NP, van der Mescht MA, Lambson BE, Everatt J, Amoako DG, Balla S, von Gottberg A, Wolter N, de Beer Z, de Villiers TR, Bodenstein A, van den Berg G, Abdullah F, Rossouw TM, Boswell MT, Ueckermann V, Bhiman JN, Moore PL.J Virol. 2024 Jul 2:e0067824. doi: 10.1128/jvi.00678-24. Online ahead of print.PMID: 38953380

Human Case of Leptospirosis During a Canine Disease Outbreak - Wyoming, 2023.
Waranius B, Tillman C, Van Houten C, Harrist A, Digianantonio R, Hasel H, Atherstone C, Curren E.MMWR Morb Mortal Wkly Rep. 2024 Jul 11;73(27):602-606. doi: 10.15585/mmwr.mm7327a1.PMID: 38990767

Factors Influencing Community Engagement during Guinea Worm and Polio Eradication Endgames in Chad: Recommendations for "Last Mile" Programming.
Delea MG, Browne L, Kaji S, Weiss AJ, Tchindebet O.Am J Trop Med Hyg. 2024 Jul 9:tpmd230635. doi: 10.4269/ajtmh.23-0635. Online ahead of print.PMID: 38981498

Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors.

Grebe E, Stone M, Spencer BR, Akinseye A, Wright D, Di Germanio C, Bruhn R, Zurita KG, Contestable P, Green V, Lanteri MC, Saa P, Biggerstaff BJ, Coughlin MM, Kleinman S, Custer B, Jones JM, Busch MP.Emerg Infect Dis. 2024 Jul 9;30(8). doi: 10.3201/eid3008.240659. Online ahead of print.PMID: 38981189

Genetic and recombination heterogeneity of Canine Bufaviruses detected in diarrheal dogs in China.
Ji J, Cui H, Zhang Z, Liu Q, Xu X, Zuo K, Bi Y, Yao L.Vet J. 2024 Jul 2:106192. doi: 10.1016/j.tvjl.2024.106192. Online ahead of print.PMID: 38964602

Natural killer cells in cancer immunotherapy.
Wang D, Dou L, Sui L, Xue Y, Xu S.MedComm (2020). 2024 Jun 15;5(7):e626. doi: 10.1002/mco2.626. eCollection 2024 Jul.PMID: 38882209

Identification of Two Linear Epitopes on MGF_110-13L Protein of African Swine Fever Virus with Monoclonal Antibodies.
Zhang SJ, Niu B, Liu SM, Zhu YM, Zhao DM, Bu ZG, Hua RH.Animals (Basel). 2024 Jul 1;14(13):1951. doi: 10.3390/ani14131951.PMID: 38998063

Maternal skepticism regarding children's vaccination in Jordan: Investigating the knowledge, attitude, and adherence.
Al-Rashdan RA, Ta'an W, Mukattash T, Williams B.PLoS One. 2024 Jul 10;19(7):e0305209. doi: 10.1371/journal.pone.0305209. eCollection 2024.PMID: 38985715

Enhancing Mass Vaccination Programs with Queueing Theory and Spatial Optimization.
Xie S, Rieders M, Changolkar S, Bhattacharya BB, Diaz EW, Levy MZ, Castillo-Neyra R.medRxiv [Preprint]. 2024 Jul 9:2024.06.14.24308958. doi: 10.1101/2024.06.14.24308958.PMID: 38947058

Antimalarial Delivery with a Ferritin-Based Protein Cage: A Step toward Developing Smart Therapeutics against Malaria.
Bhatt S, Dasgupta S, Tupe C, Prashar C, Adhikari U, Pandey KC, Kundu S, Chakraborti S.Biochemistry. 2024 Jul 16;63(14):1738-1751. doi: 10.1021/acs.biochem.3c00692. Epub 2024 Jul 8.PMID: 38975628

Structural characterization and adjuvant activity of a water soluble polysaccharide from Poria cocos.
Gu P, Xu P, Zhu Y, Zhao Q, Zhao X, Fan Y, Wang X, Ma N, Bao Y, Shi W.Int J Biol Macromol. 2024 Jul;273(Pt 1):133067. doi: 10.1016/j.ijbiomac.2024.133067. Epub 2024 Jun 10.PMID: 38866287

Two mutations on S2 subunit were critical for Vero cell tropism expansion of infectious bronchitis virus HV80.
Jiang Y, Cheng X, Gao M, Yu Y, Dou X, Shen H, Tang M, Zhou S, Peng D.Vet Microbiol. 2024 Jul;294:110134. doi: 10.1016/j.vetmic.2024.110134. Epub 2024 May 28.PMID: 38820725

CodonBERT: a BERT-based architecture tailored for codon optimization using the cross-attention mechanism.
Ren Z, Jiang L, Di Y, Zhang D, Gong J, Gong J, Jiang Q, Fu Z, Sun P, Zhou B, Ni M.Bioinformatics. 2024 Jul 1;40(7):btae330. doi: 10.1093/bioinformatics/btae330.PMID: 38788220

Escherichia coli LTB26 mutant enhances immune responses to rotavirus antigen VP8 in a mouse model.

Shi Q, Wang Q, Shen Y, Chen S, Gan S, Lin T, Song F, Ma Y.Mol Immunol. 2024 Jul 13;173:10-19. doi: 10.1016/j.molimm.2024.07.001. Online ahead of print.PMID: 39004021

Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection.
Springer DN, Camp JV, Aberle SW, Deutsch J, Lammel O, Weseslindtner L, Stiasny K, Aberle JH.J Med Virol. 2024 Jul;96(7):e29801. doi: 10.1002/jmv.29801.PMID: 38988204

Identification of *Babesia microti* immunoreactive antigens by phage display cDNA screen.
Hanada T, Empitu MA, Mines GI, Ma Q, Omorodion IL, Link A, Schwake CJ, Krueger RM, DaRosa NS, Levin AE, Vannier E, Chishti AH.Infect Immun. 2024 Jul 11;92(7):e0021524. doi: 10.1128/iai.00215-24. Epub 2024 Jun 17.PMID: 38884473

Racial (In)Equity in South Los Angeles-Community Centered Experiences with COVID-19 Syndemics.
Üsküp DK, Castellon-Lopez YM, Jolayemi O, Branch CA, Adeyiga O, Shoptaw S.Health Equity. 2024 Jul 1;8(1):446-454. doi: 10.1089/heq.2023.0188. eCollection 2024.PMID: 39011070

Lung-resident CD3-NK1.1+CD69+CD103+ Cells Play an Important Role in Bacillus Calmette-Guerin Vaccine-Induced Protective Immunity against Mycobacterium tuberculosis Infection.
Durojaye O, Vankayalapati A, Paidipally P, Mukherjee T, Vankayalapati R, Radhakrishnan RK.J Immunol. 2024 Jul 15:ji2200728. doi: 10.4049/jimmunol.2200728. Online ahead of print.PMID: 39007739

Deciphering structural variation upon biotinylation of biotin carboxyl carrier protein domain in Streptococcus pneumoniae.
Karalia S, Meena VK, Kumar V.Int J Biol Macromol. 2024 Jul 1;275(Pt 1):133580. doi: 10.1016/j.ijbiomac.2024.133580. Online ahead of print.PMID: 38960227

Diverse roles of dendritic cell and regulatory T cell crosstalk in controlling health and disease.
Yamazaki S.Int Immunol. 2024 Jul 2:dxae042. doi: 10.1093/intimm/dxae042. Online ahead of print.PMID: 38953561

External Quality Assessment (EQA) scheme for serological diagnostic test for SARS-CoV-2 detection in Sicily Region (Italy), in the period 2020-2022.
Di Gaudio F, Brunacci G, Cucina A, Giaccone V, Raso M, Lundari A, Cancilleri A, Buffa V, Russo E, Vasto S, La Rocca M, Indelicato S.Diagnosis (Berl). 2024 Jul 3. doi: 10.1515/dx-2024-0048. Online ahead of print.PMID: 38950285

Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck.
Ezzibdeh R, Diop M, Divi V.Curr Treat Options Oncol. 2024 Jul;25(7):885-896. doi: 10.1007/s11864-024-01197-1. Epub 2024 Jun 25.PMID: 38916713

Silicon or Calcium Doping Coordinates the Immunostimulatory Effects of Aluminum Oxyhydroxide Nanoadjuvants in Prophylactic Vaccines.
Li M, Yao Z, Wang H, Ma Y, Yang W, Guo Y, Yu G, Shi W, Zhang N, Xu M, Li X, Zhao J, Zhang Y, Xue C, Sun B.ACS Nano. 2024 Jul 2;18(26):16878-16894. doi: 10.1021/acsnano.4c02685. Epub 2024 Jun 20.PMID: 38899978

Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE.
Kavikondala S, Haeussler K, Wang X, Spellman A, Bausch-Jurken MT, Sharma P, Amiri M, Krivelyova A, Vats S, Nassim M, Kumar N, Van de Velde N.Infect Dis Ther. 2024 Jul;13(7):1419-1438. doi: 10.1007/s40121-024-00987-2. Epub 2024 May 27.PMID: 38802704

Mitigation measures against Coronavirus Disease 2019 (COVID-19) in overnight faith-based camps: summer 2021.
Kalu IC, Wagner BE, Armstrong SC, Permar S, Coffman S, Freeman C, D'Agostino EM.Public Health. 2024 Jul;232:82-85. doi: 10.1016/j.puhe.2024.04.013. Epub 2024 May 14.PMID: 38749152

Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.
Gillot C, Tré-Hardy M, Cupaiolo R, Blairon L, Wilmet A, Beukinga I, Dogné JM, Douxfils J, Favresse J.Virology. 2024 Jul;595:110082. doi: 10.1016/j.virol.2024.110082. Epub 2024 Apr 8.PMID: 38636363

Modulating the mesenchymal stromal cell microenvironment alters exosome RNA content and ligament healing capacity.
Chamberlain CS, Prabahar A, Kink JA, Mueller E, Li Y, Yopp S, Capitini CM, Hematti P, Murphy WL, Vanderby R, Jiang P.Stem Cells. 2024 Jul 8;42(7):636-649. doi: 10.1093/stmcls/sxae028.PMID: 38597671

The SapM phosphatase can arrest phagosome maturation in an ESX-1 independent manner in *Mycobacterium tuberculosis* and BCG.
Xander C, Rajagopalan S, Jacobs WR Jr, Braunstein M.Infect Immun. 2024 Jul 11;92(7):e0021724. doi: 10.1128/iai.00217-24. Epub 2024 Jun 17.PMID: 38884474

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Larivière Y, Matuvanga TZ, Osang'ir BI, Milolo S, Meta R, Kimbulu P, Robinson C, Katwere M, McLean C, Lemey G, Matangila J, Maketa V, Mitashi P, Van Geertruyden JP, Van Damme P, Muhindo-Mavoko H.Lancet Infect Dis. 2024 Jul;24(7):746-759. doi: 10.1016/S1473-3099(24)00058-6. Epub 2024 Mar 26.PMID: 38552653

[Enzyme immunoassay system for serological diagnosis of hemorrhagic fever with renal syndrome based on inactivated purified Puumala virus (Hantaviridae: *Orthohantavirus*)].
Ivanov AP, Dzagurova TK, Kurashova SS, Teodorovich RD, Klebleeva TD, Tkachenko EA.Vopr Virusol. 2024 Jul 5;69(3):285-289. doi: 10.36233/0507-4088-230.PMID: 38996377

Label-Free and DNAzyme-Mediated Biosensor with a High Signal-to-Noise Ratio for a Lumpy Skin Disease Virus Assay.
Cao G, Yang N, Yang J, Li J, Wang L, Nie F, Huo D, Hou C.Anal Chem. 2024 Jul 9;96(27):10927-10934. doi: 10.1021/acs.analchem.4c00962. Epub 2024 Jun 27.PMID: 38934225

Effects of different immunomodulating liposome-based adjuvants and injection sites on immunogenicity in pigs.
Šťastná E, Erbs G, Skovgaard K, Jakobsen JT, Bailey M, Pedersen GK, Jungersen G.Microbes Infect. 2024 Jul-Aug;26(5-6):105346. doi: 10.1016/j.micinf.2024.105346. Epub 2024 Apr 24.PMID: 38670217

Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.
Yagi A, Ueda Y, Oka E, Nakagawa S, Kimura T, Shimoya K.Cancer Sci. 2024 Jul;115(7):2410-2416. doi: 10.1111/cas.16167. Epub 2024 May 2.PMID: 38698561

Differentially Charged Liposomes Stimulate Dendritic Cells with Varying Effects on Uptake and Processing When Used Alone or in Combination with an Adjuvant.
Maji M, Ghosh S, Didwania N, Ali N.ACS Omega. 2024 Jun 25;9(27):29175-29185. doi: 10.1021/acsomega.3c07814. eCollection 2024 Jul 9.PMID: 39005780

Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens.
Yin M, Liu Z, Zhou Y, Li W, Yan J, Cao D, Yin L.J Control Release. 2024 Jul 13:S0168-3659(24)00455-3. doi: 10.1016/j.jconrel.2024.07.024. Online ahead of print.PMID: 39009083

Genomic diversity and evolutionary dynamics of Influenza A viruses in Colombian swine: implications for one health surveillance and control.
Ciuoderis K, Usuga J, Pérez-Restrepo LS, Gonzalez-Ramirez M, Carvajal L, Cardona A, Moreno I, Diaz A, Peña M, Hernández-Ortiz JP, Osorio JE.Emerg Microbes Infect. 2024 Dec;13(1):2368202. doi: 10.1080/22221751.2024.2368202. Epub 2024 Jul 6.PMID: 38970562

Molecular mechanism of TRIM32 in antiviral immunity in rainbow trout (Oncorhynchus mykiss).
Zhang M, Sun J, Zhang F, Zhang Y, Wu M, Kong W, Guan X, Liu M.Fish Shellfish Immunol. 2024 Jul 12:109765. doi: 10.1016/j.fsi.2024.109765. Online ahead of print.PMID: 39004296

Conjugation with the Carrier Helped to Reveal acidification-Induced Structural Shift in the Peptide from Phospholipase Domain of Parvovirus B19.
Khrustalev VV, Khrustaleva OV, Stojarov AN, Akunevich AA, Baranov OE, Popinako AV, Samoilovich EO, Yermolovich MA, Semeiko GV, Cheprasova VI, Sapon EG, Shalygo NV, Poboinev VV, Khrustaleva TA, Ranishenka BV, Kharytonova UV, Bush D.Protein J. 2024 Jul 9. doi: 10.1007/s10930-024-10209-w. Online ahead of print.PMID: 38980534

The antibodies against the A137R protein drive antibody-dependent enhancement of African swine fever virus infection in porcine alveolar macrophages.
Yang X, Sun E, Zhai H, Wang T, Wang S, Gao Y, Hou Q, Guan X, Li S, Li LF, Wu H, Luo Y, Li S, Sun Y, Zhao D, Li Y, Qiu HJ.Emerg Microbes Infect. 2024 Jul 8:2377599. doi: 10.1080/22221751.2024.2377599. Online ahead of print.PMID: 38973388

Modeling the Cost of Vaccinating a Measles Zero-Dose Child in Zambia Using Three Vaccination Strategies.
Mak J, Patenaude BN, Mutembo S, Pilewskie ME, Winter AK, Moss WJ, Carcelen AC.Am J Trop Med Hyg. 2024 May 21;111(1):121-128. doi: 10.4269/ajtmh.23-0412. Print 2024 Jul 3.PMID: 38772386

Development of a Coagulation Disorders Unit.

Szanto T, Helin T, Joutsi-Korhonen L, Lehtinen AE, El Beayni N, Lepäntalo A, Lassila R.Semin Thromb Hemost. 2024 Jul;50(5):687-694. doi: 10.1055/s-0044-1779633. Epub 2024 Feb 19.PMID: 38373723

High-throughput screen identifies non inflammatory small molecule inducers of trained immunity.
Knight HR, Ketter E, Ung T, Weiss A, Ajit J, Chen Q, Shen J, Ip KM, Chiang CY, Barreiro L, Esser-Kahn A.Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2400413121. doi: 10.1073/pnas.2400413121. Epub 2024 Jul 8.PMID: 38976741

Genetic variability of human papillomavirus type 18 based on E6, E7 and L1 genes in central China.
Li T, Yang Z, Luo P, Yang Y, Lin Z, Mei B.Virol J. 2024 Jul 5;21(1):152. doi: 10.1186/s12985-024-02424-9.PMID: 38970084

Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions.
Lee J, Whitney JB.Curr Opin HIV AIDS. 2024 Jul 1;19(4):179-186. doi: 10.1097/COH.0000000000000863. Epub 2024 May 15.PMID: 38747727

Adjuvant Human Papillomavirus Vaccination in Recurrent Respiratory Papilloma Patients Older than 45.
Ivancic R, Freeman T, de Silva B, Forrest A, Kim B, Matrka L.Laryngoscope. 2024 Jul;134(7):3226-3229. doi: 10.1002/lary.31368. Epub 2024 Feb 24.PMID: 38401115

Assessing clinical benefits of live-attenuated vaccination in post-liver transplant patients: Analysis of breakthrough infections and natural boosters.
Shinjoh M, Furuichi M, Yamada Y, Ohnishi T, Yaginuma M, Hoshino K, Nakayama T.Am J Transplant. 2024 Jul 13:S1600-6135(24)00427-1. doi: 10.1016/j.ajt.2024.07.005. Online ahead of print.PMID: 39009348

Hepatitis B vaccine among healthcare workers: factors associated with the dimensions of the Health Belief Model.
Farias Junior YC, Souza FO, Santos DVD, Heliotério MC, Pinho PS, Araújo TM.Rev Bras Epidemiol. 2024 Jul 1;27:e240036. doi: 10.1590/1980-549720240036. eCollection 2024.PMID: 38958371

Adoptive T cell therapy for ovarian cancer.
Gitto SB, Ihewulezi CJN, Powell DJ Jr.Gynecol Oncol. 2024 Jul;186:77-84. doi: 10.1016/j.ygyno.2024.04.001. Epub 2024 Apr 10.PMID: 38603955

Characterization of SLA RNA promoter from dengue virus and its interaction with the viral non-structural NS5 protein.
Brillet K, Janczuk-Richter M, Poon A, Laukart-Bradley J, Ennifar E, Lebars I.Biochimie. 2024 Jul;222:87-100. doi: 10.1016/j.biochi.2024.02.005. Epub 2024 Feb 24.PMID: 38408720

Equity Work Among Accredited Health Departments in the United States, 2015-2021.
Lang B, Kronstadt J, Rich N.Public Health Rep. 2024 Jul-Aug;139(1_suppl):106S-112S. doi: 10.1177/00333549231210033. Epub 2023 Dec 3.PMID: 38044683

New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy.

Domachowske JB.J Pediatric Infect Dis Soc. 2024 Jul 12;13(Supplement_2):S115-S124. doi: 10.1093/jpids/piae030.PMID: 38554101

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.
Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H; COV-CHIM01 study team.Lancet Microbe. 2024 Jul;5(7):655-668. doi: 10.1016/S2666-5247(24)00025-9. Epub 2024 May 1.PMID: 38703782

Acute pancreatitis complicated with diabetic ketoacidosis following COVID-19 mRNA vaccination: a case report.
Watanabe Y, Akaike E, Tokunaga Y, Murayama K, Segawa M.J Rural Med. 2024 Jul;19(3):199-203. doi: 10.2185/jrm.2024-003. Epub 2024 Jul 1.PMID: 38975045

Megastudy shows that reminders boost vaccination but adding free rides does not.
Milkman KL, Ellis SF, Gromet DM, Jung Y, Luscher AS, Mobarak RS, Paxson MK, Silvera Zumaran RA, Kuan R, Berman R, Lewis NA Jr, List JA, Patel MS, Van den Bulte C, Volpp KG, Beauvais MV, Bellows JK, Marandola CA, Duckworth AL.Nature. 2024 Jul;631(8019):179-188. doi: 10.1038/s41586-024-07591-x. Epub 2024 Jun 26.PMID: 38926578

Impact of COVID-19 Pandemic on Routine Immunization Among Tribal Children in Odisha: A Rapid Epidemiological Survey.
Alekhya G, Sahu DP, Patro BK, Behera P, Taywade M, Dash SS.Indian Pediatr. 2024 Jul 15;61(7):627-631. Epub 2024 May 25.PMID: 38803098

Japanese encephalitis virus E protein domain III immunization mediates cross-protection against Zika virus in mice via antibodies and CD8^{+}T cells.
Duan ZL, Zou WW, Chen D, Zhu JY, Wen JS.Virus Res. 2024 Jul;345:199376. doi: 10.1016/j.virusres.2024.199376. Epub 2024 Apr 20.PMID: 38643856

Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study.
Gröning R, Walde J, Ahlm C, Forsell MNE, Normark J, Rasmuson J.Int J Infect Dis. 2024 Jul;144:107046. doi: 10.1016/j.ijid.2024.107046. Epub 2024 Apr 12.PMID: 38615825

Transcriptome analysis of Vero cells infected with attenuated vaccine strain CDV-QN-1.
Chang X, Su H, Ma S, Li Y, Tan Y, Li Y, Dong S, Lin J, Zhou B, Zhang H.Microb Pathog. 2024 Jul 5;193:106786. doi: 10.1016/j.micpath.2024.106786. Online ahead of print.PMID: 38971506

Immune responses induced by Mycobacterium tuberculosis heat-resistant antigen (Mtb-HAg) upon co-administration with Bacillus Calmette-Guérin in mice.
Guo F, Wei J, Song Y, Song J, Wang Y, Li K, Li B, Qian Z, Wang X, Wang H, Xu T.Cytokine. 2024 Jul;179:156610. doi: 10.1016/j.cyto.2024.156610. Epub 2024 Apr 18.PMID: 38640558

Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V.BMC Infect Dis. 2024 Jul 12;24(1):696. doi: 10.1186/s12879-024-09593-6.PMID: 38997625

Parallel single B cell transcriptomics to elucidate pig B cell repertoire.
Bram S, Lindsey G, Drnevich J, Xu F, Wozniak M, Medina GN, Mehta AP.Sci Rep. 2024 Jul 10;14(1):15997. doi: 10.1038/s41598-024-65263-2.PMID: 38987322

Hepatitis A in Latin America: The current scenario.
Ré VE, Ridruejo E, Fantilli AC, Moutinho BD, Pisano MB, Pessoa MG.Rev Med Virol. 2024 Jul;34(4):e2566. doi: 10.1002/rmv.2566.PMID: 38970225

Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge.
Bartalucci C, Limongelli A, Nicolini LA, Ponzano M, Tigano S, Farinella ST, Carrega G, Malerba G, Magnè F, Balletto E, Giacobbe DR, Riccio G, Cenderello G, Taramasso L, Bruzzone B, Vena A, Di Biagio A, Mikulska M, De Maria A, Dentone C, Bassetti M.J Chemother. 2024 Jul;36(4):283-290. doi: 10.1080/1120009X.2023.2289269. Epub 2023 Dec 14.PMID: 38095569

Longitudinal monitoring of Torque Teno virus DNAemia in kidney transplant recipients correlates with long-term complications of inadequate immunosuppression.
Chauvelot L, Barba T, Saison C, Siska E, Kulifaj D, Bakker SJL, Koenig A, Rabeyrin M, Buron F, Picard C, Dijoud F, Manière L, Lina B, Morelon E, Dubois V, Thaunat O.J Med Virol. 2024 Jul;96(7):e29806. doi: 10.1002/jmv.29806.PMID: 39007420

Surface Display of Duck Hepatitis A Virus Type 1 VP1 Protein on Bacillus subtilis Spores Elicits Specific Systemic and Mucosal Immune Responses on Mice.
Chen B, Yang Y, Wang Z, Dai X, Cao Y, Zhang M, Zhang D, Ni X, Zeng Y, Pan K.Probiotics Antimicrob Proteins. 2024 Jul 13. doi: 10.1007/s12602-024-10323-2. Online ahead of print.PMID: 39002060

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.
Martín-Sánchez E, Tamariz-Amador LE, Guerrero C, Zherniakova A, Zabaleta A, Maia C, Blanco L, Alignani D, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Paiva B; Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) cooperative group.Blood Cancer J. 2024 Jul 10;14(1):111. doi: 10.1038/s41408-024-01089-5.PMID: 38987557

Codon usage bias of goose circovirus and its adaptation to host.
Xu Q, Cao J, Rai KR, Zhu B, Liu D, Wan C.Poult Sci. 2024 Jul;103(7):103775. doi: 10.1016/j.psj.2024.103775. Epub 2024 Apr 17.PMID: 38713985

Newly developed peptide-ELISA successfully detected anti-IgG antibodies against Maedi-Visna virus in sheep.

Koçkaya ES, Can H, Yaman Y, Kandemir Ç, Taşkın T, Karakavuk M, Değirmenci Döşkaya A, Döşkaya M, Pehlivan E, Şireli HD, Gürüz AY, Ün C.Vet Immunol Immunopathol. 2024 Jul 10;274:110806. doi: 10.1016/j.vetimm.2024.110806. Online ahead of print.PMID: 39002364

Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
Kontandreopoulou CN, Solomou EE, Kolorizos E, Diamantopoulos PT.Ann Hematol. 2024 Jul 15. doi: 10.1007/s00277-024-05869-8. Online ahead of print.PMID: 39008060

Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
Ciapponi A, Berrueta M, Argento FJ, Ballivian J, Bardach A, Brizuela ME, Castellana N, Comandé D, Gottlieb S, Kampmann B, Mazzoni A, Parker EPK, Sambade JM, Stegelmann K, Xiong X, Stergachis A, Buekens P.Drug Saf. 2024 Jul 15. doi: 10.1007/s40264-024-01458-w. Online ahead of print.PMID: 39009928

Metabolic requirements of CD160 expressing memory-like NK cells in Gram-negative bacterial infection.
Preechanukul A, Saiprom N, Rochaikun K, Moonmueangsan B, Phunpang R, Ottiwet O, Kongphrai Y, Wapee S, Janon R, Dunachie S, Kronsteiner B, Chantratita N.Clin Transl Immunology. 2024 Jul 2;13(7):e1513. doi: 10.1002/cti2.1513. eCollection 2024.PMID: 38957437

Serotype distribution, antibiotic resistance, multilocus sequence typing, and virulence factors of invasive and non-invasive Streptococcus pneumoniae in Northeast China from 2000 to 2021.
Xu Y, Zhou X, Zheng W, Cui B, Xie C, Liu Y, Qin X, Liu J.Med Microbiol Immunol. 2024 Jul 2;213(1):12. doi: 10.1007/s00430-024-00797-w.PMID: 38954065

The design and implementation of a multi-center, pragmatic, individual-level randomized controlled trial to evaluate Baby2Home, an mHealth intervention to support new parents.
Duckworth M, Garfield CF, Santiago JE, Gollan J, O'Sullivan K, Williams D, Lee Y, Muhammad LN, Miller ES.Contemp Clin Trials. 2024 Jul;142:107571. doi: 10.1016/j.cct.2024.107571. Epub 2024 May 11.PMID: 38740296

Hospital Burden of All-Cause Pneumonia and Nonbacteremic Pneumococcal Pneumonia in Adults in France Between 2013 and 2019.
Sabra A, Bourgeois M, Blanc E, Fievez S, Moïsi J, Goussiaume G, Lemaitre M, Watier L, Coulombel N, Tréhony J, Tricotel A, Baghdadi Y, Fartoukh MS.Open Forum Infect Dis. 2024 Jun 28;11(7):ofae349. doi: 10.1093/ofid/ofae349. eCollection 2024 Jul.PMID: 38994444

The cost of delivering COVID-19 vaccines in Vietnam.
Nguyen VM, Moi F, Boonstoppel L, Duong HT, Vien CC, Van Hoang M.BMC Health Serv Res. 2024 Jul 8;24(1):779. doi: 10.1186/s12913-024-11202-w.PMID: 38977967

Application of a Heuristic Framework for Multilevel Interventions to Eliminate the Impact of Unjust Social Processes and Other Harmful Social Determinants of Health.
Guilamo-Ramos V, Thimm-Kaiser M, Benzekri A, Johnson C, Williams D, Wilhelm-Hilkey N, Goodman M, Hagan H.Prev Sci. 2024 Jul;25(Suppl 3):446-458. doi: 10.1007/s11121-024-01658-x. Epub 2024 Apr 12.PMID: 38607535

Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome.
Libardi Lira Machado KL, da Costa-Rocha IA, Gonçalves Rodrigues Aguiar L, Ribeiro Moulaz I, Tatiyama Miyamoto S, Costa Martins P, Vieira Serrano E, Espíndula Gianordoli AP, da Penha Gomes Gouvea M, de Fatima Bissoli M, Maria Barbosa de Lima S, Dias Schwarcz W, de Souza Azevedo A, Fernandes Amorim da Silva J, Tourinho Santos R, Pedro Brito-de-Sousa J, Coelho-Dos-Reis JG, Campi-Azevedo AC, Teixeira-Carvalho A, Peruhype-Magalhães V, Fontana Sutile Tardetti Fantinato F, Maria Henrique da Mota L, Assis Martins-Filho O, Valim V.Hum Vaccin Immunother. 2024 Dec 31;20(1):2318814. doi: 10.1080/21645515.2024.2318814. Epub 2024 Jul 3.PMID: 38961639

Stimuli-Responsive mRNA Vaccines to Induce Robust CD8$^+$ T Cell Response via ROS-Mediated Innate Immunity Boosting.
Dong L, Deng X, Li Y, Zhu X, Shu M, Chen J, Luo H, An K, Cheng M, Zhang P, Tan W.J Am Chem Soc. 2024 Jul 2. doi: 10.1021/jacs.4c04331. Online ahead of print.PMID: 38955767

Establishment of a new equine embryo brain primary cell culture with long-term expansion.
Kasem S, Abdel-Moneim AS, Fukushi H.J Virol Methods. 2024 Jul;328:114952. doi: 10.1016/j.jviromet.2024.114952. Epub 2024 May 14.PMID: 38754768

The nexus of immigration regulation and health governance: a scoping review of the extent to which right to access healthcare by migrants, refugees and asylum seekers was upheld in the United Kingdom during COVID-19.
Van Hout MC, Madroumi R, Andrews MD, Arnold R, Hope VD, Taegtmeyer M.Public Health. 2024 Jul;232:21-29. doi: 10.1016/j.puhe.2024.04.012. Epub 2024 May 9.PMID: 38728905

Dysfunctional host cellular immune responses are associated with mortality in melioidosis.
Wright SW, Ekchariyawat P, Sengyee S, Phunpang R, Dulsuk A, Saiprom N, Thiansukhon E, Pattanapanyasat K, Korbsrisate S, Eoin West T, Chantratita N.Emerg Microbes Infect. 2024 Jul 15:2380822. doi: 10.1080/22221751.2024.2380822. Online ahead of print.PMID: 39008280

Regional disparities in measles vaccination coverage and their associated factors: an ecological study in Japan.
Machida M, Fukushima S, Tabuchi T, Nakaya T, Fukushima W, Inoue S.J Epidemiol. 2024 Jul 6. doi: 10.2188/jea.JE20240129. Online ahead of print.PMID: 38972730

Age-specific prevalence of IgG against measles/rubella and the impact of routine and supplementary immunization activities: A multistage random cluster sampling study with mathematical modelling.
Hachiya M, Vynnycky E, Mori Y, Do HT, Huynh MK, Trinh LH, Nguyen DD, Tran NAT, Hoang TT, Hoang HHT, Vo NDT, Le TH, Ichimura Y, Miyano S, Okawa S, Thandar MM, Yokobori Y, Inoue Y, Mizoue T, Takeda M, Komada K.Int J Infect Dis. 2024 Jul;144:107053. doi: 10.1016/j.ijid.2024.107053. Epub 2024 Apr 17.PMID: 38641317

Effectiveness of patient reminders on influenza vaccination coverage among adults with chronic conditions: A feasibility study in Australian general practices.

Gonzalez-Chica D, Frank O, Edwards J, Hoon E, de Oliveira Bernardo C, Knieriemen A, Stocks N.Prev Med. 2024 Jul;184:107983. doi: 10.1016/j.ypmed.2024.107983. Epub 2024 May 1.PMID: 38701953

Economic burden of cardiorespiratory hospitalizations associated with respiratory syncytial virus among United States adults in 2017-2019.
Patel DA, Marcum ZA, Chansakul A, Toyip A, Nerney K, Panozzo CA, St Laurent S, Mehta D, Ghaswalla P.Hum Vaccin Immunother. 2024 Dec 31;20(1):2364493. doi: 10.1080/21645515.2024.2364493. Epub 2024 Jul 9.PMID: 38982719

A Paper-Based Multiplexed Serological Test to Monitor Immunity against SARS-COV-2 Using Machine Learning.
Eryilmaz M, Goncharov A, Han GR, Joung HA, Ballard ZS, Ghosh R, Zhang Y, Di Carlo D, Ozcan A.ACS Nano. 2024 Jul 2;18(26):16819-16831. doi: 10.1021/acsnano.4c02434. Epub 2024 Jun 18.PMID: 38888985

Navigating vaccination choices: The intersecting dynamics of institutional trust, belonging and message perception among Congolese migrants in London, UK (a reflexive thematic analysis).
Crawshaw AF, Vandrevala T, Knights F, Deal A, Lutumba LM, Nkembi S, Kitoko LM, Hickey C, Forster AS, Hargreaves S.PLOS Glob Public Health. 2024 Jul 10;4(7):e0002620. doi: 10.1371/journal.pgph.0002620. eCollection 2024.PMID: 38985733

Impact of cultural diversity on COVID-19 vaccination hesitancy in kidney transplant recipients.
Frederick R, Ierino F, Lopez R, Goodman D.Nephrology (Carlton). 2024 Jul 9. doi: 10.1111/nep.14351. Online ahead of print.PMID: 38981586

Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS-CoV-2 study group.Allergy. 2024 Jul;79(7):1952-1961. doi: 10.1111/all.16089. Epub 2024 Mar 4.PMID: 38439527

Inhibition of dengue virus infection in vitro by fucoidan and polysaccharide extract from marine alga Sargassum spp.
Panwong S, Phinyo K, Duangjan K, Sattayawat P, Pekkoh J, Tragoolpua Y, Yenchitsomanus PT, Panya A.Int J Biol Macromol. 2024 Jul 8:133496. doi: 10.1016/j.ijbiomac.2024.133496. Online ahead of print.PMID: 38986999

[Molecular allergen IgE tests show neosensitizaions occurring during house dust mite specific immunotherapy].
Long Z, Zhang Q, Zou Z, Zheng Y, Chen J.Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Jul;38(7):572-577. doi: 10.13201/j.issn.2096-7993.2024.07.003.PMID: 38973033

A comparative analysis of COVID-19 physical distancing policies in South Africa and Uganda.
Mohammad S, Apatu E, Kapiriri L, Alvarez E.PLOS Glob Public Health. 2024 Jul 3;4(7):e0003170. doi: 10.1371/journal.pgph.0003170. eCollection 2024.PMID: 38959235

Carbon Ion and Photon Radiation Therapy Show Enhanced Antitumoral Therapeutic Efficacy With Neoantigen RNA-LPX Vaccines in Preclinical Colon Carcinoma Models.
Salomon N, Helm A, Selmi A, Fournier C, Diken M, Schrörs B, Scholz M, Kreiter S, Durante M, Vascotto F.Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):936-945. doi: 10.1016/j.ijrobp.2023.12.042. Epub 2023 Dec 30.PMID: 38163521

Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.
Schramm A, Ackermann M, Eichwald C, Aguilar C, Fraefel C, Lechmann J.PLoS One. 2024 Jul 12;19(7):e0301987. doi: 10.1371/journal.pone.0301987. eCollection 2024.PMID: 38995916

Strep Easy Kit; a bio-enrichment dual ICG-strip test for simultaneous detection of Streptococcus agalactiae serotypes Ia and III in fish samples.
Himananto O, Yoohat K, Danwisetkanjana K, Kumpoosiri M, Rukpratanporn S, Theppawong Y, Sukchai N, Siripaitoon S, Areechon N, Unajak S, Gajanandana O.J Fish Dis. 2024 Jul 15:e14000. doi: 10.1111/jfd.14000. Online ahead of print.PMID: 39010687

Hepatitis B infection and immunity in Migrant Children and Pregnant Persons in Europe: A Systematic Review and Meta-Analysis.
Hobart C, Pescarini JM, Evans L, Adil HS, Adil ST, Deal A, Carter J, Matthews PC, Hargreaves S, Clemente NS.J Travel Med. 2024 Jul 11:taae094. doi: 10.1093/jtm/taae094. Online ahead of print.PMID: 38990201

Severe Neurological Manifestation Associated With Coronavirus Disease 2019 in Children During the Omicron Variant-Predominant Period.
Kim M, Choi Y, Kim SY, Cho A, Kim H, Chae JH, Kim KJ, Park D, Kwon YS, Kim MJ, Yum MS, Kong JH, Lee YJ, Lim BC.Pediatr Neurol. 2024 Jul;156:17-25. doi: 10.1016/j.pediatrneurol.2024.04.004. Epub 2024 Apr 7.PMID: 38692086

Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease-modifying treatment.
De Troyer M, Van Remoortel A, Van Schependom J, Faille LD, D'hooghe MB, Peeters G, Nagels G, D'haeseleer M.Eur J Neurol. 2024 Jul;31(7):e16300. doi: 10.1111/ene.16300. Epub 2024 Apr 19.PMID: 38641878

Hepatitis C-related knowledge and attitude among adults on probation in a large US city.
Minturn MS, Kamis KF, Wyles DL, Scott T, Hurley H, Prendergast SJ, Rowan SE.Health Justice. 2024 Jul 11;12(1):30. doi: 10.1186/s40352-024-00287-4.PMID: 38990381

Determination of the frequency of individuals with broadly cross-reactive neutralizing antibodies against PRRSV in the sow population under field conditions.
Plaza-Soriano Á, Martínez-Lobo FJ, Garza-Moreno L, Castillo-Pérez J, Caballero E, Castro JM, Simarro I, Prieto C.Porcine Health Manag. 2024 Jul 8;10(1):26. doi: 10.1186/s40813-024-00372-y.PMID: 38978128

Inactivation of Avian Influenza Virus Inoculated into Ground Beef Patties Cooked on a Commercial Open-Flame Gas Grill.
Luchansky JB, C S Porto-Fett A, Suarez DL, Spackman E.J Food Prot. 2024 Jul 2:100325. doi: 10.1016/j.jfp.2024.100325. Online ahead of print.PMID: 38964610

GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
Jajou R, Lieber T, van Puijenbroek EP, Mulder E, Overbeek J, Hek K, van Hunsel FPAM, Kant A.Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.07.031. Online ahead of print.PMID: 39004527

Activation of Antiviral Host Responses against Avian Influenza Virus and Remodeling of Gut Microbiota by rLAB Vector Expressing rIL-17A in Chickens.
Bhowmick S, Gupta S, Mondal S, Mallick AI.ACS Infect Dis. 2024 Jul 6. doi: 10.1021/acsinfecdis.4c00377. Online ahead of print.PMID: 38970488

SARS-CoV-2 genomic surveillance of migrants arriving to Europe through the Mediterranean routes.
Tramuto F, Marotta C, Stefanelli P, Cernigliaro A, Maida CM, Silenzi A, Angeloni U, Di Naro D, Randazzo G, Guzzetta V, Barone T, Brusaferro S, Severoni S, Rezza G, Vitale F, Mazzucco W; SAMI-Surv Collaboration.J Glob Health. 2024 Jul 5;14:05017. doi: 10.7189/jogh.14.05017.PMID: 38963881

Duration of Postvaccination Neutralizing Antibodies to SARS-CoV-2 and Medication Effects: Results from the Safety and Immunogenicity of COVID-19 Vaccination in Systemic Immune-Mediated Inflammatory Diseases Cohort Study.
Habib R, Dayam RM, Hitchon C, Chandran V, Fortin PR, Boire G, Bowdish DME, Gingras AC, Flamand L, Larché MJ, Colmegna I, Lukusa L, Lee JLF, Pereira D, Bernstein CN, Lalonde N, Turnbull E, Bernatsky S; SUCCEED investigative team.ACR Open Rheumatol. 2024 Jul 1. doi: 10.1002/acr2.11697. Online ahead of print.PMID: 38952080

Novel insights into human T-lymphotropic virus type-1 (HTLV-1) pathogenesis-host interactions in the manifestation of HTLV-1-associated myelopathy/tropical spastic paraparesis.
Ahmadi Ghezeldasht S, Mosavat A, Rezaee SA.Rev Med Virol. 2024 Jul;34(4):e2567. doi: 10.1002/rmv.2567.PMID: 38937135

Single-shot dendritic cell targeting SARS-CoV-2 vaccine candidate induces broad, durable and protective systemic and mucosal immunity in mice.
Cheang NYZ, Tan KS, Tan PS, Purushotorma K, Yap WC, Tullett KM, Chua BYL, Yeoh AY, Tan CQH, Qian X, Chen H, Tay DJW, Caminschi I, Tan YJ, Macary PA, Tan CW, Lahoud MH, Alonso S.Mol Ther. 2024 Jul 3;32(7):2299-2315. doi: 10.1016/j.ymthe.2024.05.003. Epub 2024 May 6.PMID: 38715364

Immunogenicity, reactogenicity and safety of a second booster with BNT162b2 or full-dose mRNA-1273: a randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1-AGED Part B).
Stemler J, Yeghiazaryan L, Stephan C, Mohn KG, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockienė B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, König F, Posch M, Koehler P, Cornely OA; EU-COVAT-1 AGED study group on behalf of the VACCELERATE consortium.Int J Infect Dis. 2024 Jul 9:107161. doi: 10.1016/j.ijid.2024.107161. Online ahead of print.PMID: 38992789

Eighteen-Month Outcomes Among Pregnant and Nonpregnant Reproductive-Aged People Hospitalized for Coronavirus Disease 2019.
Bebell LM, Woolley AE, James KE, Kim A, Joyc MR, Gray KJ, Radford C, Bassett IV, Boatin AA, Ciaranello AL, Yawetz S, Edlow AG, Goldfarb IT, Diouf K.Open Forum Infect Dis. 2024 Jul 8;11(7):ofae278. doi: 10.1093/ofid/ofae278. eCollection 2024 Jul.PMID: 38979015

Exosomes, and the potential for exosome-based interventions against COVID-19.
Rahmani A, Soleymani A, Almukhtar M, Behzad Moghadam K, Vaziri Z, Hosein Tabar Kashi A, Adabi Firoozjah R, Jafari Tadi M, Zolfaghari Dehkharghani M, Valadi H, Moghadamnia AA, Gasser RB, Rostami A.Rev Med Virol. 2024 Jul;34(4):e2562. doi: 10.1002/rmv.2562.PMID: 38924213

Untangling the stranglehold through mathematical modelling of Streptococcus equi subspecies equi transmission.
Houben RMAC, Newton JR, van Maanen C, Waller AS, Sloet van Oldruitenborgh-Oosterbaan MM, Heesterbeek JAP.Prev Vet Med. 2024 Jul;228:106230. doi: 10.1016/j.prevetmed.2024.106230. Epub 2024 May 17.PMID: 38772119

Testing multiplexed anti-ASFV CRISPR-Cas9 in reducing African swine fever virus.
Zheng Z, Xu L, Gao Y, Dou H, Zhou Y, Feng X, He X, Tian Z, Song L, Mo G, Hu J, Zhao H, Wei H, Church GM, Yang L.Microbiol Spectr. 2024 Jul 2;12(7):e0216423. doi: 10.1128/spectrum.02164-23. Epub 2024 Apr 2.PMID: 38563791

Risk of Corneal Graft Rejection and Vaccination: A Matched Case-Control Study From a United States Integrated Health Care System.
Ku JH, Nanji AA, Tubert JE, Joe C, Srikumaran D, Winthrop KL, Brunton AE, Florea A, Fraunfelder F, Tseng T, Luo YI.Am J Ophthalmol. 2024 Jul;263:133-140. doi: 10.1016/j.ajo.2024.02.015. Epub 2024 Feb 27.PMID: 38417569

Increased Risk of Herpes Zoster in Adult Patients with Inflammatory Bowel Disease After SARS-CoV2 Infection: A Propensity-Matched Cohort Study.
Desai A, Soni A, Hayney MS, Hashash JG, Kochhar GS, Farraye FA, Caldera F.Inflamm Bowel Dis. 2024 Jul 3;30(7):1094-1102. doi: 10.1093/ibd/izad162.PMID: 37540900

T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study.
Qui M, Hariharaputran S, Hang SK, Zhang J, Tan CW, Chong CY, Low J, Wang L, Bertoletti A, Yung CF, Le Bert N.EBioMedicine. 2024 Jul;105:105203. doi: 10.1016/j.ebiom.2024.105203. Epub 2024 Jun 18.PMID: 38896919

An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
Koutsoumpli G, Stasiukonyte N, Hoogeboom BN, Daemen T.Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.05.080. Online ahead of print.PMID: 38964950

How the COVID-19 pandemic affected infant vaccination trends in rural and urban communities in Ibadan, Nigeria: a cross-sectional study.
Adegoke AA, Balogun FM.BMJ Open. 2024 Jul 1;14(7):e073272. doi: 10.1136/bmjopen-2023-073272.PMID: 38955367

Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
Chen PK, Chang SH, Chen YM, Chen HH, Huang PH, Huang CC, Yeo KJ, Lan JL, Chen DY.Clin Rheumatol. 2024 Jul 2. doi: 10.1007/s10067-024-07041-z. Online ahead of print.PMID: 38954278

Emerging Clinical Features of Acute Mastoiditis in Israel: A Registry Based Cohort.
Samuel O, Saliba W, Stein N, Shiner Y, Cohen-Kerem R.Pediatr Infect Dis J. 2024 Jul 1;43(7):620-625. doi: 10.1097/INF.0000000000004325. Epub 2024 Mar 28.PMID: 38564738

Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis.
Yin X, Li Y, Rönn MM, Li S, Yuan Y, Gift TL, Hsu K, Salomon JA, Grad YH, Yaesoubi R.PLoS Med. 2024 Jul 8;21(7):e1004424. doi: 10.1371/journal.pmed.1004424. Online ahead of print.PMID: 38976754

Infant and adult human intestinal enteroids are morphologically and functionally distinct.
Adeniyi-Ipadeola GO, Hankins JD, Kambal A, Zeng X-L, Patil K, Poplaski V, Bomidi C, Nguyen-Phuc H, Grimm SL, Coarfa C, Stossi F, Crawford SE, Blutt SE, Speer AL, Estes MK, Ramani S.mBio. 2024 Jul 2:e0131624. doi: 10.1128/mbio.01316-24. Online ahead of print.PMID: 38953637

All hands on deck during the COVID-19 pandemic. Maintaining face-to-face medical education and clinical placements.
Humphreys H, Baxter R, Gilroy J, Cavalleri GL, O'Connor T, Kerrigan SW, Fitzpatrick F, Gilligan Quinn A, McConkey S, McGrogan K.PLoS One. 2024 Jul 1;19(7):e0306129. doi: 10.1371/journal.pone.0306129. eCollection 2024.PMID: 38950018

Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
Sloot R, Breskin A, Colantonio LD, Allmon AG, Yu Y, Sakhuja S, Chen L, Muntner P, Brookhart MA, Dhalwani N.Epidemiology. 2024 Jul 1;35(4):579-588. doi: 10.1097/EDE.0000000000001730. Epub 2024 Apr 12.PMID: 38629975

Impact of the first year of COVID-19 vaccination strategy in Brazil: an ecological study.
Aguilar S, Bastos LSL, Maçaira P, Baião F, Simões P, Cerbino-Neto J, Ranzani O, Hamacher S, Bozza FA.BMJ Open. 2024 Jul 4;14(7):e072314. doi: 10.1136/bmjopen-2023-072314.PMID: 38964793

Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
van 't Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, Fellah A, Kolijn PM, Langerak AW, Moskie M, van der Oost E, Rozendaal NEM, Baart SJ, Aerts JGJV, van Eijck CHJ.J Clin Oncol. 2024 Jul 1:JCO2302585. doi: 10.1200/JCO.23.02585. Online ahead of print.PMID: 38950309

Utility of SARS-CoV-2 Subgenomic RNA in Kidney Transplant Recipients Receiving Remdesivir.
Cuesta G, Cacho J, Cucchiari D, Herrera S, Sempere A, Akter T, Villasante A, Garrido M, Cofan F, Diekmann F, Soriano A, Marcos MA, Bodro M.Infect Dis Ther. 2024 Jul;13(7):1703-1713. doi: 10.1007/s40121-024-00991-6. Epub 2024 May 24.PMID: 38789902

Risk Factors for Measles Nonimmunity in Rubella-Immune Pregnant Patients.
Kassir E, Holliman K, Negi M, Duong HL, Tandel MD, Kwan L, Lee G, Silverman NS, Rao RR, Han CS.Am J Perinatol. 2024 Jul;41(9):1178-1184. doi: 10.1055/a-1799-5714. Epub 2022 Mar 15.PMID: 35292945

Factors influencing nurses' compliance related to the use of personal protective equipment during the COVID-19 pandemic: A descriptive cross-sectional study.
Kim EJ, Park YH, Choi HR.Nurs Open. 2024 Jul;11(7):e2235. doi: 10.1002/nop2.2235.PMID: 38958036

An efficient *in vivo*-inducible CRISPR interference system for group A *Streptococcus* genetic analysis and pathogenesis studies.
Bjånes E, Stream A, Janssen AB, Gibson PS, Bravo AM, Dahesh S, Baker JL, Varble A, Nizet V, Veening J-W.mBio. 2024 Jul 2:e0084024. doi: 10.1128/mbio.00840-24. Online ahead of print.PMID: 38953375

Pneumococcal antibody response in children with recurrent respiratory tract infections: A descriptive study.
Ceuppens F, Meyts I, Bossuyt X, De Boeck K.Arch Pediatr. 2024 Jul;31(5):293-298. doi: 10.1016/j.arcped.2023.12.006. Epub 2024 May 29.PMID: 38811264

Factors associated with perceived Anaplasma marginale infection and clinical anaplasmosis cases on beef operations in California.
Chen SY, Forero L, Davy J, Stackhouse J, Harvey D, Abdelfattah E, Maier G.Ticks Tick Borne Dis. 2024 Jul;15(4):102346. doi: 10.1016/j.ttbdis.2024.102346. Epub 2024 Apr 20.PMID: 38643720

Defining indicators for disease burden, health outcomes, policies and barriers and facilitators to health services for migrant populations in the Middle East and North African region: a protocol for a suite of systematic reviews.
Seedat F, Evangelidou S, Abdellatifi M, Bouaddi O, Cuxart-Graell A, Edries H, Elafef E, Maatoug T, Ouahchi A, Mathilde Pampiri L, Deal A, Arias S, Abdelkhalek A, Arisha AH, Assarag B, Bani IA, Chaoui A, Chemao-Elfihri W, Hassouni K, Hilali M, Khalis M, Mansour W, Mtiraoui A, Wickramage K, Zenner D, Requena-Mendez A, Hargreaves S, Migrant Health Working Group M; MENA Migrant Health Working Group.BMJ Open. 2024 Jul 13;14(7):e083813. doi: 10.1136/bmjopen-2023-083813.PMID: 39002961

Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022.
Gray P, Eriksson T, Skoglund L, Lagheden C, Hellström C, Pin E, Suomenrinne-Nordvik A, Pimenoff VN, Nilsson P, Dillner J, Lehtinen M.PLoS One. 2024 Jul 11;19(7):e0305285. doi: 10.1371/journal.pone.0305285. eCollection 2024.PMID: 38990856

A Physiochemical, *In Vitro*, and *In Vivo* Comparative Analysis of Verteporfin-Lipid Conjugate Formulations: Solid Lipid Nanoparticles and Liposomes.
Shah N, Soma SR, Quaye MB, Mahmoud D, Ahmed S, Malkoochi A, Obaid G.ACS Appl Bio Mater. 2024 Jul 15;7(7):4427-4441. doi: 10.1021/acsabm.4c00316. Epub 2024 Jun 27.PMID: 38934648

The impact of the COVID-19 pandemic on adult bronchiectasis patients and the relationship between clinical parameters and bronchiectasis severity.
Gul S, Uysal MA, Abalı H, Yeter A, Akalın Karaca ES, Alagoz N, Bilici D, Ozgun Niksarlıoglu EY.Eur Rev Med Pharmacol Sci. 2024 Jul;28(13):3958-3968. doi: 10.26355/eurrev_202407_36528.PMID: 39012235

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
Benlarbi M, Ding S, Bélanger É, Tauzin A, Poujol R, Medjahed H, El Ferri O, Bo Y, Bourassa C, Hussin J, Fafard J, Pazgier M, Levade I, Abrams C, Côté M, Finzi A.mBio. 2024 Jul 2:e0090724. doi: 10.1128/mbio.00907-24. Online ahead of print.PMID: 38953636

Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
Brisuda A, Horňák J, Žemličková B, Háček J, Babjuk M.Int Urol Nephrol. 2024 Jul;56(7):2243-2250. doi: 10.1007/s11255-023-03924-3. Epub 2024 Feb 8.PMID: 38329573

Epidemiological trends in viral meningitis in England: Prospective national surveillance, 2013-2023.
Kadambari S, Abdullahi F, Celma C, Ladhani S.J Infect. 2024 Jul 8;89(3):106223. doi: 10.1016/j.jinf.2024.106223. Online ahead of print.PMID: 38986749

Practices for preventing Hepatitis B infection among health science students in Ethiopia: Systematic review and meta-analysis.
Kitil GW, Dubale AT, Shibabaw AA, Chereka AA.PLoS One. 2024 Jul 10;19(7):e0306965. doi: 10.1371/journal.pone.0306965. eCollection 2024.PMID: 38985751

HPV Vaccination Practices Among Medical Trainees in Pediatrics, Obstetrics and Gynecology, and Family Medicine.
Cagle-Colon KJ, Voigt P, Boyd L.J Low Genit Tract Dis. 2024 Jul 1;28(3):205-209. doi: 10.1097/LGT.0000000000000807. Epub 2024 Apr 23.PMID: 38661333

Background incidence rates of health outcomes of interest for COVID-19 vaccine safety monitoring in a US population: a claims database analysis.
Banga S, Khromava A, Serradell L, Chabanon AL, Pan C, Estevez I, Schilsky S, Kreisberg H.BMJ Open. 2024 Jul 11;14(7):e083947. doi: 10.1136/bmjopen-2024-083947.PMID: 38991681

Next-generation nanovaccine induces durable immunity and protects against SARS-CoV-2.
Ross KA, Kelly S, Phadke KS, Peroutka-Bigus N, Fasina O, Siddoway A, Mallapragada SK, Wannemuehler MJ, Bellaire BH, Narasimhan B.Acta Biomater. 2024 Jul 15;183:318-329. doi: 10.1016/j.actbio.2024.05.048. Epub 2024 Jun 4.PMID: 38844193

Development and Bayesian validation of a competitive inhibition ELISA for detection of antibodies against Brucella abortus in cattle.
Novoa MB, Aguirre N, Valentini B, Signorini M, Aznar N, Vanzini V, Torioni-de-Echaide S.Acta Trop. 2024 Jul 5;257:107319. doi: 10.1016/j.actatropica.2024.107319. Online ahead of print.PMID: 38972562

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
Bonnin FA, Talarico LB, Ferolla FM, Acosta PL, Phung E, Kumar A, Toledano A, Caratozzolo A, Neira P, Mascardi N, Satragno D, Contrini MM, Graham BS, Ruckwardt TJ, López EL; GUTI Respiratory Infections Network.Vaccine. 2024 Jul 12:S0264-410X(24)00781-3. doi: 10.1016/j.vaccine.2024.07.020. Online ahead of print.PMID: 39003106

Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease.
Brenner EJ, Weaver KN, Zhang X, Kastl AJ, Strople JA, Adler J, Dubinsky MC, Bousvaros A, Watkins R, Dai X, Chen W, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda EA, Farraye FA, Chun KY, Zikry M, Bastidas M, Firestine A, Craig RG, Boccieri ME, Long MD, Kappelman MD.Clin Gastroenterol Hepatol. 2024 Jul;22(7):1475-1486.e4. doi: 10.1016/j.cgh.2024.02.001. Epub 2024 Feb 17.PMID: 38369224

SARS-CoV-2 seroprevalence among Beninese pregnant women in the third year of the pandemic.
Figueroa-Romero A, Atchadé A, Yadouleton A, Fiogbe M, Bonnet E, Yovo E, Accrombessi M, Hounsa S, Paper T, Dupont R, Gaudart J, Le Hesran JY, Massougbodji A, Cottrell G, González R.BMC Public Health. 2024 Jul 2;24(1):1762. doi: 10.1186/s12889-024-19087-4.PMID: 38956517

Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.
Schäfer TE, Knol LI, Haas FV, Hartley A, Pernickel SCS, Jády A, Finkbeiner MSC, Achberger J, Arelaki S, Modic Ž, Schröer K, Zhang W, Schmidt B, Schuster P, Haferkamp S, Doerner J, Gebauer F, Ackermann M, Kvasnicka HM, Kulkarni A, Bots STF, Kemp V, Hawinkels LJAC, Poetsch AR, Hoeben RC, Ehrhardt A, Marchini A, Ungerechts G, Ball CR, Engeland CE.EBioMedicine. 2024 Jul;105:105219. doi: 10.1016/j.ebiom.2024.105219. Epub 2024 Jun 27.PMID: 38941955

Phase 1b/2a randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with chronic hepatitis B.
Tak WY, Chuang WL, Chen CY, Tseng KC, Lim YS, Lo GH, Heo J, Agarwal K, Bussey L, Teo SL, Tria A, Brown A, Anderson K, Vardeu A, O'Brien S, Kopycinski J, Rutkowski K, Kolenovska R, Barnes E, Evans TG.J Hepatol. 2024 Jul 5:S0168-8278(24)02333-X. doi: 10.1016/j.jhep.2024.06.027. Online ahead of print.PMID: 38972484

Coronavirus Disease 2019 Infections Among Emergency Health Care Personnel: Impact on Delivery of United States Emergency Medical Care, 2020.
Weber KD, Mower W, Krishnadasan A, Mohr NM, Montoy JC, Rodriguez RM, Giordano PA, Eyck PT, Harland KK, Wallace K, McDonald LC, Kutty PK, Hesse EM, Talan DA; Project COVERED Emergency Department Network.Ann Emerg Med. 2024 Jul;84(1):40-48. doi: 10.1016/j.annemergmed.2024.01.023. Epub 2024 Mar 16.PMID: 38493375

Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B.
Zhang JW, Lai RM, Wang LF, Wang SL, Xue HX, Li C, Zheng ZZ, Li J, Zhu YY, Zeng DW, Chen J, Ou QS, Chen TB, Xun Z, Jiang JJ, Zheng Q.J Hepatol. 2024 Jul 9:S0168-8278(24)02338-9. doi: 10.1016/j.jhep.2024.06.033. Online ahead of print.PMID: 38992769

SARS-CoV-2 seroprevalence and associated factors among people living with HIV in Sierra Leone.
Sun W, Song J, Lakoh S, Chen J, Jalloh AT, Sahr F, Sevalie S, Jiba DF, Kamara IF, Xin Y, Ye Z, Ding F, Dai LZ, Wang L, Zheng X, Yang G.Immun Inflamm Dis. 2024 Jul;12(7):e1338. doi: 10.1002/iid3.1338.PMID: 38990142

Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study.
Turpin A, Semenzato L, Le Vu S, Jabagi MJ, Bouillon K, Drouin J, Bertrand M, Kanagaratnam L, Weill A, Dray-Spira R, Zureik M, Botton J.J Infect Public Health. 2024 Jul;17(7):102450. doi: 10.1016/j.jiph.2024.05.007. Epub 2024 May 14.PMID: 38823086

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([01.07.2024 TO 16.07.2024]) *as the publication date 58 records.*

1.WO/2024/144272VACCINE COMPOSITION COMPRISING NOROVIRUS GII MRNA
WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/KR2023/021767Applicant K-BIOCELF INC.Inventor OH, Myung Ryurl
The present invention relates to a vaccine composition comprising mRNA encoding the structural protein VP1 of a norovirus GI genotype. The mRNA vaccine composition was prepared by deriving the consensus sequence of a norovirus GI genotype VP1 antigen, and the immunogenicity of the vaccine composition was confirmed. Therefore, the vaccine composition can be effectively used to prevent and treat norovirus infection.

2.WO/2024/144267VACCINE COMPOSITION COMPRISING HIV-1 MRNA
WO - 04.07.2024
Int.Class A61K 39/21Appl.No PCT/KR2023/021756Applicant K-BIOCELF INC.Inventor OH, Myung Ryurl
The present invention relates to a vaccine composition comprising an HIV-1 MRNA. The mRNA vaccine composition is prepared by deriving the common sequence of an HIV-1 antigen, and the immunogenicity of the vaccine composition is identified, and thus the present invention can be effectively used in the prevention and treatment of HIV infection.

3.WO/2024/144262VACCINE COMPOSITION COMPRISING NOROVIRUS GI MRNA
WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/KR2023/021746Applicant K-BIOCELF INC.Inventor OH, Myung Ryurl
The present invention relates to a vaccine composition comprising mRNA encoding the structural protein VP1 of the norovirus genotype GI. An mRNA vaccine composition was prepared by deriving a common sequence of a norovirus genotype GI VP1 antigen, and through identification of the immunogenicity of the vaccine composition, the composition can be usefully employed to prevent and treat norovirus infection.

4.20240226256COMBINATION THERAPY TUMOUR CELL VACCINE
US - 11.07.2024
Int.Class A61K 39/00Appl.No 18561772Applicant Queen's University at KingstonInventor Kyle Seaver
A cancer vaccine includes at least one tumour associated antigen (TAA), at least one Toll-like receptor (TLR) agonist, at least one cytokine, and a pharmaceutically acceptable vehicle. The at least one TAA may be provided by dead tumour cells, such as γ-irradiated tumour cells or lysis and UV treated tumour cells, the at least one TLR agonist may comprise 5 CpG-1826 and the at least one cytokine may comprise IL-27. When administered to a mammalian subject the cancer vaccine prevents, inhibits, or slows tumour development in the subject, and the vaccine may provide a long-term T cell activation and memory against tumour development in the subject.

5.20240226282NANT COVID VACCINE CROSS REACTIVITY
US - 11.07.2024
Int.Class A61K 39/215Appl.No 18620192Applicant ImmunityBio, Inc.Inventor Patrick Soon-Shiong

Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.

6.WO/2024/143748COMPOSITION FOR INCREASING STABILITY OF ANIMAL VACCINE OR DIAGNOSTIC ANTIGEN, CONTAINING AMINO ACIDS AS ACTIVE INGREDIENT, AND USE THEREOF
WO - 04.07.2024
Int.Class A61K 39/00Appl.No PCT/KR2023/012012Applicant CHOONGANG VACCINE LABORATORIES CO., LTD (CAVAC)Inventor YOON, In-joong
The present invention relates to a composition for increasing the stability of an animal vaccine or a diagnostic antigen, comprising amino acids as an active ingredient, and use thereof. The stability-increasing composition according to the present invention can effectively maintain a prophylactically-effective virus titer without loss of infectivity titer in virus vaccines, and can facilitate transport and storage of vaccines, and thus can be effectively used in related fields.

7.WO/2024/146068USE OF TRIPTERINE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF IN PREPARATION OF VACCINE ADJUVANT
WO - 11.07.2024
Int.Class A61K 39/39Appl.No PCT/CN2023/098745Applicant NATIONAL VACCINE AND SERUM INSTITUTE (NVSI)Inventor WANG, Zhibiao
The present invention provides a use of tripterine or a pharmaceutically acceptable derivative thereof in the preparation of a vaccine adjuvant, and a vaccine adjuvant containing the tripterine or the pharmaceutically acceptable derivative thereof. The present invention finds that the immune response of an organism to an antigen can be enhanced by using the tripterine or the pharmaceutically acceptable derivative thereof as the vaccine adjuvant. Compared with metal salt adjuvants such as an aluminum adjuvant that is not easy to metabolize in vivo and has a risk of accumulation, the tripterine or the pharmaceutically acceptable derivative thereof in the present invention is a small molecule compound, is easy to degrade and excrete, is high in safety, and has a better immunogenicity enhancement effect than that of the aluminum adjuvant.

8.20240216498LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE
US - 04.07.2024
Int.Class A61K 39/12Appl.No 18523331Applicant Takeda Vaccines, Inc.Inventor Joseph David Santangelo
The present invention provides methods for large-scale flaviviral vaccine production and manufacture. The methods provided herein are specifically contemplated for large-scale production and manufacture of live, attenuated flaviviral vaccines such as live, attenuated, dengue virus vaccines. Further, the methods provided herein pertain to formulation of live, attenuated, monovalent, divalent, trivalent, or tetravalent viral vaccine products.

9.WO/2024/139647HUMAN PAPILLOMAVIRUS TYPE 16 DNA VACCINE AND USE THEREOF
WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/CN2023/128073Applicant INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCESInventor XU, Xuemei
Disclosed are a human papillomavirus type 16 DNA vaccine and use thereof, which relate to the technical field of biology. An antigen gene of the present invention is an optimized human papillomavirus type 16 E6 protein and E7 protein fusion gene, and a human heat shock protein 70 gene is further fused downstream thereof. A vaccine plasmid further comprises a replication origin and a CpG motif-based immunostimulatory sequence. The human papillomavirus type 16 DNA vaccine disclosed can induce an HPV16 E6 and E7 antigen specific

cellular immune response by means of intramuscular injection electroporation immunization. The DNA vaccine can be used for preventing and treating HPV16 infection, and treating infection-related precancerous lesions and malignant tumors.

10.2024204248COMBINATION THERAPY WITH NEOANTIGEN VACCINE
AU - 04.07.2024
Int.Class C07K 16/28Appl.No 2024204248Applicant Dana-Farber Cancer Institute, Inc.Inventor Fritsch, Edward F.
The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.

11.20240216499PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS
US - 04.07.2024
Int.Class A61K 39/145Appl.No 18461862Applicant Icosavax, Inc.Inventor Andrew Lawrence Feldhaus
Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.

12.4396198NEW CORONAVIRUS VACCINE AND METHOD FOR DESIGNING AND OBTAINING A VIRUS VACCINE
EP - 10.07.2024
Int.Class C07K 14/005Appl.No 22772886Applicant MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFTInventor DE LA ROSA KATHRIN
The present invention relates to a mutant receptor-binding domain (mRBD) of a coronavirus (mRBD-CORONA) or a fragment thereof and mutant spike protein of the coronavirus (CORONA-mSpike) or a fragment thereof comprising the CORONA-mRBD or the fragment thereof. Furthermore, the present invention relates to a polypeptide or protein comprising the mRBD-CORONA or the fragment thereof or CORONA-mSpike or the fragment thereof and a nucleic acid comprising a nucleotide sequence encoding for the mRBD-CORONA or the fragment thereof or the CORONA-mSpike or the fragment thereof. Furthermore, the present invention relates to a vaccine composition comprising one or more CORONA-mRBDs or fragments thereof, one or more CORONA- mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention. Furthermore, the present invention relates to the one or more CORONA-mRBDs or fragments thereof, the one or more CORONA-mSpikes, the one or more polypeptides or proteins, the one or more nucleic acids and/or the vaccine composition according to the present invention for use in the prevention and/or treatment of diseases caused by coronaviruses in a subject. Furthermore, the present invention relates to a method for designing and/or obtaining an active ingredient for a vaccine composition and to a VIRUS-mRBD or a fragment thereof designed and/orobtained by the method for obtaining the VIRUS-mRBD according to the present invention.

13.WO/2024/144254VACCINE COMPOSITION COMPRISING ZIKA VIRUS INACTIVATED BY EPIGALLOCATECHIN-3-GALLATE AS ACTIVE INGREDIENT
WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/KR2023/021729Applicant GREENVAX INC.Inventor SEONG, Baik Lin
The present invention relates to a vaccine composition comprising Zika virus inactivated by Epigallocatechin-3-gallate (EGCG) as an active ingredient, wherein it is confirmed that the Zika virus vaccine inactivated by

EGCG not only has a superior vaccine effectiveness due to a neutralizing antibody compared to existing Zika virus vaccines inactivated by formaldehyde which is a virus inactivating material, but also significantly improves a cytotoxic immune effect caused by an antibody, and thus, EGCG alone can be effectively utilized as a Zika virus vaccine composition without a separate inactivating material or combination with an adjuvant.

14.4396333UTILIZATION OF MICRO-RNA FOR DOWNREGULATION OF CYTOTOXIC TRANSGENE EXPRESSION BY MODIFIED VACCINIA VIRUS ANKARA (MVA)
EP - 10.07.2024
Int.Class C12N 7/00Appl.No 22772951Applicant BAVARIAN NORDIC ASInventor HAUSMANN JÜRGEN
The invention relates to a recombinant Modified Vaccinia Virus Ankara (MVA) comprising a series of miRNA target sequences arranged in a miRblock that is linked to a transgene, wherein each miRNA target sequence corresponds to a miRNA in a eukaryotic MVA producer cell. The present invention also relates to medical uses of the recombinant MVA.

15.WO/2024/144348VACCINE COMPOSITION COMPRISING IONIC COMPLEX OF CATIONIC MOLECULAR TRANSPORTER AND MRNA
WO - 04.07.2024
Int.Class A61K 39/00Appl.No PCT/KR2023/021981Applicant BIOPHARMA CORP.Inventor RHEE, Jinseol
The present invention relates to an mRNA-based vaccine composition comprising mRNA encoding an antigen peptide or protein, a liposome, and a cationic molecular transporter (SG6). The vaccine composition of the present invention has no cytotoxicity, high mRNA delivery efficiency, excellent stability and safety, and excellent antigen peptide or protein expression efficiency, and thus can be effectively used as an mRNA-based vaccine composition. Meanwhile, the present invention was made with the support of the Korea Health Industry Development Institute's health and medical technology research and development project by funding from the Ministry of Health and Welfare (Project identification number: HQ21C0274).

16.WO/2024/138836HEAT-RESISTANT PROTECTIVE AGENT FOR LIVE VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 04.07.2024
Int.Class A61K 47/26Appl.No PCT/CN2023/075359Applicant JINYUBAOLING BIO-PHARMACEUTICAL CO., LTDInventor LI, Chao
A heat-resistant protective agent for a live vaccine, a preparation method therefor, and use thereof. The protective agent for a live vaccine comprises: an inulin, gelatin, glycine, polyvinylpyrrolidone, bovine serum albumin, proteolyzed casein, D-sorbitol, a water-soluble phospholipid, pollen pini, and a tocopherol, wherein the mass ratio of pollen pini to the tocopherol is (1-2):1. The components of the protective agent are simple and effective, the raw materials are safe and readily available, and the preparation method is convenient and fast. When the protective agent is used to prepare a live Mycoplasma bovis vaccine, the protective agent can effectively reduce the loss rate of live mycoplasma bacteria during lyophilization and extend the shelf life, and meanwhile the vaccine can induce a long-lasting, efficient immune response in an organism.

17.WO/2024/144193VACCINE COMPOSITION COMPRISING GOLD-NANOPARTICLE-CARRIER HAVING DOUBLE-STRANDED DNA BOUND THERETO
WO - 04.07.2024
Int.Class A61K 39/385Appl.No PCT/KR2023/021565Applicant NES BIOTECHNOLOGY CO., LTD.Inventor LEE, Kangseok
The present invention relates to a vaccine composition containing double-stranded DNA transported into cells by means of gold nanoparticles and, more particularly, to a vaccine composition characterized in that the double-stranded DNA is derived from viruses, bacteria, or cancer genes and expresses an antigen to induce an immune response.

18.4395818STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE
EP - 10.07.2024
Int.Class A61K 39/00Appl.No 22865813Applicant VAXCYTE INCInventor GRAINGER CHRISTOPHER LAIN
The present disclosure provides stabilized vaccine compositions that resist the formation of unsuitable adjuvant flocculant or aggregates. These compositions comprise an aluminium adjuvant, a non-aluminium phosphate salt, sodium chloride and a polypeptide-polysaccharide conjugate comprising at least two non-natural amino acids. The present disclosure further provides methods of using such compositions to induce immune responses against infections in subjects.

19.WO/2024/147556COMPOSITION FOR ANTICANCER VACCINE COMPRISING K-RAS MUTANT MULTIPLE EPITOPE POLYPEPTIDE AS ACTIVE INGREDIENT
WO - 11.07.2024
Int.Class A61K 39/00Appl.No PCT/KR2023/021882Applicant MYONGJI MEDICAL FOUNDATIONInventor LEE, Wang Jun
The present invention relates to a composition for an anticancer vaccine, the composition comprising, as an active ingredient, a K-ras mutant multiple epitope polypeptide consisting of the amino acid sequence of SEQ ID NO: 1. Using the composition for an anticancer vaccine according to the present invention enhances the immune surveillance function against cancer cells expressing mutations in the K-ras protein such that cancer cells are detected and killed early through immune response mechanisms and cancer cells that have already formed are selectively killed, thus making it possible to prevent and treat cancer.

20.WO/2024/145150PSEUDORABIES VIRUS LIVE ATTENUATED VACCINE FOR PIGS, COMPRISING A DELETION OF GENE UL23
WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/US2023/085345Applicant ZOETIS SERVICES LLCInventor KONG, YiBo
This disclosure provides an attenuated suid herpesvirus 1 (a Pseudorabies virus) wherein the TK, gl and gE genes thereof are modified relative to a parent field strain, such that the resultant virus is safe and effective for use as a live vaccine that protects swine animals from challenge with a virulent Pseudorabies virus.

21.20240226270NOVEL VACCINE COMPOSITIONS FOR PORCINE EPIDEMIC DIARRHEA VIRUS AND PORCINE DELTACORONAVIRUS
US - 11.07.2024
Int.Class A61K 39/215Appl.No 17177724Applicant Zoetis Services LLCInventor Jacqueline Gayle Marx
The present invention is directed to novel immunogenic compositions that protect swine from disease caused by porcine epidemic diarrhea virus (PEDV). The present invention is also directed to novel immunogenic compositions that protect swine from disease caused by porcine deltacoronavirus (PDCoV), alone or as combination vaccine to protect against PEDV. The compositions of the invention provide killed viruses whose effectiveness is enhanced by the selection of preferred adjuvants. Novel culture methods are also employed to increase reproducible yield of cultured viruses. Live vaccines are also provided from the Calaf14 PEDV isolate.

22.4393505VACCINE FOR PREVENTING AFRICAN SWINE FEVER, COMPRISING AFRICAN SWINE FEVER VIRUS-DERIVED ANTIGEN PROTEIN
EP - 03.07.2024
Int.Class A61K 39/187Appl.No 22861612Applicant BIOAPPLICATIONS INCInventor KANG HYANGJU
The present invention relates to: a recombinant vector comprising a nucleotide sequence of antigen protein(s) Lectin, CD2v, p72, p54, p30, p15, p35, E199L, and/or F317L of an African swine fever virus; a transformant transformed by means of the recombinant vector; and a vaccine composition for preventing African swine

fever, comprising, as an active ingredient, African swine fever virus antigen protein(s) Lectin, CD2v, p72, p54, p30, p15, p35, E199L, and/or F317L, isolated from the transformant; and the like.

23.4395820NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE
EP - 10.07.2024
Int.Class A61K 39/39Appl.No 22773176Applicant CUREVAC SEInventor BAUMHOF PATRICK
The invention relates to a vaccine composition comprising a) at least one nucleic acid encoding at least one antigen or fragment or variant thereof; and b) a carrier composition, wherein the carrier composition comprises the phospholipid phosphatidylserine. The present invention further relates to a pharmaceutical composition comprising the vaccine composition and a pharmaceutically acceptable carrier, diluent or excipient, and to the vaccine composition or pharmaceutical composition for use in the treatment or prophylaxis of (as well as a corresponding method of treatment thereof) infectious diseases; cancer or tumor diseases, disorders or conditions; specific liver diseases; allergies; or autoimmune disease, disorder or condition; in a subject. Still further, the present invention is concerned with a kit or kit of parts, comprising the vaccine composition or the pharmaceutical composition as well as a method of inducing an immune response in a subject. Finally, the present invention is concerned with a use of a vaccine composition or the pharmaceutical composition or the kit or kit of parts for (i) inducing an immune response and for (ii) inducing an antigen specific T-cell response in a subject.

24.4392065SHIGELLA VACCINE
EP - 03.07.2024
Int.Class A61K 39/112Appl.No 22761566Applicant GLAXOSMITHKLINE BIOLOGICALS SAInventor MICOLI FRANCESCA
The present invention relates to immunogenic compositions and their use in providing protection against illness caused by infection with Shigella. The immunogenic compositions comprise Shigella GMMA with particular doses of O-antigen.

25.20240228981ATTENUATED VIRUSES USEFUL FOR VACCINES
US - 11.07.2024
Int.Class C12N 7/00Appl.No 18512196Applicant The Research Foundation for The State of University New YorkInventor Eckard Wimmer
This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

26.4395746STABILIZATION OF ANTIGENS FOR LONG TERM ADMINISTRATION IN TRANSDERMAL MICRONEEDLE PATCHES
EP - 10.07.2024
Int.Class A61K 9/10Appl.No 22865833Applicant UNIV CONNECTICUTInventor AGRAHARI VIVEK
Described herein are compositions and methods for stabilizing RNA and protein antigens for long-term storage and use in transdermal microneedle patches, methods for filling microneedles, and methods of use. A stabilized RNA vaccine composition comprises: a complex of RNA with one or more cationic polymers; and one or more cationic lipid entities. A method for stabilizing RNA comprises: forming a complex comprising the RNA with one or more cationic polymers; mixing the complex with one or more cationic lipid entities comprising

liposomes or lipid nanoparticles to form a lipid mixture; and drying the lipid mixture under vacuum. The compositions and methods may be employed in the preparation of vaccine medicaments.

27.4392066IMMUNOGENIC COMPOSITIONS AND THEIR USE
EP - 03.07.2024
Int.Class A61K 39/145Appl.No 22768820Applicant OSIVAXInventor LE VERT ALEXANDRE
The invention relates to immunogenic compositions and their use as a vaccine for the prevention of influenza disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition as a vaccine or immunotherapy in the prevention or treatment of influenza disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) an influenza nucleoprotein antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail, wherein an amount of 180 µg, or more, of said fusion protein is administered to said human subject.

28.20240216502UNIVERSAL VACCINE PLATFORM
US - 04.07.2024
Int.Class A61K 39/29Appl.No 18504962Applicant Hugh MASONInventor Hugh MASON
The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.

29.4393955ANTIBODY SPECIFICALLY BINDING TO CD47, RECOMBINANT ONCOLYTIC VIRUS THEREOF AND USE THEREOF
EP - 03.07.2024
Int.Class C07K 16/30Appl.No 22860533Applicant SHANGHAI SINOBAY BIOTECHNOLOGY CO LTDInventor XU JIANQING
Provided is an antibody capable of specifically binding to CD47 or an antigen binding fragment thereof. Also provided is a recombinant oncolytic virus, which is operably inserted with or comprises a gene coding sequence of an anti-CD47 antibody or a CD47 ligand, wherein the anti-CD47 antibody comprises an Fc mutant having A330L/I332E mutations (ALIE antibody), i.e., the anti-CD47 antibody is αCD47-Fc(ALIE).Also provided are a preparation method for the recombinant oncolytic virus, a use of the recombinant oncolytic virus in preparation of anti-tumor drugs, and a vaccinia virus Tiantan strain capable of efficiently expressing an αCD47-Fc(ALIE) gene.

30.WO/2024/140767POLYNUCLEOTIDE MOLECULE FOR PREVENTING OR TREATING HPV INFECTION-RELATED DISEASES
WO - 04.07.2024
Int.Class C12N 15/62Appl.No PCT/CN2023/142229Applicant RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor CEN, Shan
The present application relates to a polynucleotide molecule that can be used for preventing or treating HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.

31.4396197VIRAL-LIKE PARTICLES FOR THE TREATMENT OR PREVENTION OF AN INFECTION BY A CORONAVIRIDAE VIRUS
EP - 10.07.2024
Int.Class C07K 14/005Appl.No 22765924Applicant UNIV SORBONNEInventor KLATZMANN DAVID
The invention pertains to new viral-like particles (VLPs), pharmaceutical compositions comprising the same and methods of using the same to prevent or treat an infection by a Coronaviridae virus. Advantageously, these VLPs can be used as a vaccine to be orally or nasally administrated.

32.4392040GLYCATED CHITOSANS FOR TREATMENT OF VIRAL INFECTIONS
EP - 03.07.2024
Int.Class A61K 31/722Appl.No 22862137Applicant IMMUNOPHOTONICS INCInventor LAM SIU KIT
Methods of treating, preventing and/or inhibiting one or more of the symptoms of a respiratory viral infection in a subject by administering a therapeutically effective amount of a glycated chitosan (GC) polymer with characteristics as disclosed herein or a vaccine composition comprising such GC polymer in combination with one or more viral antigens are provided. Methods of reducing morbidity and/or mortality of a respiratory viral infection in a subject, methods of inducing an innate immune response in mucosa of a subject, methods of generating mucosal secretory IgA antibodies and/or neutralizing serum IgG antibodies in a subject, and methods of vaccinating a subject against a respiratory viral infection, wherein these methods comprise administering to the subject a therapeutically effective amount of a glycated chitosan (GC) polymer as disclosed herein or a vaccine composition comprising such GC polymer in combination with one or more viral antigens are further provided.

33.4392100PRE-FILLED BLOW-FILL-SEAL INTRADERMAL INJECTION SYSTEM
EP - 03.07.2024
Int.Class A61M 5/28Appl.No 22790120Applicant KOSKA FAMILY LTDInventor KOSKA MARC
A pre-filled blow-fill-seal (BFS) IntraDermal (ID) medical agent injection system (600) assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a BFS vial (610) to a patient in an auto-disable fashion.

34.WO/2024/139848NUCLEIC ACID DELIVERY CARRIER, PREPARATION METHOD THEREFOR, AND USE THEREOF
WO - 04.07.2024
Int.Class A61K 9/16Appl.No PCT/CN2023/132937Applicant CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD.Inventor WANG, Haomeng
A lipid nanoparticle composition, a preparation method therefor, and use thereof in nucleic acid delivery. An mRNA drug or vaccine can be prepared on the basis of the lipid nanoparticle composition. The starting materials of the lipid nanoparticle composition comprise an ionizable cationic lipid, an auxiliary phospholipid, a sterol compound, a lipid polyethylene glycol conjugate, and a buffer.

35.WO/2024/147503TROP2 IMMUNOGENIC PEPTIDE
WO - 11.07.2024
Int.Class C07K 14/47Appl.No PCT/KR2023/020268Applicant ASTON SCIENCE INC.Inventor JUNG, Hun
The present invention relates to TROP2 immunogenic peptides and a use thereof. The TROP2 immunogenic peptide according to the present invention selectively binds to MHC class II to enhance only the immunogenicity of specific immune cells capable of killing cancer cells and thus can be advantageously used as an excellent cancer vaccine for the prevention and/or treatment of cancer by minimizing the immune escape mechanism of cancer cells.

36.20240216493CANCER THERAPY COMPOSITIONS AND USES THEREOF
US - 04.07.2024
Int.Class A61K 39/00Appl.No 18607029Applicant HDT Bio CorpInventor Steven Gregory Reed
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Nucleic acids provided herein include those encoding for cancer antigens (full length proteins or fragments) as well as antibodies. Methods of using the compositions as a therapeutic vaccine for the treatment of a cancer are also provided.

37.WO/2024/148169NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY

WO - 11.07.2024
Int.Class A61K 9/127Appl.No PCT/US2024/010326Applicant HDT BIO CORP.Inventor KIMURA, Taishi
The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject that, optionally, have reduced reactogenicity and promotes a local innate immune response in the subject while promoting an adaptive immune response. Compositions described herein include nanoparticles, optionally including an inorganic particle, capable of admixing with nucleic acids encoding proteins, antibodies, or immunomodulators. Methods of using the compositions as a therapeutic vaccine for the treatment of an infection or cancer are also provided.

38.20240226258IN-VITRO TRANSCRIPT MRNA AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
US - 11.07.2024
Int.Class A61K 39/02Appl.No 17905830Applicant ABION INC.Inventor Young Key SHIN
The present invention relates to an RNA in-vitro transcript mRNA for intracellular expression of a gene of interest and a pharmaceutical composition comprising same for vaccines. When injected into animal cells, the in-vitro transcript mRNA including the gene of interest according to the present invention allows the protein of interest to be expressed in the animal cell in large quantities, and, as such, can be used as a gene vaccine against autoimmune diseases, infectious diseases, cancer- or tumor-related diseases, inflammatory diseases, and so on.

39.20240229143FORMULATION OF PEPTIDE IMMUNOTHERAPIES
US - 11.07.2024
Int.Class C12Q 1/6886Appl.No 18256243Applicant IOGENETICS, LLCInventor Jane Homan
This invention provides a method for maximizing the immune response to mutated tumor specific proteins, either by means of stimulation of dendritic cells or T cells in vitro followed by administration of these cells to a patient, or by means of administration of a neoantigen vaccine in which de novo peptides, or their encoding nucleic acids, have been designed to ensure an appropriate level of binding affinity to a particular cancer patient's MHC alleles. This invention further provides for modulating the immune response in an immunopathology

40.202370610METHODS OF VACCINE ADMINISTRATION TO SALMONIDS
DK - 12.07.2024
Int.Class A61K 39/02Appl.No PA 2023 70610Applicant ZOETIS Services LLCInventor Adérito Luis MONJANE
The disclosure provides compositions and methods for salmonid vaccination against PMCV and at least one other pathogen

41.4397318IMMUNOSTIMULATORY FORMULATION, AND COSMETIC, FOOD, FEED ADDITIVE, AND QUASI-DRUG CONTAINING SAID IMMUNOSTIMULATORY FORMULATION
EP - 10.07.2024
Int.Class A61K 47/64Appl.No 21955905Applicant JAPAN ECO SCIENCE CO LTDInventor MIYAMOTO HIROKUNI
Without being limited to an epitope of a conventional antigen, it is possible to perform relatively simple formulation for activating a mucosal immune system and inducing highly diverse immunoglobulins by a non-invasive method. In a conventional vaccine, it is difficult to select an epitope antigen, and it takes time to approve the vaccine; therefore, it is assumed that it may be difficult to obtain an effect after approval for a pathogen target such as a virus that is likely to be mutated. In addition, since vaccination is not basically administered by the non-invasive method, suitable medical practice in a medical institution has been essential. Provided is an immunostimulatory preparation which is a protein obtained by fusing a bacteria-derived heat

shock protein (HSP: heat shock protein) and a viral peptide antigen, and enables induction of a highly diverse immunoglobulin by simultaneously stimulating nasal, respiratory, and oral administration. Provided are a feed, a feed additive, and an environmental symbiotic preparation for livestock, or a cosmetic, a food, and a quasi-pharmaceutical product for humans, which enable symbiosis with an environmental microorganism containing the immunostimulatory preparation. Provided are a preparation, a cosmetic for humans, a food, and a quasi-pharmaceutical product that enable symbiosis with environmental microorganisms utilizing livestock-derived IgA, IgG, and IgY among the immunoglobulins.

42.20240228980CRYPTIC PROTEINS EXPRESSED FROM DEFECTIVE VIRAL GENOMES INTERFERE WITH INFLUENZA VIRUS REPLICATION
US - 11.07.2024
Int.Class C12N 7/00Appl.No 18495338Applicant Wisconsin Alumni Research FoundationInventor Andrew Mehle
The disclosure provides for methods for making and using modified influenza gene products, alone or in combination, e.g., to inhibit wild-type influenza virus replication, to serve as an immunostimulatory agent, and/or as attenuated vaccine backbones. In one embodiment, the genomes of the DIPs provide for inhibitory activity, producing a dual effect in which both the RNA itself and the encoded protein coordinate to interfere with replication. Thus, the ability of DIPs to block replication of WT virus provides for a treatment for infection, use as an immunostimulatory agent, and as attenuated viruses for vaccination.

43.4397676NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
EP - 10.07.2024
Int.Class C07K 14/47Appl.No 24164808Applicant IMMATICS BIOTECHNOLOGIES GMBHInventor MAHR ANDREA
The present invention relates to a peptide, nucleic acid and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to a tumor-associated T-cell peptide epitope, alone or in combination with other tumor-associated peptides that can for example serve as an active pharmaceutical ingredient of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. The peptide bound to molecules of the major histocompatibility complex (MHC), or the peptide as such, can also be the target of antibodies, soluble T-cell receptors, and other binding molecules.

44.20240229007INACTIVATED VACCINES & NUCLEIC ACID APTAMER THERAPEUTICS DERIVED THEREFROM
US - 11.07.2024
Int.Class C12N 13/00Appl.No 17313798Applicant Universal Stabilization Technologies, Inc.Inventor Victor Bronshtein
Methods for producing dry thermostable inactivated vaccines with improved inactivation/killing without compromising antigenicity are disclosed. The methods provide for microbes to be irradiated with an ionizing radiation dose above 24 kGy without compromising the integrity of useful epitopes. To achieve enhanced inactivation, microorganisms (virions, bacterium, fungi, etc.) are first immobilized in a dry glassy matrix, then subsequently irradiated at elevated radiation dose while immobilized in the glass. Aptamers can be isolated from the inactivated microbes, such as inactivated SARS-COV-2, and modified or developed as therapeutics for neutralizing infectious disease. Additionally, non-neutralizing aptamers can be combined to produce an enhanced vaccine.

45.WO/2024/140251PHARMACEUTICAL COMPOSITION FOR INDUCING IMMUNE RESPONSE OF MAMMAL AGAINST NOROVIRUS, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 04.07.2024
Int.Class A61K 39/12Appl.No PCT/CN2023/138780Applicant GRAND THERAVAC LIFE SCIENCES (NANJING) CO., LTD.Inventor LI, Jianqiang
Provided are a pharmaceutical composition for inducing an immune response of a mammal against norovirus, a preparation method therefor, and use thereof. The pharmaceutical composition is composed of the following components: i) a norovirus VLP protein, an active fragment of the protein, a variant of the protein, or a mixture of at least two thereof; ii) an aluminum adjuvant; iii) sodium chloride; and iv) water. Further provided are a vaccine and a kit comprising the pharmaceutical composition and uses thereof. The pharmaceutical composition is not only suitable for various norovirus valence types, but also has superior adsorption completeness, blocking antibody titer and specific IgG antibody titer.

46.20240216491NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS
US - 04.07.2024
Int.Class A61K 39/00Appl.No 18433142Applicant KORANEX CAPITALInventor Tze Chieh SHIAO
Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

47.WO/2024/146614HUMAN PAPILLOMAVIRUS TYPE 51 L1 PROTEIN MUTANT, METHOD FOR REDUCING DEGRADATION OF RECOMBINANT PROTEIN AND USE
WO - 11.07.2024
Int.Class C07K 14/025Appl.No PCT/CN2024/070680Applicant BEIJING HEALTH GUARD BIOTECHNOLOGY, INC.Inventor WU, Shuming
A human papillomavirus type 51 L1 protein mutant, a method for reducing the degradation of a recombinant human papillomavirus type 51 L1 protein using same and the use thereof. The mutation of R at position 422 of the amino acid sequence of HPV51L1 into T or Q by means of a genetic engineering technique successfully solves a protein degradation problem thereof. Experiments show that the mutations both do not affect the expression of the corresponding mutated L1 protein, the degradation ratio of the modified L1 protein is obviously reduced, and the immunogenicity of the corresponding VLP is also not affected. By means of mutation of the human papillomavirus type 51 L1 protein, the protein degradation problem is avoided, so that the corresponding HPV51L1-VLP obtained by recombinant expression of the modified sequence or the assembly thereof is more suitable as a vaccine antigen protein to prevent this type of papillomavirus infection.

48.4396206METHODS FOR ISOLATION OF LIPID-DISC COMPOSITIONS AND USES THEREOF
EP - 10.07.2024
Int.Class C07K 14/245Appl.No 22769710Applicant VIB VZWInventor REMAUT HAN
The invention relates to the field of bacterial membrane protein structures. More specifically, the invention relates to lipid nanodiscs compartmentalized by SlyB protein oligomers isolated from the outer membrane of Gram-negative bacteria. More specifically, the invention provides for a SlyB nanodisc structure wherein the SlyB-oligomer forms the membrane scaffold protein belt, which is surrounded by outer saccharolipid moieties anchored to the SlyB proteins, and which encloses a lipid bilayer nanodomain containing one or more

phospholipid layers, wherein macromolecules such as (outer) membrane protein molecules may be captured and stabilized. More specifically, methods to produce and isolate chemically defined stable SlyB nanodisc particles are disclosed herein. Finally, the invention relates to the use of said SlyB nanodiscs as a self-adjuvanting vehicle, as part of an immunogenic composition, and provides for novel means for use in eliciting an immune response against macromolecules enclosed in said SlyB nanodiscs, or for use in a vaccine composition.

49.WO/2024/146613HUMAN PAPILLOMAVIRUS 56-TYPE L1 PROTEIN MUTANT, METHOD FOR REDUCING RECOMBINANT PROTEIN DEGRADATION, AND APPLICATION
WO - 11.07.2024
Int.Class C07K 14/025Appl.No PCT/CN2024/070679Applicant BEIJING HEALTH GUARD BIOTECHNOLOGY, INC.Inventor CHEN, Xiao
A human papillomavirus (HPV) 56-type L1 protein mutant, a method for reducing the degradation of a recombinant HPV 56-type L1 protein, and an application. The modification of mutating the R at position 420 of an amino acid sequence of HPV56L1 into T or Q by using the genetic engineering technology successfully solves the problem of the degradation of the protein. The mutation does not affect the expression of a corresponding mutated L1 protein, the degradation ratio of a modified L1 protein is significantly reduced, and the immunogenicity of a corresponding VLP is not influenced. The HPV 56-type L1 protein is mutated and modified, so that the degradation problem is solved, the manufacturing difficulty is reduced, and the qualitative trait is improved. Thus, a corresponding HPV56L1-VLP obtained by recombinant expression of a modified sequence and assembly is more suitable as a vaccine antigen protein for preventing this type of papillomavirus infection.

50.20240228547POLYPEPTIDE FOR RESISTING NOVEL CORONAVIRUS AND APPLICATION THEREOF
US - 11.07.2024
Int.Class C07K 14/005Appl.No 18441563Applicant INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventor Fu GAO
The present application relates to a polypeptide for preventing or treating a novel coronavirus and an application thereof. The polypeptide is P3 polypeptide and any one of P3-1 polypeptide, P3-2 polypeptide, P3-3 polypeptide, P3-4 polypeptide, and P3-5 polypeptide derived from the P3 polypeptide. The amino acid sequences of the P3 polypeptide, the P3-1 polypeptide, the P3-2 polypeptide, the P3-3 polypeptide, the P3-4 polypeptide, and the P3-5 polypeptide are respectively shown in SEQ ID NOs: 1-6. The polypeptide of the present application has a strong inhibitory effect on original strains and a plurality of variant strains of the novel coronavirus, and can be used for preparing a drug or a vaccine for preventing and/or treating diseases caused by the novel coronavirus. The polypeptide is expected to also have the potential of preventing and/or treating new variant strains appearing in the future and sarbecovirus.

51.313190NASAL VACCINE-SPRAYING FORMULATION FOR SIMULTANEOUSLY TARGETING NASAL MUCOSA AND NASOPHARYNX
IL - 01.07.2024
Int.Class A61K 35/76Appl.No 313190Applicant TOKO YAKUHIN KOGYO Co., LTD.Inventor KAMISHITA, Taizou

52.WO/2024/139640NOVEL CORONAVIRUS IGA ANTIBODY DETECTION IMMUNOPROBE, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 04.07.2024
Int.Class G01N 33/558Appl.No PCT/CN2023/127731Applicant XIAMEN FORTUNE BIOTECH CO., LTDInventor CHEN, Zhilong

A novel coronavirus IgA antibody detection immunoprobe, a preparation method therefor and a use thereof. The novel coronavirus IgA antibody detection immunoprobe comprises colloidal gold, wherein the colloidal gold adsorbs an anti-human IgA antibody protein or a new coronavirus spike protein. A novel coronavirus IgA antibody detection test strip comprises a bottom plate (7), and a sample pad (1), a gold pad (2), a chromatography membrane (5), and a water absorption pad (6) which are provided on the bottom plate (7) and arranged in sequence; the chromatography membrane (5) is a solid-phase nitrocellulose membrane composed of a test line (3) and a quality control line (4); the gold pad (2) is coated with an immunoprobe. When the immunoprobe coated on the gold pad (2) contains the anti-human IgA antibody protein, the test line (3) is coated with the new coronavirus spike protein; or when the immunoprobe coated on the gold pad (2) contains the new coronavirus spike protein, the test line (3) is coated with the anti-human IgA antibody protein; the quality control line (4) is coated with a quality control protein. The present invention is used for evaluating the level of IgA generated by nasal mucosa after a novel coronavirus nasal spray vaccine is inoculated.

53.4396204ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION
EP - 10.07.2024
Int.Class C07K 14/005Appl.No 22871020Applicant KOTLYAR DAVIDInventor KOTLYAR DAVID
Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

54.20240226281ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION
US - 11.07.2024
Int.Class A61K 39/215Appl.No 18608668Applicant David KotlyarInventor David Kotlyar
Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

55.20240226273HIGHLY ATTENUATED REPLICATION-COMPETENT RECOMBINANT POXVIRUS AS A VACCINE PLATFORM AND METHODS OF USE
US - 11.07.2024
Int.Class A61K 39/215Appl.No 18283042Applicant Arizona Board of Regents on behalf of Arizona State UniversityInventor Bertram Jacobs
Recombinant poxvirus expressing severe acute respiratory syndrome coronavirus 2 structural proteins and virus-like particles are described, along with methods of making and using the same.

56.WO/2024/146109A NOVEL MRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
WO - 11.07.2024
Int.Class A61K 39/12Appl.No PCT/CN2023/107199Applicant VIROGIN BIOTECH (SHANGHAI) LTD.Inventor ZHANG, Kuan
Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. In various embodiments, the immunogenic protein is derived (e.g., mutated) from an HPV strain such as HPV 16, 18, 31, 33,35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Also provided are compositions (e.g., mRNA compositions) encoding such immunogenic proteins, as well as method for treating and preventing HPV infections.

57.WO/2024/145863A NOVEL MRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
WO - 11.07.2024
Int.Class C12N 15/62Appl.No PCT/CN2023/070634Applicant VIROGIN BIOTECH (SHANGHAI) LTD.Inventor ZHANG, Kuan
Immunogenic proteins are provided which have been derived from a strain of HPV which causes or is associated with causing cancer, which are mutated so that they do not cause increased cell proliferation. Within various embodiments of the invention the immunogenic protein is derived (e.g., mutated) from an HPV strain such as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Also provided are compositions (e.g., mRNA compositions) encoding such immunogenic proteins, as well as method for treating and preventing HPV infections.

58.WO/2024/141791COMBINED DELIVERY OF ANTIGENS AND TOLEROGENIC SIGNALS VIA DUAL-SIZED HYDROGEL SPHERES AND MOF COMPOSITES FOR TYPE-1 DIABETES VACCINE DEVELOPMENT
WO - 04.07.2024
Int.Class A61K 47/69Appl.No PCT/IB2023/000798Applicant THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGYInventor CHUNG, Jin Teng
The subject invention pertains to a novel platform for the sustained release of Type-1 diabetes antigens. More specifically, the subject invention provides a combination of dual sized hydrogel particles for the delivery of Type-1 diabetes antigens and multi-component adjuvants to confer immune tolerance.

---

responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES